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Abstract 
 
Opiate drugs, such as codeine, morphine and heroin are powerful analgesics and drugs of 
abuse. The unborn child is invariably exposed to opiate drugs as a consequence of maternal 
use. Studies that have investigated the impact of opiate drugs demonstrated opioid system 
expression in proliferating regions of the developing brain, as well as on proliferative 
astroglia taken from the developing central nervous system. The effects of opiates on 
astroglial proliferation (largely mediated by the mu opioid receptor) are predominantly 
inhibitory, but are extremely context dependent. This context dependency exists because of 
the complexity resident within the opioid signalling system. However, since this previous 
research was conducted, there has been impressive progress made in the field of 
developmental neurobiology with the demonstration that cells of astrocytic lineage are 
responsible for the generation of the central nervous system. 
 
It was therefore the aim of the current research project to investigate the developmental 
impact of opiate exposure in the context of the foetal mouse cerebral cortex. This aim was 
divided into 3 separate aims that comprised of; determining the cellular localisation of the 
mu opioid receptor, the effects of opiate exposure on cortical progenitor cells, and to 
determine the effect of opiate exposure on the development of the cerebral cortex itself. 
The mu opioid receptor was expressed on proliferative radial glia of both the embryonic 
day 15.5 (neurogenic) and embryonic day 18.5 (gliogenic) ventricular zone of the dorsal 
forebrain. Interestingly and significantly, the mu opioid receptor-positive glia observed in 
the embryonic day 18.5 mouse forebrain were also observed at a comparable 
 III 
developmental stage in the foetal human forebrain. Morphine exposure slowed down G2 
phase of the cell cycle at embryonic day 15.5 in the neurogenic murine cortical ventricular 
zone. This opiate-induced slowing in cell cycle progression was shown not to impact on 
proliferation in the ventricular zone, although future research should address whether this 
perturbation altered differentiation or developmental maturation of the radial glia. 
Morphine exposure throughout corticogenesis decreased levels of doublecortin expression 
(a migratory neuronal marker) at the end of gestation. Postnatally, mice exposed to 
morphine during corticogenesis also showed decreased numbers of neurons in layer V of 
the cerebral cortex. 
 
Collectively, this thesis presents the first evidence that shows morphine affects cortical 
progenitor cells in vivo. This research supports the possibility that the opioid system plays 
an endogenous role in corticogenesis. The clinical significance is morphine has the 
potential to perturb normal development of the cerebral cortex. 
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1. Introduction 
 
1.1 The Opioid Signalling System: Historical Aspects 
 
The use of opium dates as far back as 3000 BC. It was extracted from the opium poppy by 
Sumerians in modern day Iraq, where it was probably used in religious ceremonies. 
Although opium use had reached Europe and Asia by the middle ages, China developed a 
severe opium addiction problem as a consequence of free opium trade (reviewed in 
Brownstein, 1993), enforced by the British during the opium war that spanned from 1840-
1842 (Fay, 1975). The analgesic properties of morphine, the active ingredient of opium, 
were utilised after invention of the hypodermic syringe in the 1850s. Ironically, the search 
for a non-addictive opiate compound that could be used as an analgesic resulted in the 
synthesis of diacetylmorphine, or heroin (reviewed in Pasternak, 2001). 
 
At the beginning of the logarithmic expansion of knowledge on the endogenous opioid 
system and its pharmacology in the 1970s, a review written by Martin (1967) summarised 
the opioid field, outlining concepts such as adoption of the term ‘opioid’, opioid receptor 
agonism, partial agonism and antagonism and importantly, receptor dualism. Martin 
attempted to explain observations made with ‘morphine-like agents’ and ‘nalorphine-like 
agents’ by introducing the idea of multiple receptor populations. Pasternak and Snyder 
(1975) determined the existence of two types of opiate receptor, a high and a low affinity 
binding site, by using naloxone and dihydromorphine. Originally, it was proposed that 
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these two binding sites, represented by biphasic binding to the “opiate receptor”, were a 
result of different receptor conformations. However, less than 10 years after Martin (1967) 
had argued for the existence of multiple opioid receptors, the three classical opioid 
receptors, delta (DOR), kappa (KOR) and mu (MOR), were delineated using prototypic 
ligands and comparisons between different physiological systems (Snyder and Pasternak, 
2003). MOR and KOR were originally defined in the chronic spinal dog (Martin et al., 
1976). These receptors were named after their prototypic ligands, morphine and 
ketocyclazocine, respectively. Evidence for the existence of DOR came initially from the 
discovery that the mouse vas deferens requires 10 times more naloxone to inhibit 
enkephalin-induced contraction than what the mouse ileum required (Lord et al., 1977). It 
was proposed by Lord et al. (1977) that as binding profiles of specific opioids were 
different in different systems, opioid receptor sites must be heterogeneous, rather than just 
one homogenous population. The postulated existence of high affinity enkephalin binding 
sites (DOR) in the vas deferens was confirmed in later studies (Leslie and Kosterlitz, 1979). 
 
The first endogenous opioid ligands to be characterised, the enkephalins, were extracted 
from crude brain homogenates (Terenius and Wahlstrom, 1975; Hughes, 1975; Hughes et 
al., 1975a; 1975b). These ligands were first recognised for their ability to block opiate 
receptor binding by dihydromorphine (Terenius and Wahlstrom, 1975). Thus, as the opioid 
system receptors were some of the first receptors in neuroscience to be characterised by 
ligand binding, the endogenous opioid ligands were some of the first neuropeptides to be 
characterised by receptor binding (Pasternak, 2004). 
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1.2 Molecular Biology and Biochemistry of the Opioid Receptors 
 
1.2.1 Molecular Biology of the Opioid receptors 
 
The classical opioid receptor system now includes three cloned receptors. DOR was cloned 
first using functional screening with enkephalin (Evans et al., 1992; Kieffer et al., 1992). 
Isolation of cDNAs coding for KOR (Chen et al., 1993a; Li et al., 1993; Meng et al., 1993; 
Minami et al., 1993) and MOR (Chen et al., 1993b; Eppler et al., 1993; Thompson et al., 
1993; Wang et al., 1993), using homologous probes based on DOR sequence, soon 
followed. Cloning the opioid receptors provided structural information that confirmed that 
they were 7-transmembrane domain G-protein coupled receptors. Homology models of the 
opioid receptors have been made utilising the closely related structure of the rhodopsin 
receptor (Subramanian et al., 2000; Fowler et al., 2004). Fowler et al. (2004) used 
homology modelling and mutagenesis techniques to determine important ligand binding 
residues for MOR (Fig. 1.1). The opioid receptors signal preferentially through an 
overlapping profile of pertussis toxin-sensitive G-proteins. This encompasses the Gi and the 
Go alpha subunits (reviewed in Connor and Christie, 1999) and leads to affects such as 
inhibition of adenylyl cyclase and modulation of calcium signalling. Ligands that bind to 
DOR, KOR and MOR along with their affinities are listed in Table 1.1. 
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Fig. 1.1. A stereo-image of MOR, as seen from an extracellular view point. MOR (in blue) has 7 
transmembrane alpha-helices. A cyclic peptide ligand, JOM6 (green), is seen bound within the ligand binding 
pocket where important binding residues described in Fowler et al. (2004) are shown in white. This image 
was generated using Rasmol v2.6 and a PDB file retrieved from 
http://mosberglab.phar.umich.edu/resources/index.php (Fowler et al., 2004). 
 
Ligand DOR 
(nM) 
KOR 
(nM) 
MOR 
(nM) 
Notes 
 
Exogenous agonists 
 
    
Morphine 
 
160 
>1000 
47 
538 
1.8 
14 
(Clark et al., 1988; 1989) 
(Raynor et al., 1994) 
Active ingredient in opium. 
Codeine >1000 >1000 79 (Raynor et al., 1994) 
Active ingredient in poppies 
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Fentanyl >1000 255 0.39 (Raynor et al., 1994) 
Common analgesic 
Methadone >1000 >1000 0.72 (Raynor et al.,1994) 
PL017 >1000 >1000 30 (Raynor et al., 1994) 
Etorphine 0.4 0.8 2.0 (Lewis and Husbands, 2004) 
Ethylketocyclazocine 101 0.4 3.1 (Raynor et al., 1994) 
U-50,488 >1000 0.12 >1000 (Raynor et al., 1994) 
U-69,593 >1000 0.59 >1000 (Raynor et al., 1994) 
DAMGO >1000 >1000 2.0 (Raynor et al., 1994) Synthetic 
enkephalin analogue 
DPDPE 14 >1000 >1000 (Raynor et al., 1994) Synthetic 
enkephalin analogue 
DSLET 
 
 
Exogenous antagonists 
 
4.8 >1000 39 (Raynor et al., 1994) Synthetic 
enkephalin analogue 
(-)-Naloxone 17 2.3 0.93 (Raynor et al., 1994) 
Naltrexone 149 3.9 1.0 (Raynor et al., 1994) 
Naloxonazine 8.6 11 0.054 (Raynor et al., 1994) 
Nalorphine 148 1.1 0.97 (Raynor et al., 1994) 
CTOP >1000 >1000 0.18 (Raynor et al., 1994) 
Beta-FNA 48 2.8 0.33 (Raynor et al., 1994) 
Norbinaltorphamine 65 0.027 2.2 (Raynor et al., 1994) 
 
Endogenous peptide ligands 
 
    
Met-enkephalin 18.3 2338 25.2 (Janecka et al., 2004) 
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Leu-enkephalin 8.05 1507 27.7 (Janecka et al., 2004) 
Beta-endorphin 1.0 142 1.0 (Janecka et al., 2004) 
Endomorphin-1 1506 >500 0.36 (Goldberg et al., 1998) 
Endomorphin-2 9233 >500 0.69 (Goldberg et al., 1998) 
Dynorphin A >1000 0.5 32 (Raynor et al., 1994) 
[D-Ala2]Deltorphin II 3.3 >1000 >1000 (Erspamer et al., 1989) Selective 
DOR peptide ligand isolated from 
frog skin  
Dermorphin >1000 >1000 0.33 (Melchiorri and Negri, 1996) Very 
potent MOR peptide ligand isolated 
from frog skin  
Table 1.1: Opioid receptor ligands. This table shows common opioid receptor ligands shown with Ki values 
against receptor-selective ligands taken from the literature. Raynor et al. (1994) used tritiated U69,593 
(KOR), naltrindole (DOR) and DAMGO (MOR) for determination of Ki values. 
 
To date, only three opioid receptors have been cloned; DOR, KOR and MOR. Two other 
opioid related receptors have also been cloned. The opioid receptor-like 1 (ORL1) receptor 
bears high homology to the opioid receptors (in particular KOR), to the extent it was 
originally identified by screens based on opioid receptor nucleotide sequence. Its ligand, 
nociceptin also bears striking resemblance to dynorphin, the endogenous KOR ligand. In 
vivo, the ORL1 receptor modulates anti-opioid affects (reviewed in Meunier, 1997). 
Another receptor, the opioid growth factor receptor (OGFr), was cloned and identified 
using expression libraries and antibody raised against opioid growth factor (met-
enkephalin) binding proteins that were identified on a 2-dimensional gel (Zagon et al., 
1999a).  
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Although only one MOR gene (Oprm1) has been cloned, a multitude of MOR splice 
variants have been discovered, most notably in the mouse (reviewed in Pan, 2005). MOR 
splice variants have also been described in the rat (Zimprich et al., 1995; Pasternak et al., 
2004) as well as in the human (Bare et al., 1994; Pan et al., 2003; Pan et al., 2005a). 
Alternative splicing is an important step in introducing increased complexity (thus 
increased control) in gene expression. Alternative splicing is a process that wields great 
influence over brain development, as seen with alternative splicing of fibroblast growth 
factor and numb gene products (reviewed in Li et al., 2007). At least 25 MOR splice 
variants have been isolated from the mouse (encompassing MOR-1, MOR-1A through 
MOR-1T) (Pan, 2005). The different MOR carboxy-terminus splice variants also show 
different ligand binding and receptor stimulation profiles (Bolan et al., 2004). Interestingly, 
both carboxy as well as amino terminus splice variants of MOR differ in terms of 
immunohistochemical localisation within the adult rodent brain (Abbadie et al., 2000; 
Abbadie et al., 2004). 
 
The numerous splice variants are driven from two promoters. The first one that was 
discovered was the promoter region immediately upstream of exon 1 of the Oprm1 gene 
(Min et al., 1994; Liang et al., 1995). This murine MOR promoter region contains two 
promoter sites (Liang et al., 1995), one proximal site at 268 base pairs upstream of the exon 
1 translation start point and another distal transcription start point at 793 base pairs 
upstream of the translation start point. This distal transcription start point is of particular 
interest as it is under the positive control of sox6, sox18 and sox21 (Hwang et al., 2003). 
Sox transcription factors are important for developmental processes (Wegner and Stolt, 
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2005). Sox6 is neurogenic in that it is required for the retinoic acid induced neuronal 
differentiation of P19 embryonal carcinoma cells (Hamada-Kanazawa et al., 2004a; 2004b) 
and that over expression of sox6 is sufficient to induce neurogenesis by itself. Sox21 is also 
neurogenic such that overexpression causes cells within the developing central nervous 
system (CNS) to exit the cell cycle and become neurons (Sandberg et al., 2005). This is 
interesting given that MOR also has pro-neurogenic properties (Kim et al., 2006) and that 
expression of murine MOR transcript from the distal promoter site begins at embryonic day 
(E)8.5 (Ko et al., 2002), at the very beginning of neurogenesis in the developing mouse 
CNS (reviewed in Götz and Huttner, 2005). 
 
The second major promoter that drives transcription from exon 11 was discovered and 
analysed when exon 11-containing splice variants were cloned (Pan, 2002). These splice 
variants contained exons 5’ of exon 1, thus they were the product of promoter activity 
upstream of the exon 1 promoter region (Pan et al., 2001). Evidence for alternative splicing 
of DOR and KOR transcripts remains to be presented. The exon 1 and exon 11 MOR 
promoters are subject to differential developmental regulation (Xu et al., 2006). Exon 1 
promoter activity has been reported in the E7.5 mouse brain whereas in the same study, 
exon 11 promoter activity was detected later at E11.5. 
 
1.2.2 Phamacological Variants of the Opioid Receptors 
 
Although only three classical opioid receptors have been cloned, several pharmacological 
subtypes of the opioid receptors have been proposed. Two pharmacological MOR binding 
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sites were characterised using naloxazone. These binding sites were the high affinity mu1 
(Kd < 1 nM) and the lower affinity mu2 (Kd > 3 nM) (Wolozin and Pasternak, 1981). It was 
found that naloxazone, as well as naloxonazine (Hahn and Pasternak, 1982) abolished 
binding to the high affinity mu1 binding sites. 
 
Naloxazone and naloxonazine (mu1 receptor antagonists with no antagonistic properties at 
the mu2 receptor binding site) were used to determine the pharmacological significance of 
the identified mu1 and mu2 binding sites. Whereas beta-funaltrexamine (beta-FNA) 
universally antagonised morphine’s effects in vivo, naloxonazine and naloxazone were 
much more selective. Naloxazone was used to demonstrate that prolactin release, but not 
growth hormone release, was dependent on mu1 (Spiegel et al., 1982). Other studies have 
shown that mu1 binding sites are critical for morphine induced catalepsy (Ling and 
Pasternak, 1982). Morphine induced analgesia is also modulated by pharmacological MOR 
variants. Both mu1 and mu2 binding sites are involved with MOR induced analgesia 
depending on whether the analgesia is spinal or supraspinal (Ling and Pasternak, 1983; 
Paul et al., 1989). Furthermore, studies have demonstrated that pharmacological properties 
of morphine can be dissociated using mu1 specific antagonists. Such studies have 
demonstrated the separation of morphine induced analgesia and respiratory depression 
(Ling et al., 1983; 1985), morphine induced analgesia and dependence and withdrawal 
(Ling et al., 1984), as well as separation of opioid peptide mediated analgesia and 
opioidergic modulation of peristalsis (Heyman et al., 1988). The activity of mu1 and mu2 
binding sites in modulation of respiration was further delineated by Colman and Miller 
(2001) who demonstrated the involvement of both mu subtypes in respiratory depression 
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using the MOR agonists fentanyl and dermorphin. Another line of evidence that has been 
used to support the existence of multiple mu binding sites is mu opioid synergy. Bolan et 
al. (2002) demonstrated that L-methadone displays synergy with some mu opioids such as 
morphine, morphine-6-beta-glucuronide, 6-acetylmorphine and codeine, but not others such 
as fentanyl and meperidine. 
 
An attempt to reconcile the now copious evidence for both MOR splice variants and the 
pharmacological MOR variants, mu1 and mu2, argues that mu opioid ligand activity is a 
summation of action across all splice variants (Pasternak, 2004). Thus different 
pharmacological activities given by different mu opioids exist as different mu opioids 
stimulate different MOR splice variants to varying extents. As it has also been shown that 
different MOR splice variants have differing localisations, it is not hard to imagine how 
specific mu opioid ligand-MOR splice variant pairs could generate unique pharmacological 
effects. This goes a long way in reconciling pharmacological classification with the known 
molecular biology of opioid receptors. 
 
DOR and KOR also have reported pharmacological variants. Evidence for DOR 
pharmacological variants came in the form of a lack of antinociceptive cross-tolerance to 
the highly selective delta opioid agonists [D-pen2,D-pen5]enkephalin (DPDPE) and 
deltorphin II (Mattia et al., 1991). DOR mediated antinociception by different DOR 
selective ligands was also sensitive to different opioid antagonists (Jiang et al., 1991). 
Further characterisation of DOR subtypes was conducted by Xu et al. (1991) who also 
provided evidence for two DOR binding sites. 
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The kappa1 and kappa2 binding sites were differentiated based on high and low binding 
affinity (respectively) to KOR ligands such as U69,593, U50,488 and bremazocine (Zukin 
et al., 1988). Subsequently, evidence was presented for the existence of a third kappa 
opioid binding site, kappa3, using the high affinity ligand naloxone benzoylhydrazone 
(Clark et al., 1989). Another study resolved these three kappa opioid binding sites into four 
pharmacological variants (Rothman et al., 1990). 
 
The existence of multiple pharmacological variants of the opioid receptors has attracted 
criticism. Naloxone benzoylhydrazone was recognised as the prototypic kappa3 agonist. In 
a recent study, it was shown that naloxone benzoylhydrazone was a partial agonist at all 
three cloned classical opioid receptors, DOR, KOR and MOR, and a pure antagonist at 
ORL1 (Olianas et al., 2006). Connor and Kitchen (2006) use these data, as well as the fact 
that none of the proposed kappa pharmacological subtypes have ever been cloned, to argue 
that the idea of multiple opioid receptors, KOR in particular, should be put to rest until 
more sound supporting data comes to light. 
 
1.2.3 Homo- and Heterodimerisation of the Opioid Receptors 
 
 
Adding further complexity to the opioid field, opioid receptor homo and heterodimerisation 
has now been characterised. DORs homodimerise in an agonist-dependent manner. DOR 
dimers dissociate to monomers in the presence of increasing DOR agonist, such as [D-
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Ala2,D-Leu5]enkephalin (DADLE). This event preceded internalisation, suggesting a 
relationship between dimerisation and internalisation (Cvejic and Devi, 1997). 
Interestingly, in the same study, the agonist morphine did not produce the same dissociation 
effect. Morphine has also been noted for its unique inability to induce opioid receptor 
internalisation amongst opioid receptor ligands. Arden et al. (1995) demonstrated that 
morphine could not induce receptor internalisation even though [D-Ala2,NMePhe4,Gly-
ol]enkephalin (DAMGO, a selective MOR agonist) could. Morphine is also unable to 
internalise DOR, at concentrations that lead to receptor activation (Keith et al., 1996). 
Wang et al. (2005), using quantitative bioluminescence resonance energy transfer, provided 
supporting evidence for the idea that all opioid receptors have the ability to homodimerise. 
 
A substantial amount of data shows that MOR also heterodimerises with DOR. 
Heterodimerisation of MOR and DOR was demonstrated using immunoprecipitation 
studies as well as bioluminescence resonance energy transfer (George et al., 2000; Gomes 
et al., 2000; 2004; Law et al., 2005; Wang et al., 2005; Rozenfeld and Devi, 2007). Several 
studies have shown that DOR-MOR heterodimerisation has distinct functional 
consequences. Unlike DOR-DOR homodimers, agonist treatment increases the binding of 
DOR and MOR agonists, such as deltorphin II and [D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin 
(DAMGO) to the DOR-MOR heterodimer, and these ligands display synergy at 
heterodimer sites (Gomes et al., 2000). Evidence for in vivo heterodimerisation has also 
been presented. DOR-MOR heterodimers have been isolated from spinal cord membranes 
of the mouse. In line with this, it has been shown that DOR antagonism greatly enhances 
MOR induced analgesia (Gomes et al., 2004). Rozenfeld and Devi (2007) demonstrated 
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that heterodimerisation affects opioid receptor signalling through extracellular-signal 
regulated kinase (ERK). ERK phosphorylation occurs rapidly (within 5 mins) upon opioid 
agonist treatment. The opioid receptor monomer is responsible for this rapid activation. 
However, the DOR-MOR heterodimer induces a robust second phase of ERK 
phosphorylation, not seen when the opioid receptor dimer is not present. MOR (Wang et 
al., 2005) as well as DOR (Jordan and Devi, 1999) has also been shown to heterodimerise 
with KOR in transfected cell studies. 
 
Opioid receptor pharmacology extends beyond dimerisation between the classical opioid 
receptors. MOR can also heterodimerise with ORL1 (Wang et al., 2005). Furthermore, this 
interaction desensitises MOR signalling and is suggested to contribute towards the anti-
opioid effects of the ORL1 receptor. Significant pharmacological interaction seen between 
MOR and cannabinoid signalling may also be, in part, a result of receptor 
heterodimerisation. Using bioluminescence resonance energy transfer, Rios et al. (2006) 
demonstrated close physical interaction between MOR and cannabinoid-1 receptors. 
 
Opioid receptor signalling at the level of the opioid receptor is complicated by multiple 
ligands, receptor variants and receptor interaction. Endogenous as well as exogenous 
ligands display promiscuity with multiple receptor subtypes. Pharmacological opioid 
receptor variants have not been reconciled with the molecular characterisation of multiple 
MOR splice variants and remain unsubstantiated by molecular data. Furthermore, recent 
evidence shows that opioid receptors may signal via both homo- and heterodimers. 
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1.3 Physiological Roles of the Opioid System 
 
Opioid compounds have been used extensively as powerful analgesics. MOR is responsible 
for opiate mediated analgesia, however KOR and DOR also play more subtle, complicated 
roles in pain perception. MOR mediated analgesia occurs directly at the spinal level (in the 
sensory dorsal horns) but also acts at supraspinal sites that are involved in pain such as the 
amygdala, insular cortex, hypothalamus, periaqueductal grey and the medulla. At a cellular 
level, MOR accomplishes these effects by inhibition of inhibitory gamma amino butyric 
acid (GABA) release to activate neurons that inhibit pain or by direct inhibition on neurons 
that cause pain by activating G-protein coupled inwardly rectifying potassium channels 
(reviewed in Fields, 2004). 
 
MOR has been implicated in reward and addiction in the ventral tegmental area-nucleus 
accumbens pathway. MOR stimulation in the ventral tegmental area dis-inhibits 
dopaminergic neurons that project into the nucleus accumbens by inhibition of GABAergic 
neurons. Increases in cAMP levels and cAMP response element binding protein (CREB) 
associated with chronic opiate use in the nucleus accumbens is also linked to tolerance and 
dependence. KOR works in opposition to MOR to inhibit the ventral tegmental area-
nucleus accumbens pathway (reviewed in Nestler, 2004). 
 
Other physiological roles that the opioid system regulates include reward-related feeding 
(reviewed in Levine and Billington, 2004), gastrointestinal transit (reviewed in Bohn and 
Raehal, 2006), respiratory depression (Colman and M
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in Hull and Dominguez, 2007). Pharmacological effects of the opioid system have been 
verified using opioid receptor knockout animals (Tian et al., 1997; reviewed in Kieffer and 
Gaveriaux-Ruff, 2002). Interestingly, MOR knockout (KO) mice displayed defective 
maternal attachment behavior such that mouse pups failed to display signs of distress 
vocalisation when separated from their mothers (Moles et al., 2004). 
 
Importantly, opioids also modulate the immune system. Opioids are immunosuppressive in 
that they alter cytosolic activity and antibody production in immunocytes as well as 
suppressing proliferation of lymphocytes, possibly by direct activation of opioid receptors 
expressed by these cells (reviewed in Wei et al., 2003). In support for a role of the opioid 
receptor system in proliferation in the immune system, homozygous disruption of MOR 
resulted in higher rates of proliferation in myeloid progenitor cells taken from the spleen 
and bone marrow (Tian et al., 1997). 
 
The opioid system has a broad range of physiological roles, the most well known of which 
are in analgesia and reward. KO studies of the opioid receptors have yielded supporting 
evidence for these roles, including modulation of proliferation in the immune system. 
Another proposed role for the opioid receptor system is for modulation of proliferation in 
the CNS. 
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1.4 The Opioid System and Proliferation within the CNS 
 
1.4.1 Opioid Signalling System Expression in the Foetal Brain 
 
1.4.1.1 Opioid Receptor Ligand Expression 
 
Although very few studies have directly investigated opioid signaling and opioid/opioid 
receptor gene expression at the time of neurogenesis in the foetal brain, there is a growing 
body of evidence in the literature that demonstrates all elements of the opioidergic 
signaling system are expressed within the developing foetal brain. Studies that investigated 
the presence of the opioid peptide precursors and their cognate peptidases have made use of 
mRNA in situ hybridisation and immunohistochemistry. Data from the literature showed 
that endogenous opioid peptides, including the enkephalins, dynorphin, and beta–
endorphin, can be found in the foetal rodent brain. 
 
Both met- and leu-enkephalin have been isolated from E13-E16 rat brain homogenates by 
HPLC (Dahl et al., 1982). Extensive proenkephalin mRNA expression has been shown in 
the ventricular zone (VZ) of the lateral ventricle (LV) in the E15 and E21 rat (Leslie et al., 
1998). This study showed that proenkephalin expression was also exclusive to the 
neuroepithelia of the telencephalon. Proenkephalin expression in the rat VZ, however, was 
biphasic such that early in corticogenesis (E13), proenkephalin mRNA expression was 
relatively high, whereas expression dropped to nearly nothing at E17 only to peak again at 
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birth (E22). In another study by Zagon et al. (1994), proenkephalin mRNA was intensely 
expressed in the E18 choroid plexus, although in contrast to Leslie et al. (1998), this study 
reported widespread expression throughout the brain as well. 
 
Several studies have looked at proenkephalin expression in the developing cerebellum with 
particular reference to the external granule layer (EGL), a secondary proliferative zone. 
Proenkephalin mRNA as well as enkephalin protein expression has been reported in the rat 
cerebellum from late gestation to adulthood (Zagon et al., 1985; 1994). Early in 
development, proenkephalin mRNA was expressed in the EGL. In the adult cerebellum, 
this expression was limited to the Purkinje cells and Golgi II cells (Zagon et al., 1994). In 
contrast, proenkephalin mRNA was not found in cells of the EGL by Osborne et al. (1991; 
1993). Interestingly, small amounts of enkephalin peptide were detected in the EGL in the 
same study (Osborne et al., 1993). 
 
Data on the localisation of beta-endorphin expression within foetal neuroepithelia have yet 
to be presented. However, the ontogeny of beta-endorphin within the hypothalamus and the 
pituitary gland has been described. The appearance of proopiomelanocortin (the precursor 
protein to beta-endorphin) immunoreactivity (IR) appears in the rat hypothalamus at E12. 
Proopiomelanocortin IR in the pituitary gland appears at E15 (Khachaturian et al., 1983). 
Interestingly, proopiomelanocortin mRNA expression was higher in the E20 rat 
hypothalamus than in the postnatal rat hypothalamus (Angelogianni et al., 2000). The 
increased expression of proopiomelanocortin mRNA before birth, as opposed to after birth, 
is mirrored in results by Rius et al. (1991) who showed that beta-endorphin was detectable 
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in whole brain homogenates from E11.5 onwards and that these levels peak just before 
birth in the mouse, only to drop off dramatically just afterwards. Beta-endorphin peptide 
remained low even at postnatal day (P)3. Expression of prodynorphin mRNA, which codes 
for KOR peptide-ligand, dynorphin A, is abundant in rat hindbrain neuroepithelia, peaking 
at E15 and dropping to nothing at birth (Leslie et al., 1998). Rius et al. (1991) found that 
dynorphin A was expressed from E11.5, but whole mouse foetal brain homogenates 
exhibited lower amounts of dynorphin A than enkephalin or beta-endorphin peptides. 
Dynorphin A levels in the whole foetal brain were 100 times lower than in the whole adult 
brain. In contrast to the other opioid peptides, the specific, high affinity MOR ligands, 
endomorphin-1 and endomorphin-2 were not expressed at all until P7 in the rat brain (Barr 
and Zadina, 1999); however, met- and leu-enkephalin, which are expressed prenatally, have 
high affinities for MOR. 
 
Further support for a developmental role for the opioid system has come from investigation 
of cell surface peptidases that degrade opioid peptides. Endopeptidase 24.11 
(enkephalinase) is known to cleave and inactivate enkephalins, and also has the potential to 
cleave dynorphin and the endorphins (reviewed in Erdos and Skidgel, 1989). Enkephalins 
are also degraded by aminopeptidase N (reviewed in Luan and Xu, 2007). Interestingly, the 
choroid plexus of the developing rat brain (E14 onwards) strongly expresses enkephalinase 
at the mRNA level (Dutriez et al., 1992; Spencer-Dene et al., 1994) and protein level 
(Spencer-Dene et al., 1994). Enkephalinase IR has also been shown in the ependymal 
linings of the rat brain ventricular system from E14 onward. Inhibition of enkephalinase in 
the whole rat embryo at E9.5 causes gross but asymmetric overgrowth of the 
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prosencephalic neuroepithelia (Spencer-Dene et al., 1994). Thus although enkephalinase 
does have other substrates, such as substance P, the localisation of a major component of 
the opioid system in structures such as the choroid plexus, as well as the VZ of the 
ventricular system further implicates opioid system signaling in development of the brain. 
 
1.4.1.2 Opioid Receptor Expression 
 
Expression of the opioid receptors occurs from their TATA-less promoters (with the 
exception of the mouse exon 11 promoter, which does contain a TATA box (Pan, 2002)) 
and is regulated by numerous transcription factors, indicating complex control over gene 
transcription (Wei and Loh, 2002). The earliest ontological studies that assessed opioid 
receptor radioligand binding in rodent foetal brain homogenates found that [3H]naloxone 
(Coyle and Pert, 1976) and [3H]naltrexone (Clendeninn et al., 1976) binding increased from 
E14 until adulthood. Early in situ studies using radioligand binding for opioid receptors in 
the developing rodent foetus claimed that opioid binding sites within the rat striatal 
subventricular zone (SVZ) first appeared around E14 (Kent et al., 1982, reviewed in Leslie 
and Laughlin, 1993). At E16 (at the peak of cortical neurogenesis in the rat), Kent et al. 
(1982) reported opioid receptor binding in the rat SVZ. This ligand binding extended 
further down into the rat striatal SVZ toward the ventricular wall until E20, when it reached 
the ventricular edge.  
 
In contrast to later studies that failed to identify opioid receptor mRNA in the developing 
cerebellum, early studies also found opioid binding sites within the cerebellum. Etorphine 
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bound to opioid receptors in cerebellar homogenates (Meunier and Zajac, 1979). Binding 
was greatest in molecular layer homogenates although some binding was seen in granular 
layer and white matter cerebellar homogenates of rabbits. DOR, KOR and MOR binding 
sites have been reported in rat and guinea-pig cerebellar homogenates. The density of 
opioid receptor binding sites declines to a low level at adulthood (Barg and Simantov, 
1989). 
 
Some studies that have looked at mRNA distribution in the developing embryo have 
completely discounted the expression of opioid receptors in the VZ of the developing brain. 
Radio in situ hybridisation studies showed no expression of opioid receptors in the 
proliferative regions of the embryonic mouse and rat CNS (Leslie et al., 1998; Zhu et al., 
1998). In contrast, other in situ hybridisation studies found MOR transcript in the rat 
striatal neuroepithelium from E13 onwards (Georges et al., 1998) as well as in the E16 rat 
EGL of the cerebellum (Mrkusich et al., 2004). These findings were consistent with earlier 
ligand binding studies. Tong et al. (2000) also detected MOR mRNA expression in 
germinal zones of the E12 rat brain. An immunohistochemical study of the embryonic 
mouse brain has found evidence of DOR, KOR and MOR expression in the VZ of the 
dorsal telencephalon (Reznikov et al., 1999).  
 
1.4.1.3 Opioid Signaling System KOs 
 
Although the endogenous opioid system is suggested to play a role in development, KO of 
elements of the opioid system produces a remarkable lack of developmental phenotypes 
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(reviewed in Gaveriaux-Ruff and Kieffer, 2002 and Kieffer and Gaveriaux-Ruff, 2002). 
Single opioid receptor KOs and even combined opioid receptor KO mice appear healthy 
and, apart from insensitivity to opioid related responses, relatively normal, indicating no 
major developmental pathologies. 
 
Investigation of developmental processes by way of gene KO has not always provided a 
faithful means of identifying gene function. KO of doublecortin (DCX) (a causative gene in 
type I lissencephaly in humans) in the mouse resulted in normal cortical laminar 
architecture (Corbo et al., 2002). Only when DCX was knocked down via RNA 
interference in the developing rat brain was the human pathology recapitulated (subcortical 
band heterotopias and ectopically positioned neurons) (Bai et al., 2003). The authors of this 
study reconcile their results with the DCX KO study (Corbo et al., 2002) by suggesting that 
gene KO from conception allows the developing system time to implement compensatory 
measures. Also, Bai et al. (2003) state that as knockdown is not 100% effective, some cells 
within the same system will express the target gene at wild type levels. A similar 
observation was reported by Mizutani and Gaiano (2006) who noted that whereas the 
Foxg1 heterozygote KO had no reported developmental defect, an RNA interference 
knockdown of Foxg1 to 50% in cortical progenitor cells produced an observable 
phenotype. Mizutani and Gaiano (2006) also speculated that compensatory measures taken 
by the KO animal may have accounted for this discrepancy. Opioid receptor knockdown 
experiments have been conducted have investigated opioidergic modulation of 
antinociception in the adult rodent CNS (Bilsky et al., 1996; Wang et al., 1996). The 
closest a developmental study has come to acute disruption of the endogenous opioid 
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signaling system (without introducing exogenous opioid receptor ligands) was the 
pharmacological inhibition of enkephalinase by Spencer-Dene et al. (1994), which did 
result in developmental disruption of the brain. 
 
1.4.2 Opiates and Development  
 
1.4.2.1 Opiates and Growth of the Developing Rodent 
 
Early studies using methadone (a MOR agonist used as a narcotic substitute) showed no 
gross teratogenicity with rabbits and rats. It was noted that animals being treated with 
methadone ate less and gained less weight during pregnancy (Markham et al., 1971). The 
same study concluded that methadone was not teratogenic. The apparent lack of 
teratogenicity of methadone was an observation that was backed up by Chandler et al. 
(1975). Chandler et al. (1975) also noted that pups that were dissected out of the mother 
just before birth were lighter than control animals, an observation that was corroborated by 
Hutchings et al. (1976). Buchenauer et al. (1974) reported increased pup mortality and pup 
growth retardation in methadone treated pregnant rats; however, the same study also failed 
to produce any truly teratogenic effects. Methadone treatment over E8-E22 in the rat has 
been shown to reduce birth weight in a dose-dependent manner (Hutchings et al., 1976). 
However, by the time of weaning, methadone-induced weight effects had all but 
disappeared. Hutchings et al. (1976) also showed that the opiate methadone readily crosses 
the placenta to reach the foetus. Methadone administration to rats before, during and after 
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gestation results in lowered RNA and protein content in the brains of the offspring (Peters, 
1977). Peters (1977) also reported lowered DNA content in the brain; however, they also 
noted that these data were in line with a general reduction in body weight. Zagon and 
McLaughlin (1977b) also reported a methadone induced reduction in body size of the pup 
and a reduction in brain DNA content. As well as for methadone, a reduction in rat pup 
body weight during postnatal development was seen with chronic morphine treatment over 
gestation (Tao et al., 2001). 
 
A rigorous study by Hutchings et al. (1992) used osmotic minipumps to administer 
methadone to pregnant rats from E8 until the end of gestation. This study found that 
gradual osmotic release of methadone produced greatly reduced maternal and foetal 
toxicity as compared to equivalent doses of injected methadone in the rat. Hutchings et al. 
(1992) did not see any difference in birth-weights for control or methadone treated animals. 
However, they did report a transitory deficit in growth for high dose methadone pups (15 
mg/kg/day). Interestingly this same group displayed altered rest patterns similar to what has 
been observed in studies that use injections as opposed to osmotic pumps. 
 
In contrast to the results of Hutchings et al. (1976), another study reported lasting weight 
changes in animals exposed to methadone throughout gestation and lactation (Zagon and 
McLaughlin, 1977a). The opioid antagonist, naltrexone (50 mg/kg/day) significantly 
enhanced development in neonatal rats (P0 to P21) (Zagon and McLaughlin, 1983) as 
naltrexone was shown to enlarge bodyweight as well as the size of the brain. Overall, 
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animal studies that investigate the effect of opiates on growth of the foetus and pup 
demonstrate mild negative effects that are dependent on dose and mode of delivery. 
 
1.4.2.2 Human Development and In Utero Opiate Exposure 
 
Opiate drugs are liable to abuse by humans due to their ability to elicit feelings of euphoria 
and extremely high addictive potential. A significant proportion of people who abuse 
opiates are women of child bearing age. Of the studies that analysed the effect of in utero 
opiate exposure on the developing child, early studies demonstrated effects on intellectual 
performance and motor development, as well as behavioural problems (Wilson et al., 1981; 
Rosen and Johnson, 1982; Bunikowski et al., 1998). However, it is now recognised that 
confounding variables such as poly-drug exposure, socio-economic status, parental care and 
small sample sizes were responsible for the early observed effects (Lester et al., 2001). 
Other studies have also noted that detrimental developmental effects associated with in 
utero opiate exposure are more likely a result of poor environmental conditions (Lifschitz 
et al., 1985; Ornoy et al., 1996; Hans and Jeremy, 2001; Lester et al., 2002; Messinger et 
al., 2004). It has been observed that along with opiates, people also abuse cocaine, 
marijuana, tobacco and alcohol (Lester et al., 2001; Lejeune et al., 2006), all of which are 
harmful to the developing foetus. 
 
Even after collection of sufficiently large sample sizes and consideration of detrimental co-
variates such as socio-economic status and poly-drug abuse, in utero opiate exposure still 
has subtle effects on the developing child. After extensive adjustment for co-variates, in 
 25 
utero opiate exposed infants (1 month old) have fewer short utterances and had more 
hyperphonation (very high pitched cries) (Lester et al., 2002). Acoustic parameters of an 
infant’s cry gives information on the biological integrity of an infant. Infants that have 
suffered brain damage of various causes have higher pitch cries. In infants that have 
suffered neurological damage, a higher cry pitch was correlated with a poorer 
neurodevelopmental outcome (Corwin et al., 1996). Infants of opiate abusing mothers also 
displayed longer latencies to wave V on auditory brain stem tests (Lester et al., 2003). This 
represents a slowing of nervous conduction from the cochlea to the inferior colliculus. 
 
1.4.3 Opiates and Cellular Proliferation in the CNS 
 
The effects of opiates on growth, illustrated extensively in animal studies using methadone, 
are largely explained in the literature by an inhibitory effect on cellular proliferation. The 
characterisation of opioidergic modulation of cellular proliferation has culminated recently 
with the finding that opioid receptor signalling is involved in embryonic stem cell 
proliferation and differentiation. Kim et al. (2006) place MOR and KOR expression on 
pluripotent stem cells at embryonic day 3.5, albeit in cell culture. At mitosis, the stem cells 
switched from a symmetric, self-renewing division to an asymmetric division that yielded 
nestin and sox-1-positive neuronal progenitors. Kim et al. (2006) also showed that retinoic 
acid-differentiated embryonic stem cell (neuronal progenitor cell) proliferation was 
inhibited by kappa and mu opioid signalling. KOR stimulation also increased proliferation 
in nestin-positive neural precursor cells isolated from ~E42 human embryonic tissue 
(Sheng et al., 2007). Interestingly, when murine retinoic acid-derived neuronal progenitor 
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cells were exposed to the same kappa and mu opioid agonists, an antiproliferative effect 
was observed (Kim et al., 2006). 
 
1.4.3.1 Opiates and Proliferation in the Rodent Forebrain 
 
Studies have shown that opioids impact upon proliferation in the developing forebrain, 
although few of these studies detail these effects in the foetal forebrain. DOR mediates pro-
neuronal differentiation in the MEB5 cell line (multipotent stem cells taken from E14.5 
forebrain). These cells differentiate to form neurons when exposed to DOR ligand SNC80 
(Narita et al., 2006). In the same study, the selective MOR ligand, DAMGO and the KOR 
selective ligand, U50,488H did not affect proliferation or differentiation. This study 
contrasts with other studies that have found kappa and mu to be responsible for opioid 
mediated effects on proliferation (Barg et al., 1993; Knapp et al., 1998; Kim et al., 2006; 
Sheng et al., 2007).  
 
Reznikov et al. (1999) showed that MOR stimulation by DAMGO in utero modulated the 
cell cycle within the cortical ventricular neuroepithelium of the E16 mouse (labelled E15 in 
our study). The authors of this study showed that acute DAMGO and bremazocine (KOR 
agonist) exposure increased the number of S-phase cells (cells that incorporated 
[3H]thymidine) as well as the number of mitotic nuclei. The authors of this study 
interpreted these data as an increased duration of both S phase and mitosis of proliferative 
cells. In the same study, [D-ser8-leu]enkephalin[Thr] (DSLET) (a DOR agonist) reduced 
the number of [3H]thymidine labelled nuclei and mitotic nuclei. 
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Unfortunately, Reznikov et al. (1999) indicated that they used only one pregnant dam per 
experimental group. The use of multiple littermates in one experimental group to inflate the 
n value leaves the study susceptible to confounding litter effects (discussed further in 
Chapter 2) (Holson and Pearce, 1992; Zorrilla, 1997). Interpretation of the study by 
Reznikov et al. (1999) must be approached with caution.  
 
In the postnatal forebrain, morphine decreased [3H]thymidine incorporation into the rat 
brain at P1 and P4. Older rats (up until P12) did not show this effect (Kornblum et al., 
1987). Morphine treatment (from E12-P6) has also been shown to modulate corticogenesis 
in vivo in the developing rat by reducing neuronal density of the somatosensory cortex 
without affecting its thickness (Seatriz and Hammer, 1993). Interestingly, in the same 
study, naltrexone administration did not increase numbers of neurons. Beta-endorphin 
produced a robust decrease in [3H]thymidine incorporation in the brain that persisted for 11 
h in the P20 rat (Bartolome et al., 1991). This affect was successfully antagonized by 
naloxone. Lorber et al. (1990) demonstrated that proliferation in the postnatal brain showed 
a developmentally sensitive response to beta-endorphin mediated inhibition with maximal 
effect observed during P4-P8. Beta-endorphin mediated inhibition of DNA synthesis in the 
pre-weanling rat brain was also antagonized by a sulfated fragment of cholecystokinin 
(Bartolome et al., 1994). DNA synthesis in the P11 forebrain also decreased in response to 
[D-Met2-Pro5]enkephalinamide (Vertes et al., 1982).  
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Opioid antagonism also has effects on the postnatal forebrain. Naloxone shows biphasic 
effects on DNA synthesis in the P11 rat brain (Vertes et al., 1982). Incorporation of 
[3H]thymidine in the forebrain increased in response to naloxone treatment up until 3 h 
post-treatment. Proliferation then dropped dramatically lower than in control animals. In 
addition, it was shown that the opiate antagonist, naltrexone, produced a long-lasting 
increase in cellular proliferation in the 4-12 week old rat subependymal zone (Schmahl et 
al., 1989). Amazingly, this effect was still present 11 weeks after naltrexone treatment had 
ceased. Naltrexone, however, did not produce a difference in [3H]thymidine incorporation 
in the brain of rats younger than two weeks of age (Kornblum et al., 1987). 
 
Seatriz and Hammer (1993) showed that naltrexone treatment from E12-P6 in the rat 
increased cortical thickness but did not have an effect on the number of neurons in the 
cerebral cortex. Zagon and McLaughlin (1986b) studied the effect of different doses of 
naltrexone on the postnatal cerebral cortex (P0-P21). This study showed that whereas high 
dose naltrexone (50 mg/kg/day, subcutaneous (s.c.) injection), or permanent opioid receptor 
blockade, decreased the density of neurons in the cerebral cortex (in accordance with the 
study of Seatriz and Hammer, (1993)), low dose naltrexone (1 mg/kg/day, s.c. injection), or 
temporary opioid receptor blockade, increased the density. These changes in density 
occurred simultaneously with changes in cortical thickness such that it was not likely that 
the absolute number of neurons in the cortex had changed. 
 
In light of these data that support an inhibitory mode of action for opioid ligands and 
cellular proliferation in the developing rodent forebrain, it is surprising that acute morphine 
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treatment increases [3H]thymidine uptake in the subependymal zone of the adult rat 
(Messing et al., 1979; Miller et al., 1982). Interestingly, in the same studies, naloxone by 
itself did not have an effect. This indicates that there is no tonic control by the opioid 
system over proliferation in the adult forebrain. Thus in the developing forebrain, there is a 
great paucity of data for how opiates affect proliferation during embryogenesis. However, 
the data that exists for opioids and cellular proliferation in the postnatal forebrain details a 
temporally sensitive relationship that requires further clarification. 
 
1.4.3.2 Opiates and Proliferation in the Cerebellum 
 
Cell counts demonstrated cell numbers in the cerebellum were markedly increased in both 
the internal granule layer and the molecular layer in response to naltrexone treatment (50 
mg/kg/day) in neonatal rats (P0 to P21) (Zagon and McLaughlin, 1983). Zagon and 
McLaughlin (1986a) added to their 1983 study by showing that as high dose naltrexone 
increased cerebellar size, low dose naltrexone reduced cerebellar size. During this postnatal 
period, proliferative activity in the cerebellum is also inhibited by beta-endorphin (Lorber 
et al., 1990). 
 
Interestingly, in vitro, neural precursors taken from the EGL of the cerebellum significantly 
decreased proliferation in response to morphine (Opanashuk and Hauser, 1998; Hauser et 
al., 2000). Opanashuk and Hauser (1998) demonstrated that the substantial reduction in 
proliferation induced by morphine in EGL neuroblasts was completely overridden by 
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heparin binding epidermal growth factor, suggesting a degree of interaction between opioid 
and EGF signaling pathways. 
 
1.4.3.3 Opiates and Proliferation in the Adult Hippocampus 
 
Unlike in the developing brain, where opioids fulfill an inhibitory function with regards to 
cellular proliferation, studies that have investigated the impact of opioidergic modulation of 
proliferation in the hippocampus have, at face value, been conflicting and are most likely 
reflective of an extremely complicated relationship between opioids and proliferation in the 
adult hippocampus. Chronic morphine treatment dramatically decreased cellular 
proliferation (Eisch et al., 2000; Mandyam et al., 2004) and decreased polysialylated 
NCAM expression (Kahn et al., 2005) in the adult rodent hippocampus. Importantly, 
morphine-induced decrease in hippocampal proliferation was also shown to be independent 
of hormone release from the adrenal gland, since rats that had undergone adrenalectomy 
showed the same antiproliferative response to morphine exposure (Eisch et al., 2000). 
Adrenal hormone release itself impacts upon neural proliferations (Gould et al., 1992). 
However, acute morphine exposure (2 h prior to BrdU labelling) did not inhibit 
proliferation (Eisch et al., 2000). Interestingly, in the same chronic morphine treatment 
regime in the mouse, morphine exposure elicited premature mitosis (Mandyam et al., 
2004). These results appear contradictory to studies of morphine exposure in the 
hippocampus by Persson et al. (2003a; 2003b). 
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In vitro, adult hippocampal progenitor cells (AHPs) were sensitive to both mu and delta 
opioid ligands. AHPs, however did not express KOR nor did they respond to its ligands 
(Persson et al., 2003a). MOR and DOR signalling in AHPs in vitro caused increased 
proliferation, indicating a direct signalling pathway for opioids and cellular proliferation in 
the hippocampus. Conversely, opioid antagonism decreases proliferation of AHPs in vitro 
(Persson et al., 2003b). Opioid antagonism with a non-selective opioid antagonist, 
naloxone, was found to decrease proliferation of AHPs. A similar result was seen with 
MOR selective antagonist, beta-FNA and DOR antagonist, naltrindole. Opioid antagonism 
with acute naltrexone also decreased cellular proliferation in the adult hippocampus 
(Holmes and Galea, 2002), although these results are directly contradictory to the studies 
by Eisch et al. (2000) and Mandyam et al. (2004) that showed an inhibitory effect of 
morphine, an agonist, on proliferation. Opioid receptor antagonism with naloxone 
(presumably through MOR and DOR) was also shown to affect differentiation (Persson et 
al., 2003b). After 10 days of treatment, naloxone decreased gliogenesis (for both astrocytic 
and oligodendrocytic markers). Naloxone exposure increased numbers of cells expressing 
the neuronal markers MAP2ab and alpha-internexin. These data suggest an anti-neuronal 
role for opioid signalling and differentiation in AHPs, which contrasts with the pro-
neuronal differentiation observed in embryonic stem cells (Kim et al., 2006). 
 
Proliferation in the hippocampus of spontaneously hypertensive rats is increased by chronic 
naltrexone treatment (Persson et al., 2004). However, this effect of opioid signalling on 
cellular proliferation is extremely context dependent. For example, in the same study it was 
shown that naltrexone decreased proliferation in the hippocampus after the rats had been 
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exercising. Ra et al. (2002) demonstrated that exercise increases cellular proliferation in the 
adult hippocampus but failed to show an effect with naloxone. Persson et al. (2004) also 
demonstrated an increase in met-enkephalin in the hippocampus of exercising rats. This 
increase correlates well with the observed increase in proliferation (which, in the adult 
hippocampus, correlates mainly to neurogenesis (Harburg et al., 2007)).  
 
Two recent studies using knockout (KO) mice have clearly shown that the 
endogenous opioid system modulates neurogenesis in the adult hippocampus. 
Kolodziej et al. (2008) using a MOR KO demonstrated that the KO mouse showed 
increased hippocampal neurogenesis after ischemic brain injury, while Koehl et al., 
(2008) using a beta-endorphin KO showed that the increased hippocampal 
proliferation due to exercise was dependent on beta-endorphin. These studies firmly 
establish a role for the opioid system in adult neurogenesis. This context dependency 
 (exercising or sedentary) could explain the discordance between the studies of Eisch 
et al. (2000), Mandyam et al. (2004) and Kahn et al. (2005), with those of Holmes and 
Galea (2002) and Persson et al. (2003a; 2003b). Although beta-endorphin signals 
through both DOR and MOR, the selective DOR antagonist, naltrindole, had no effect 
on proliferation in the hippocampus of running rats (Persson et al., 2004) suggesting 
that MOR was the receptor involved in the observed modulation of hippocampal 
proliferation. 
 
1.4.4 Met-Enkephalin (Opioid Growth Factor) and OGFr 
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As well as the classical opioid receptors (DOR, KOR and MOR), OGFr is proposed to 
mediate proliferation on stimulation with the opioid ligand, met-enkephalin (Zagon et al., 
1999a). A large amount of material has been published on the effects of the opioid growth 
factor receptor by Zagon and colleagues detailing the inhibitory growth effects of the 
opioid growth factor receptor in cancer, angiogenesis and developing systems (reviewed in 
Zagon et al., 2002). However, this data awaits corroboration from other labs. 
 
1.4.5 Other Opioid Effects on Neuronal Cells in the Developing Brain 
 
As well as affecting neuronal proliferation, opiates also modulate other aspects of neurons 
such as spine formation and neurite outgrowth. Hauser et al. (1987; 1989) demonstrated 
that chronic blockade of opioid receptors using naltrexone (50 mg/kg/day) increased both 
dendrite length and spine number in the hippocampus, cerebral cortex and the cerebellum. 
Intermittent opioid receptor blockade using low doses of naltrexone (1 mg/kg/day) 
inhibited growth of dendrites and spine number (Hauser et al., 1989). A later study showed 
that DOR stimulation also decreased neurite length, interpreted as evidence for a role in 
modulating differentiation (Hauser et al., 2000). 
 
Methadone has been shown to reduce outgrowth from cerebellar explants taken from 
neonatal rat pups. Additionally, explants taken from the rat pups that were exposed to 
methadone during gestation also showed reduced outgrowth (Willson et al., 1976). In 
contrast, cellular and neuritic outgrowth from explants of embryonic and neonatal rat 
sympathetic and dorsal root ganglia and spinal cord were greatly enhanced by opioid 
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peptide treatment (Ilyinsky et al., 1987). Thus opioid effects on outgrowth of neurites can 
be positive or negative depending on the region examined. 
 
1.4.6 Opiates and Gliogenesis 
 
A large body of literature that was established in the 1990s details how opiates impact upon 
macroglial proliferation, in vitro. Macroglia is the collective term for astrocytes and 
oligodendrocytes in the CNS. Astrocytes were once regarded as simply support cells for 
neurons. However, more and more research is outlining much more complicated roles for 
astrocytes that range from the expression of neuropeptide systems, such as the opioid 
system as well as assuming the role of neuronal progenitors (see below). Oligodendrocytes 
are involved with myelination in the CNS that is responsible for the efficient conductance 
of action potentials down axons. 
 
1.4.6.1 Expression of Opioid Receptors and Ligands in Macroglia 
 
Endogenous opioid signaling components have been characterised in macroglia of the 
developing brain. Opioid system ligands are expressed by astrocytes in primary culture 
(Vilijn et al., 1988; Hauser et al., 1990; Stiene-Martin et al., 1991a). Cultured astrocytes 
from neonatal rat brains expressed large amounts of proenkephalin mRNA and peptide that 
was regulated by cAMP signalling (Shinoda et al., 1989). Melner et al. (1990) found that 
only the flattened, adherent, type I astrocytes cultured from the neonatal rat brain, 
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expressed proenkephalin mRNA, as opposed to the stellate type II astrocytes or the 
oligodendrocytes. Spruce et al. (1990) showed that proenkephalin protein was expressed by 
astrocytes in vitro when taken from P8 rats. This expression increases into adulthood. The 
same study also showed that immunohistochemical staining for proenkephalin peptide in 
histological sections of rat cerebellum first appeared at P5. Developmentally regulated 
temporal changes in proenkephalin mRNA expression also exist in the rat brain. In primary 
cultures of astrocytes taken from both the cerebellum and the cerebrum, proenkephalin 
mRNA expression increased from E20 to adulthood. Interestingly, met-enkephalin peptide 
was shown to decrease markedly from E20 to adulthood (Shinoda et al., 1992). In addition 
to temporal patterns of enkephalin expression, astrocytes also display differential spatial 
patterns. This was cited as an example of how astrocytes mimic what were once considered 
to be the exclusive properties of neurons (Shinoda et al., 1989; Ruzicka et al., 1995). 
 
Macroglia also express opioid receptors. Astrocytes taken from 1 day-old mice expressed 
DOR, KOR and MOR (Ruzicka et al,. 1995; Stiene-Martin et al., 1998). Strikingly, opioid 
receptor expression was shown to interact with the cell cycle. Of the neonatal astrocytes 
that expressed MOR and DOR, a disproportionately large number of these astrocytes were 
in the G2/M phase of the cell cycle as compared to their non-opioid receptor expressing 
counterparts (Stiene-Martin et al., 1998). As well as differential temporal expression 
patterns, astrocytes also exhibited differential opioid receptor expression profiles depending 
on which part of the brain they were cultured from (Ruzicka et al,. 1995). 
Oligodendrocytes, in vitro, expressed both MOR and KOR, in that order during 
differentiation (Knapp et al., 1998). In vivo, opioid receptors on macroglia showed cell and 
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developmental-specific expression patterns. A higher percentage of both GFAP-positive 
astrocytes and O4-positive oligodendroglia expressed opioid receptors in the SVZ of the P5 
mouse than in the adult mouse SVZ. Of the opioid receptors, MOR was the most highly 
expressed (Stiene-Martin et al., 2001). 
 
1.4.6.2 Opioids and Macroglial Proliferation 
 
Morphine (Stiene-Martin et al., 1991b; Stiene-Martin and Hauser, 1993; Hauser et al., 
1996), and other opioid receptor ligands (Stiene-Martin and Hauser, 1990; Hauser and 
Stiene-Martin, 1991; Stiene-Martin and Hauser, 1991) have been shown to consistently 
decrease DNA synthesis in cultured type I astrocytes taken from neonatal rodent brain. Just 
as proenkephalin expression in primary cultures of astrocytes and opioidergic modulation 
of proliferation in the postnatal forebrain displayed developmentally regulated patterns of 
activity, opioid-induced reductions in proliferation of macroglia, in vitro, also displayed 
temporal patterns (Hauser and Stiene-Martin, 1991). Cultured astrocytes taken from 
neonatal mouse brains showed reduced proliferation in response to met-enkephalin 
treatment, when taken from P3 or P5 mouse brains. Inhibition of proliferation was not seen 
in astrocytes taken from P19 mice. Intriguingly, astrocytes did not display decreased 
proliferation when taken from E19 mouse brains early during cell culture (within 6 days in 
vitro). However, cells were affected by met-enkephalin when maintained in culture for 11 
days or more, suggesting that additional maturation was needed before the astrocytes 
became receptive to opioid mediated antiproliferative affects (Hauser and Stiene-Martin, 
1991). Stiene-Martin et al. (2001) showed that morphine negatively, and naltrexone 
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positively influenced DNA synthesis in astroglia within neonatal (P2-5) murine SVZ and 
striatum. In contrast to astrocytes, immature oligodendrocytes show increased proliferation 
in vitro with a MOR specific ligand, PL017. This effect was not observed in more mature 
oligodendroglia (Knapp et al., 1998). 
 
1.4.7 Opioid Receptor Signalling Pathways Associated With Proliferation 
 
Considerable work has gone into elucidating the relationship between opioids, proliferation 
and mitogen activated kinase (MAP kinase) pathway signalling. The MAP kinase pathway 
is important for cellular proliferation (reviewed in Raman et al., 2007) and neuronal 
differentiation of embryonic stem cells (Li et al., 2006). Opioid receptors have been shown 
to influence ERK phosphorylation in AHPs (Persson et al., 2003b), embryonic stem cells 
(Kim et al., 2006) as well as in glial cell lines (Bohn et al., 2000a,b; Belcheva et al., 2003; 
Belcheva et al., 2005). However, different opioid receptors stimulate the ERK pathway via 
different mechanisms (Belcheva et al., 2005). Belcheva et al. (2005) provided evidence 
which supports the following series of signalling events from MOR and KOR stimulation 
in astrocytes. Signalling via MOR with DAMGO in neonatal rat cortical astrocytes initiated 
a signalling cascade that activated phospholipase C (PLC) via calmodulin release from 
MOR (c.f. Wang et al., 1999), resulting in the generation of the secondary messenger, 
diacylglycerol (DAG). DAG release stimulated the phosphorylation of protein kinase C 
(PKC)-epsilon. PKC-epsilon is thought to activate the metalloprotease, A Disintegrin And 
Metalloproteinase (ADAM) which has been shown to release epidermal growth factor 
(EGF) ligands from the cell membrane (Prenzel et al., 1999). This stimulated EGF 
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receptors (Belcheva et al., 2000; 2003) and ultimately, the MAP kinase pathway (Belcheva 
et al., 2005). In systems that do not express EGF, such as C6 glioma cells, MOR signalling 
transactivated the fibroblast growth factor (FGF) receptors (Belcheva et al., 2002).  
 
KOR signals to ERK via a mechanism that differs from MOR-ERK signalling. KOR 
mediated release of the G-beta-gamma subunit activated phosphoinositide-3-kinase (PI3K)-
gamma. This was proposed to activate the atypical PKC-zeta via a PIP3-3’-PI dependent 
protein kinase 1 complex (c.f. Hirai and Chida, 2003). PKC-zeta then mobilized calcium 
ions. KOR trans-activation of the EGF pathway was dependent on calcium release, and it is 
thought that this may modulate proteases such as ADAM (Belcheva et al., 2005). The 
calcium dependent nature of KOR signalling and proliferation is corroborated by studies 
from the Hauser group. As well as inhibition of proliferation, morphine exposure also 
caused premature maturation in astrocytes which occurred through a calcium dependent 
mechanism. This effect was shown to be a result of KOR, rather than MOR stimulation by 
using receptor specific ligands (Stiene-Martin et al., 1993). Signaling through KOR was 
subsequently shown to increase intracellular calcium while decreasing proliferation 
(Gurwell et al., 1996). 
 
Chronic morphine inhibits astrocyte replication via MOR signalling through a mechanism 
that depends on intracellular calcium stores and calcium mediated calcium release (Hauser 
et al., 1996). This effect was only seen after 48 h of exposure, thus, chronic opioid 
treatment at the cellular level has dramatically different effects from acute exposure 
(measured in intervals that last 5-10 min in studies by Belcheva et al. (2005) on cultured 
 39 
astrocytes). Interestingly, chronic (>2 h) MOR and KOR activation induces a decrease in 
EGF induction of ERK phosphorylation in COS-7 cells (Belcheva et al., 1998). In support 
of a mechanism by which opioids signal via receptor tyrosine kinases, morphine was not 
able to induce any inhibitory effect on proliferating neuroblasts in the presence of heparin-
binding-EGF (Opanashuk and Hauser, 1998).  
 
These studies demonstrate that opioid receptors can signal to the MAP kinase pathway via 
transactivation of EGFR. Transactivation of EGFR via liberation of membrane EGFs such 
as heparin-binding-EGF by ADAM metalloproteases (Prenzel et al., 1999) has emerged as 
an important mediator of GPCR signaling (Rozengurt, 2007). A number of different GPCR 
agonists can signal via ‘triple-membrane passing signaling’ via EGFR including 
angiotensin II, ATP, bombesin, bradykinin, carbachol, endothelin, phenylephrine, thrombin 
(reviewed in Wetzker and Bohmer, 2003), as well as the cannabinoid receptor agonists, 
anandamide, THC and Win55,212-2 (Hart et al., 2004). Although signaling from GPCRs to 
the MAP kinase pathway may be modified by more classical means of intracellular 
signaling. This includes activation of PLC, generation of DAG, and phosphorylation of 
PKC, raf, MEK and ERK (Rozengurt, 2007). Activation of ERK itself has been implicated 
with proliferation in a number of ways and has been labeled as a regulator of G1 to S phase 
transition (Meloche and Pouyssegur, 2007). Roovers and Assoian (2000) suggested that 
both the duration as well as the intensity of ERK activation impacts on proliferation, as 
ERK activation has been associated with both proliferative and anti-proliferative effects. 
Whereas strong induction of ERK followed by sustained moderate activation leads to 
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proliferation, a strong induction followed by sustained strong induction will arrest the cell 
cycle. 
 
Opioidergic activation of ERK is context dependent, which is reminiscent of the extremely 
variable, or case dependent relationship between opioids and proliferation that is 
demonstrated in the literature. Opioidergic activation of ERK in embryonic stem cells is 
sustained over 24 h and is responsible for neuronal differentiation (Kim et al., 2006). In the 
same study, opioidergic stimulation of ERK in neuronal progenitor cells (which are 
analogous to radial glia and express astrocytic markers such as astrocyte-specific glutamate 
transporter (GLAST) (Bibel et al., 2004)) was shown to be transient and independent of 
observed antiproliferative effects (Kim et al., 2006). Rat cortical astrocytes display only 
transient increases in ERK phosphorylation upon DAMGO administration, whereas, 
U69,593, a KOR agonist, elicits a sustained activation. KOR signalling with U69,593 in C6 
glioma cells is potently mitogenic (Bohn et al., 2000a). In the same astrocytic glia, MOR 
signalling strongly counters the proliferative effects of kappa opioid signalling as well as 
the mitogenic effect of endothelin by inhibiting phosphoinositide and MAP kinase 
signalling pathways (Bohn et al., 2000b). It is interesting that opioids have shown very 
different effects in vitro in what are, apart from embryonic stem cells, all essentially cells 
that display astrocytic markers. However, these studies illustrate at a cell autonomous level, 
that opioidergic signalling affects proliferation, potentially and interestingly through a 
second extracellular receptor tyrosine kinase signalling system, the EGF receptor. 
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Opioid receptor signalling is also influenced by receptor desensitisation. MOR 
desensitisation is considered a mechanism that participates in opiate tolerance (Christie, 
2008). MOR internalisation can contribute to receptor desensitisation. After activation by 
an agonist (such as DAMGO), MOR is phosphorylated by G-protein-coupled receptor 
kinase 2 which results in binding of beta-arrestin 2. This can lead to receptor internalisation 
by a dynamin dependent-dependent mechanism (Connor et al., 2004). Interestingly, 
morphine induced MOR desensitisation can occur in the absence of beta-arrestin 2 (Chu et 
al., 2008). 
 
The literature published on how opioids affect development has several main themes. 
Opioids have a negative impact on growth in the developing brain, apart from in neuronal 
progenitor cells taken from the human, where KOR activation stimulates proliferation 
(Sheng et al., 2007). There is a large body of literature to show that opioids inhibit 
proliferation in macroglia, but again, this has its exceptions. In the adult, the relationship 
between opioids and proliferation is context dependent and appears unpredictable. The 
complicated relationship between cellular proliferation (particularly in the adult brain) and 
opioids mirrors the many levels of complexity resident within opioid system signalling. 
Opioid ligands display often promiscuous opioid receptor binding. A cell may express any 
one or any combination of the three opioid receptors, which are all under complicated 
transcriptional control. Of the three opioid receptor genes, multiple pharmacological classes 
and splice variants (at least for MOR) exist. Opioid receptors may also homo or 
heterodimerise. Each of these receptors may associate with different subtypes of G-protein 
and are capable of signalling through multiple secondary messengers, as well as different 
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receptor systems. Context dependency of opioid signalling effects on development on both 
a cell type-specific as well as a temporal level has been noted previously (Hauser and 
Mangoura, 1998). Even given all of this, opioid receptor knockout animals demonstrate that 
opioids are not strictly necessary for normal development and therefore are only a part of a 
milieu of incoming antiproliferative/proliferative signals that interact and impact upon each 
other.  
 
When all the data is taken into account, it supports the idea that the opioids represent a 
system that a developing or proliferating system may use to modulate or alter events that 
are already unfolding and are largely under the control of other molecular systems and 
programs. The idea that the opioid system occupies a lower-level role in development and 
proliferation that influences more dominant molecular systems operating at the time, 
accounts for the often contradictory and complicated observations that arise from research 
that involves opioids and proliferation in the CNS. Perhaps the answer to the question 
“what is the role of the opioid system in development and proliferation?” is simply, “it 
depends on what molecular systems are already operating within a proliferative 
environment”. Further research on opioids and development must therefore be placed 
within the specific context of the whole developing brain. This prospect is exciting given 
the huge increase in knowledge on brain development that has been generated by means of 
sensitive genetic and molecular techniques (reviewed in Rakic, 2006) since the 1980s and 
1990s when most of the background studies on brain development and opioids were 
conducted. 
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1.5 The Cerebral Cortex 
 
The cerebral cortex is arguably the one structure that makes us human (Rakic, 2006). The 
cerebral cortex is massively expanded in primates, and it is thought that the large size of the 
human cerebrum is due to mutations in genes that are attributed to microcephaly, a disease 
characterised by reduced cranial volume and mental retardation. These genes are all 
associated with the mitotic spindle and are thought to be involved with determining 
asymmetric or symmetric cellular divisions in the embryonic brain (reviewed in Cox et al., 
2006). Interestingly, an allele of the ASPM gene, the most frequently mutated gene in 
microcephaly, is still under positive selection pressure in the human species, suggesting 
human brains are still evolving (Mekel-Bobrov et al., 2005). 
 
Each hemisphere of the cerebrum in humans is divided into different lobes that are made of 
convoluted sulci and gyri to allow for efficient packaging of cortical tissue. These lobes are 
the frontal, parietal, temporal and occipital lobes. The frontal lobe contains the primary 
motor cortex that controls movement in the body in conjunction with the basal ganglia, 
cerebellum, brain stem and spinal cord. The parietal lobe contains the primary 
somatosensory cortex that contains a map of the sense of touch of the human body. The 
temporal cortex contains the auditory primary cortex, and the occipital lobe houses the 
primary visual cortex. The cerebral cortex is also responsible for aspects of our personality 
(particularly the frontal lobe), language, memory and integration of sensory information in 
regions of association cortex (adapted from Kandel, 2000). 
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1.5.1 Cerebral Development 
 
The human brain develops from the primary cerebral vesicles. These consist of the 
hindbrain (rhombencephalon), the midbrain (mesencephalon) and the forebrain 
(prosencephalon). The rostral portions of the prosencephalon that contribute to the 
formation of the cerebral cortex gives rise to the telencephalon. After the prosencephalon 
develops, two lateral diverticula appear that form the optic vesicles. Before the end of the 
fourth week of gestation, rudiments of the cerebral hemispheres appear as two “pouches” 
either side of the forebrain.  The growing cerebral hemispheres of the telencephalon 
proceed to enlarge forwards, upwards and backwards such that the cerebral hemispheres 
acquire an oval shape. It is in this way that the medial regions of the cerebral hemispheres 
become separated by the longitudinal fissure. The very large cerebrum present in mammals, 
especially in humans, continues to grow caudally to overlap the diencephalon (by the 
second month of gestation), mesencephalon and the cerebellum. The surface of the 
cerebrum remains smooth until the beginning of the fourth month. By the seventh month all 
major sulci are present as the cerebral cortex expands in size (adapted from Warwick and 
Williams, 1973). How the cerebral cortex develops at the cellular level, however, is 
currently a subject of much research. 
 
1.5.2 Histogenesis of the Cerebral Cortex 
 
After splitting of the preplate to form the marginal zone and the subplate, the cerebral 
cortex forms in an inside-out manner (Angevine and Sidman, 1961) in a tight 7-day period 
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of cellular proliferation during late gestation in the mouse (E12 to E18) (Takahashi et al., 
1996a); corticogenesis takes almost 17 times longer in humans, but the process is similar 
(reviewed in Caviness Jr. et al., 1999). In the mouse (a highly utilised animal model for 
corticogenesis), the 7-day ‘neurogenic interval’ is comprised of 11 integer cell cycles 
(Takahashi et al., 1995a). Cellular proliferation that fuels generation of the cerebral cortex 
occurs in the VZ (so named by the Boulder Committee (1970)), a pseudo-stratified epithelia 
which rests below the developing cortical plate (Fig. 1.2, panel B). The VZ consists of two 
broadly defined populations of cells – the proliferative pool of cells (P) and the quiescent, 
migrating neuroblasts that have exited the cell cycle (Q) (Takahashi et al., 1993). Once 
neurons have been born in the VZ, they migrate up towards the developing cortical plate 
via the radial glial scaffold. This idea was first put forward by Rakic (1972) and Levitt and 
Rakic (1980), who used histological analysis of glial fibre tracts and migrating neuroblasts 
to obtain clues to the cells’ developmental relationships. In the rodent, excitatory neurons 
migrate radially up radial glial fibres from the VZ of the dorsal telencephalon. In contrast, 
inhibitory neurons that populate the murine cerebral cortex must migrate from the medial 
and lateral ganglionic eminences, in the ventral telencephalon, in a tangential manner (Fig. 
1.2, panel A) (reviewed in Parnavelas, 2000; Nadarajah et al., 2003). 
 
1.5.3 A Model of Corticogenesis 
 
Corticogenesis in the mouse has been divided into three stages (Smart, 1973), based on the 
type of cell output of the VZ. In the developing mouse telencephalon, stage one (E10 to 
E12) is dominated by proliferation that enlarges the progenitor cell pool of the VZ, that is, 
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no differentiation takes place. Stage two (E13) is characterised by a balance between 
proliferation and differentiation. Stage three (E14 to E18) is dominated by neurogenerative 
proliferation with the progenitor cell pool beginning a steady decline. By E18 the 
pseudostratified epithelium of the VZ is replaced by the cuboidal epithelium of 
subependymal layer (Takahashi et al., 1995a). Previously, it was thought that neuronal 
corticogenesis ceased at the end of gestation in the mouse. Astonishingly, however, GFAP-
positive astroglia in the P5 mouse brain were shown to be the ancestors of neurons that 
integrated into the cerebral cortex (Ganat et al., 2006). 
 
During corticogenesis in the mouse embryo, proliferative cells undergo a lengthening in 
cell cycle that had been described in a number of studies using cumulative BrdU labelling. 
At E11, proliferative cells had an average cell cycle time of 8.1 h (Takahashi et al., 1995a). 
At E16, the practical limit of cumulative BrdU labelling in the VZ, the cell cycle increased 
to 18.4 h. This was due to a 4-fold increase in G1 phase (Takahashi et al., 1995a). Although 
the vast majority of work on the developing cerebral cortex has been conducted in the 
rodent, the primate neurogenic interval was characterised by an increase in cell cycle time 
from 22.7 h at E40 (the onset of primate neurogenesis in the cerebral cortex) until mid-
corticogenesis when the cell cycle time was 54.1 h. Surprisingly, this was followed by a 
large decrease in cell cycle time to 27.4 h at the commencement of genesis of layer III of 
the cerebral cortex (Kornack and Rakic, 1998). 
 
As cell cycle time increases in the rodent VZ, so does neuronal output. Two fractions of 
cells exist within the neurogenic embryonic VZ, the P and Q cellular fractions. At E11, the 
 47 
P fraction for the VZ is 1 (Takahashi et al., 1996a). This means that all divisions within the 
VZ will produce two more proliferative cells. As corticogenesis progresses, this P fraction 
steadily decreases. By E14, after 8 of the 11 neurogenic cell cycles have elapsed, the P 
fraction drops below 0.5. This marks the point at which the VZ stops growing, and begins 
to shrink. This continues until E17, at which point it disappears entirely and is replaced by 
the ependymal layer that surrounds the LV in the adult. A simple relationship between Q 
(for a given cell cycle) and cell cycle number has been proposed (Caviness et al., 1999). Q 
is proportional to the square of the cell cycle number (CC, which in the mouse, for 
example, can be anything from 1 to 11). This relationship is also modified by a constant, k, 
which is species specific. 
 
Q = kCC1.97 
 
The total neuronal output from the neurogenic interval is modified by the constant k, which 
is 0.009 in the mouse. This produces 11 integer cell cycles in which the cerebral cortex is 
produced (at which time, Q = 1). By decreasing this species-specific constant, the total 
output of the neurogenic interval is increased. For example, to produce a brain the size of a 
monkey’s, k drops to 0.0016. This results in a neurogenic interval that is 28 cell cycles 
long. 
 
The observation that cell cycle length increases with neuronal output is more than just 
correlation. An elegant study by Calegari and Huttner (2003) showed that neurogenic 
progenitors (Tis21-positive) had longer cell cycle times than their proliferative 
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counterparts. Using cumulative BrdU labelling to give an indication of cell cycle time, it 
was reported that neuronal progenitors in the same neuroepithelia, at the same time in 
development, had different cell cycle times depending on what progeny they were 
committed to produce. These observations prompted a theory of neurogenesis, put forward 
by Götz and Huttner (2005). Essentially intrinsic determinants that influence the fate of the 
cell (to remain within the P fraction or to become a part of the Q fraction) exert their effect 
during a certain part of the cell cycle, i.e.: G1 phase. However, these determinants require 
time to work. Therefore, a cell that cycles through G1 quickly will not be sufficiently 
influenced to leave the cell cycle and will remain proliferative. However, a cell that takes a 
long time to transition through G1 will incur a higher probability of cell cycle exit. 
 
The rate of change of Q for cells in the VZ does not vary and is proposed to be guided 
almost solely by cell-intrinsic mechanisms (Caviness Jr. et al., 1999). It has previously 
been shown that early neuronal progenitor cells which produce neurons destined for the 
lower (VI and V) cortical layers, can contribute to upper cortical layers when transplanted 
to a developmentally more mature VZ (McConnell, 1988). However, the reverse is not true. 
Progenitor cells taken from an older developing cortex cannot generate earlier, lower layers 
of cortex (Frantz and McConnell, 1996). These studies show cell intrinsic fates are 
important in neuronal maturation; however, cells can also be manipulated by the 
surrounding environment. The idea that developmental maturation of cortical progenitors is 
guided by cell intrinsic mechanisms gained further support with the discovery that before 
the first quiescent cell emerges in the telencephalon, some clonal lineages are already 
entirely restricted to glial fates (McCarthy et al., 2001). Shen et al. (2006) further 
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elaborated on cell intrinsic cues within the developing cerebral cortex by showing that 
cortical progenitor cells taken from E10.5 mouse brains and grown in vitro first gave rise to 
Cajal-Retzius cells, followed by deep layer neurons and finally upper layer neurons. Cajal-
Retzius cells are a transient population of cells that inhabit layer I of the cerebral cortex and 
express the large extracellular protein, reelin. They are thought to play important roles 
during development of the cortex which range from modulation of neuronal migration to 
radial glial maturation (Soriano and Del Rio, 2005). The study by Shen et al. (2006) 
demonstrated that before E10.5, a progenitor cell is programmed to produce a complex 
order of neuronal progeny. 
 
Experimental validation of the model of corticogenesis put forward by Takahashi and 
colleagues has involved genetic manipulation of the cell cycle regulatory gene, p27(Kip1) 
(p27), which is expressed at high levels during mid corticogenesis (Delalle et al., 1999). 
p27 is a CDK inhibitor that checks the cell cycle at the G1 restriction point and is 
responsible for lengthening of G1 phase (Mitsuhashi et al., 2001). Cells that pass this point 
in the cell cycle will pass through to mitosis. Cells that leave the cell cycle must leave at 
this restriction point. p27 activity increases the likelihood that a cell will exit the cell cycle 
and join the Q fraction. The E14 p27 KO mouse was shown to already have a cerebral wall 
23% larger than its wild-type littermates (Caviness et al., 2003) since a higher proportion of 
proliferative divisions expands the progenitor cell pool. The leaving Q fraction at this stage 
was 5% lower than normal littermates. At P21, the p27 KO mouse possessed 23% more 
supragranular cerebral cortex (layers III and II) (Goto et al., 2004). There was no change in 
cell density but interestingly there was a 17% increase in excitatory projection neurons. 
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GABAergic inhibitory neurons were not overrepresented in layers II and III of the p27 KO 
mouse cortex. Conversely, over expression of p27 during cycles 3-4 of the neurogenic 
interval decreased the thickness of the cerebral cortex at P21 (Tarui et al., 2005). Contrary 
to expectation, in the same study, p27 over-expression in the E14 mouse VZ did not 
increase the duration of G1, nor did it increase the neurogenic interval. Collectively, these 
studies demonstrate that generation of the cortical layers can be manipulated via cell-
intrinsic control over the cell cycle.  
 
1.5.4 Radial Glia – Neuronal Progenitors 
 
The radial glia that populate the VZ were recently discovered to be the neuronal progenitor 
cells of the CNS (Malatesta et al., 2000; Noctor et al., 2001; Miyata et al., 2001; Malatesta 
et al., 2003; Anthony et al., 2004), although the clonal relationship between radial glia and 
neurons was previously suggested by Gray and Sanes (1992) who used retroviral labelling 
of radial glia in the embryonic chicken optic tectum. Golgi staining revealed that once 
neurogenesis was over, radial glial cells became the astrocytes of the adult brain 
(Schmechel and Rakic, 1979). 
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Fig. 1.2. Neuronal migration and nomenclature in the developing cerebral cortex. Panel A shows types of 
neuronal migration in the embryonic rodent cortex. Excitatory neurons that arise within the dorsal 
telencephalon migrate radially outward towards the cortical plate (blue arrows). Inhibitory GABAergic 
neurons are born in the ventral rodent telencephalon, within the medial and lateral ganglionic eminences 
(MGE and LGE, respectively). These neurons must migrate tangentially into the cortical plate (red arrow) 
(adapted from Parnavelas, 2000). Panel B shows a transverse section of developing cortex (enlarged from 
panel A). The VZ, a pseudo-stratified epithelium which sits on top of the LV, is populated by radial glia 
(green), which give rise to neurons that migrate into the cortical plate via the radial glial scaffold. 
Neurogenesis also occurs in the SVZ from basal progenitor cells (blue). The cell sparse intermediate zone 
separates the SVZ from the developing cortical plate (red cells) (panel B is adapted from The Boulder 
Committee (1970)). 
 
At the onset of neurogenesis, neuroepithelial cells that form the lining of the neural tube 
differentiate to form radial glia. Both radial glia and neuroepithelial cells undergo a process 
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called interkinetic nuclear migration (INM) (see text below); however, unlike radial glia, 
neuroepithelial cell nuclei migrate along the entire cell length that extends from the 
ventricular surface to the outer pial surface; whereas, radial glial cell nuclei are restricted to 
the VZ. Both types of cell express nestin (reviewed in Pinto and Götz, 2007) and RC2 
(Hartfuss et al., 2001) and both have apical-basal polarity. Importantly, at a molecular 
level, differentiation to radial glia involves expression of astrocytic markers such as brain-
lipid binding protein (BLBP), GLAST, vimentin and in the primates/human, glial fibrillary 
acidic protein (GFAP) (reviewed in Götz and Huttner, 2005). Hartfuss et al. (2001) 
proposed that radial glia represented a heterogeneous population, based on astrocytic 
antigen expression profiles. However, Anthony et al. (2004) have proposed that radial glia 
represent a homogenous population, but that radial glia at different stages of development 
express different antigens. Anthony et al. (2004) showed that all radial glia expressed both 
GLAST and BLBP at some stage in their development. The first study to find direct 
evidence that radial glia are neuronal progenitors was Malatesta et al. (2000), after finding 
that mouse embryonic brain cells that were FACS sorted for the glial antigen, GLAST, 
could generate neurons when seeded onto a developing rat cortex. 
 
Radial glial contributions to the final neuronal population of the CNS is a topic of debate. 
Malatesta et al. (2003) used Cre-recombinase under control of a human GFAP promoter 
that induced the expression of a reporter construct to show that the vast majority of neurons 
in the cerebral cortex were derived from radial glia. Interestingly, these authors also 
showed that relatively few neurons in the basal ganglia originate from radial glia (21% in 
the striatum and 13% in the globus pallidus). Furthermore, they showed that although most 
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glutamatergic projection neurons had radial glial ancestry, most GABAergic interneurons 
did not. In stark contrast to this study by Malatesta et al. (2003), Anthony et al. (2004) 
argued that nearly all neurons of the brain, even those of the ventral telencephalon, showed 
evidence of radial glial ancestry. Like Malatesta et al. (2003), Anthony et al. (2004) used a 
Cre-recombinase reporter fate mapping system. However, Anthony et al. (2004) used a 
BLBP promoter to drive Cre-recombinase expression. Whereas the human GFAP promoter 
is only expressed in the ventral telencephalon from E14.5, BLBP is expressed several days 
earlier. This makes a big difference between the two fate mapping experiments since by 
E14.5, the ventral telencephalon is largely gliogenic (Anthony et al. 2004). 
 
1.5.5 Radial Glial Mitotic Outcomes 
 
During neurogenesis, radial glial mitoses can have a number of outcomes. Neurons that are 
born at the ventricular surface in the E14 mouse inherit the basal radial glial process to give 
rise to a “radial neuron” that undergoes somal translocation to reach the cortical plate (Fig. 
1.3 E) (Miyata et al., 2001). Miyata et al. (2004) detailed the behaviour of radial glia 
around the time the cortical plate emerges in the mouse (E13 to E14). They found that at 
this stage, most radial glial cell divisions at the ventricular edge produced two proliferative 
daughter cells (P/P divisions, P = proliferative). Several different types of P/P divisions can 
be achieved at the ventricular wall. After a radial glial cell undergoes a P/P division at the 
ventricular surface, the proliferative daughter cells may both migrate back to the ventricular 
surface to divide. This is called a type I division. However, after the initial surface division, 
one of the proliferative daughter cells may remain near the SVZ (becoming an intermediate 
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progenitor cell) to divide and produce two quiescent neurons (Q/Q divisions, Q = 
quiescent). This is referred to as a type II division. 
 
Interestingly, in the stage two VZ, type II divisions preferentially occurred beneath thicker 
(thus more developmentally advanced), lateral regions of cortical plate. Type II divisions 
can be further broken down into two groups (Fig. 1.3 B and C). Type IIa divisions occur 
when the intermediate progenitor cell inherits the basal (or pial) process from its mother 
cell. In type IIb divisions, the non-surface dividing cell inherits the ventricular process. In 
both cases, the vast majority of intermediate progenitor cell divisions have been shown to 
produce two quiescent neurons, identified by expression of Hu RNA binding protein, a 
neuronal cell marker. 
 
To add further complexity to progenitor cell types in the VZ of the developing rodent, Gal 
et al. (2006) showed that radial glial cells share the VZ with another type of progenitor cell, 
the short neuronal precursor. In contrast to the radial glial cell that spans the entire 
developing cortex with its basal process, the short neuronal precursor cell has an apical 
process and a basal process of variable length (Gal et al., 2006). Thus whereas modern 
studies of radial glia have proposed that radial glia are solely responsible for neurogenesis 
out of the VZ, the actual situation in the embryonic rodent VZ may more closely match that 
of the human, where neuronally restricted precursor cells that are not radial glia have been 
characterised (Zecevic, 2004). In saying this, it cannot be ruled out that short neuronal 
precursor cells are derived from radial glia. 
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1.5.6 Radial Glia and INM 
 
During cellular division, progenitor cell nuclei in the VZ undergo the process of INM, as 
first described by Sauer (1935), whereby the nuclei migrate between the basal VZ, where 
they reside during S phase, and the apical surface of the VZ, where mitosis occurs. This 
process occurs in neuroepithelia throughout the developing CNS, including the developing 
retina. Here, INM is thought to heavily influence neurogenesis by positioning cell nuclei in 
apical-basal neurogenic gradients (Baye and Link, 2007a). The nucleus accomplishes this 
migration by using the motor protein kinesin to pull itself along the microtubules in its 
ascent to the basal regions during G1 phase and dynein and dynactin during its descent in 
G2 phase to the apical VZ (reviewed in Baye and Link, 2007b). 
 
Migration of proliferative nuclei within the VZ is not a smooth movement. Takahashi et al. 
(1993) revealed that INM to the apical surface of the VZ was a process in which movement 
varied as the nucleus accelerated and stalled. This was confirmed by real-time imaging of 
INM (Tsai et al., 2005). At E14, it was observed that nuclei descending to the apical 
surface descended in two different phases. The first half of the descent was completed in S 
phase, which took approximately 4 h. The second half of the descent which occurs during 
G2 phase was observed to take only 1 h (Takahashi et al., 1993). 
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Fig. 1.3. INM and neurogenic divisions within the dorsal telencephalon. A) Radial glia (green) display nuclear 
migration within the VZ. During G1 phase of the cell cycle, radial glial nuclei migrate away from the LV to 
undergo S phase. At the start of G2 phase, the nucleus rapidly descends to the ventricular surface to undergo 
mitosis. If the radial glial cell produces a basal progenitor cell, the basal progenitor (blue) may inherit either 
the basal (B) or the apical (C) process. After loss of these processes, the basal progenitor cell will produce two 
quiescent neurons that will migrate to the cortical plate (red cells) (D). Alternatively, a radial glial cell may 
produce a neuron at the ventricular, or apical surface of the VZ. The neuron inherits the basal process of the 
radial glial cell and migrates by somal translocation to the cortical plate (E). 
 
The functional consequences of INM in the CNS are poorly understood; however, it seems 
that the relationship between cell cycle and INM can be easily uncoupled. Previously, 
perturbation of INM in the Cdc42 KO mouse (Cappello et al., 2006) as well as in the Pax6 
KO rat (Tamai et al., 2007) resulted in an uncoupling of G2 phase time and INM. In both 
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studies, INM perturbation caused ectopic mitoses. Murciano et al. (2002) and Messier and 
Auclair (1974) demonstrated that pharmacological inhibition of INM with cytochalasin B, 
which inhibits actin polymerisation, in other neuroepithelia also led to ectopic mitoses, 
since G2 phase was left unchanged. 
 
As it has been documented that inhibition of INM does not impact upon G2 phase time, it 
has also been shown that interrupting the cell cycle at S phase does not disturb INM 
(Murciano et al., 2002). Another study, however, showed that knocking out the amyloid 
precursor protein gene produced a slowing in G2 phase (Lopez-Sanchez et al., 2005) 
without ectopic mitoses. Ueno et al. (2006) showed that cell cycle progression is required 
for normal INM to the apical surface of the VZ; however, treatment with the powerful cell 
cycle inhibitors 5-azacytidine and cyclophosphamide induced massive apoptosis within the 
VZ. 
 
In an attempt to identify functional consequences of INM, Murciano et al. (2002) 
investigated the relationship between INM and the anti-neurogenic gradient of Notch1-
Delta1 (Notch1 ligand) expression and signalling. Interestingly, expression of Notch1 was 
restricted to the ventricular wall (where radial glial nuclei are positioned during late 
G2/M/early G1 phases), and BrdU labelling showed that Notch1 was expressed by cells in 
G2 phase, but not by cells in S phase or early G2 (Murciano et al., 2002). It was shown that 
INM positions cells such that notch1 expressing neuronal progenitors are exposed to the 
maximum amount of anti-neurogenic ligand, Delta1, which is also expressed by cells at the 
apical VZ. Pharmacological perturbation of this positioning resulted in less anti-neurogenic 
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Notch1 signalling and more neurogenesis, which, in turn, would decrease the final 
cumulative neuronal output. 
 
1.5.7 Role of the SVZ in Foetal Corticogenesis 
 
Neurogenesis also occurs in the foetal SVZ, where basal neuronal progenitors undergo 
mitosis (Haubensak et al., 2004; Miyata et al., 2004; Calegari et al., 2005). The 
proliferative cells that make up the SVZ are a secondary proliferative population and were 
originally thought to be largely gliogenic, owing to their contribution to the glial cell pool 
in the postnatal brain (reviewed in Noctor et al., 2007). Study of cell cycle and proliferative 
behaviour in this zone was slow due to the fact that there is no hard boundary between the 
VZ and the SVZ, as well as the fact that the population of the SVZ is intermingled with 
postmitotic cells (Takahashi et al., 1995b). These basal progenitor cells do not undergo 
INM (Smart, 1973), and most undergo terminal divisions to generate two neurons during 
embryogenesis (Noctor et al., 2004). Interestingly, Tarabykin et al. (2001), using the non-
coding RNA, Svet1, as a SVZ marker, provided evidence to support the idea that the SVZ 
may be largely responsible for generation of the upper layers of the cerebral cortex. This 
hypothesis was supported by the fact the SVZ undergoes massive expansion during 
generation of the upper cortical layers (Noctor et al., 2007). However, unlike the SVZ of 
the developing rodent, which primarily produces excitatory neurons, the dorsal SVZ of the 
human is also a major source of GABAergic interneurons for the cerebral cortex (Letinic et 
al., 2002). In the rodent, most GABAergic interneurons are derived from the ventral 
telencephalon. 
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Fig. 1.4. A simplified diagram of neuronal lineage. Neuroepithelial cells, which exist in the VZ prior to 
neurogenesis, give rise to radial glial cells. Radial glial cells can produce neurons via basal progenitor cells 
(adapted from Götz and Huttner, 2005). Note that this diagram does not describe astrogliogenesis.  
 
1.5.8 Postnatal Neurogenesis in the Mammalian Forebrain 
 
In the neonatal mouse, radial glial cells are present until at least P7, where they still 
proliferate and even undergo INM (Tramontin et al., 2003). However, unlike the VZ that 
eventually becomes replaced by a single cell ependymal layer, the SVZ survives past 
corticogenesis where neurogenesis and gliogenesis manages to persist into adulthood (Lois 
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and Alvarez-Buylla, 1993). Neuronal proliferation around the lateral ventricles fuels the 
rostral migratory stream with migratory neuroblasts destined to differentiate into different 
types of interneurons within the olfactory bulbs (Young et al., 2007). Interestingly, the 
rostral migratory stream has recently been identified within the human telencephalon 
(Curtis et al., 2007a), however, not without controversy (Sanai et al., 2007; Curtis et al., 
2007b). 
 
The existence of neuronal stem cells around the adult lateral ventricles in the rat and mouse 
is a relatively recent finding. Doetsch et al. (1999) were the first to show that these adult 
neural stem cells were phenotypically astrocytes. Neuronal production around the LV 
originates at the astrocytic neuronal stem cells (type B cells of the adult SVZ) and proceeds 
through to a progenitor cell step (type C cells, or transit amplifying cells) that produces the 
migrating neurons of the rostral migratory stream (type A cells) (Doetsch et al. 1999). It 
seems as if these astrocytic neuronal stem cells represent the last vestiges of their 
neurogenic radial glial ancestors, in mammals at least. Merkle et al. (2004) used Cre-loxP 
based fate mapping to show that type B cells of the SVZ were descendants of radial glia 
that existed in the P0 mouse forebrain. Thus, even though rodent radial glia have all but 
disappeared from the VZ by the second week of life, neurogenic potential in the postnatal 
brain continues in the form of astrocytes. 
 
Our understanding of development of the cerebral cortex has increased dramatically in 
recent years. It is now apparent that although extrinsic signalling does play some part in 
corticogenesis, developmental progression within the embryonic brain seems to be 
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controlled by cell-intrinsic mechanisms, which includes cell cycle progression. Importantly, 
the past decade has seen the rise of the astrocytic glial cell as the major source of neurons 
for the entire CNS. Remarkably, astrocytes continue to proliferate in the adult brain and 
provide a source of neurons. It is therefore interesting that postnatal astrocytes have been 
shown to express a fully functional opioid signalling system and proliferating astrocytes 
taken from the postnatal brain are very sensitive to the antiproliferative affects of opiates. 
Unfortunately, by the time it was determined that radial glia produce neurons for the 
embryonic brain, and that astrocytes are responsible for adult neurogenesis, studies on how 
opiates impact on astrocytic proliferation had largely ground to a halt, particularly in vivo, 
perhaps for want of a reason to continue. With this in mind, the current research project 
aimed to characterise the impact of opiate exposure in the context of the embryonic brain. 
This general aim consisted of 3 objectives. Firstly, expression of MOR in the prenatal brain 
was analysed on a single-cell level. The second objective of this thesis research was to 
characterise the effects of morphine exposure on the proliferating VZ. The final objective 
was to analyse the effect of morphine exposure during corticogenesis on histogenesis of the 
cortical plate. 
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2. General Methods 
 
2.1 Animals 
 
All experiments involving animals were approved by the Victoria University Animal Ethics 
Committee.  
 
2.1.1 Timed Mating 
 
C57BL/6J mice were mated overnight (9 pm – 9 am) at the Malaghan Institute of Medical 
Research. All mice had access to food and water ad libitum and were separated during 
pregnancy. Basic environmental enrichment was provided. Mice that had vaginal plugs 
present in the morning were considered E0. Mice were taken for experiments on E15 or 
E18 or were left until parturition and taken for tissue dissection at P5 or P12. At the end of 
the experimental protocol, pregnant dams were sacrificed by cervical dislocation. An 
incision was made from the pelvis to the ribcage and uterine horns were removed and put 
into ice-cold PBS. Foetuses were dissected out of the uterus and were blotted briefly, then 
weighed to gauge developmental progress of the foetus before further dissection. Postnatal 
pups were sacrificed by decapitation. 
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2.1.2 5-Bromo-2′-Deoxyuridine Injections 
 
Animals that received a single injection of 5-bromo-2′-deoxyuridine (BrdU, Sigma-Aldrich, 
858811-500MG) received it as an intraperitoneal injection of PBS containing 10 mg/ml of 
BrdU at a dose of 50 mg/kg. Animals were sacrificed at different times after injection of 
BrdU. 
 
2.2 Molecular Analysis 
 
2.2.1 Real-Time PCR Analysis of DCX Gene Expression 
 
2.2.1.1 Tissue Dissection 
 
Cerebral cortical tissue was dissected from E18.5 mouse cerebral cortex and was 
immediately homogenized in 100 µl of PBS in 1.5 ml microcentrifuge tubes, using a small 
plastic pestle. An aliquot of cortical homogenate (20 µl) was transferred to 200 µl of TRIzol 
(Invitrogen, 15596-018). Both the PBS homogenate and the TRIzol homogenate were 
immediately frozen at -80 °C until further use. 
 
2.2.1.2 RNA Extraction 
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Upon thawing, TRIzol samples were centrifuged at 13,000 x g for 15 minutes at 4 °C to 
remove lipid and cellular debris. Supernatant was transferred to a new microcentrifuge 
tube. Chloroform (100 µl) was added to every 1 ml of TRIzol supernatant, and the mixture 
was mixed by vortexing, then centrifuged at 13,000 x g for 10 min to separate the organic 
phase from the aqueous phase. The aqueous phase was collected by micropipette and mixed 
with 0.5 volumes of absolute ethanol. The sample was then further purified using a High 
Pure RNA Isolation Kit (Roche, 1 828 665). The resulting RNA was eluted in 40 µl of 
ddH2O. RNA was quantified with an ND-1000 Spectrophotometer (Nanodrop, Wilmington, 
DE) by obtaining an absorbance at 260 nm and a 260 nm/280 nm ratio of absorbance to 
give an indication of contamination of the RNA by protein as well as phenol from the RNA 
extraction process. 
 
2.2.1.3 Reverse Transcription 
 
RNA (300 ng) was reverse transcribed into cDNA by Superscript III (Invitrogen, 18080-
085). Reverse transcription reactions included RNAseOUT (Invitrogen, 10777-019) to 
inhibit RNAse A, B and C activity. Oligo dT18 (2.5 µM) was used as a primer to selectively 
reverse transcribe messenger RNA. 
 
2.2.1.4 Real-Time PCR 
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One µl of cDNA (Superscipt III reaction mixture) was used per 25 µl PCR reaction. PCR 
reactions were based on Platinum SYBR Green qPCR SuperMix-UDG (supplied at 2x 
concentration, Invitrogen, 11733-046) to which template (cDNA), primers (final 
concentration of 200 nM) and fluorescein were added. Fluorescein was added to the 
reaction mixture at a final concentration of 20 nM. Fluorescein was necessary for the iQ4 
real-time PCR detection system based on an iCycler platform (Bio-rad, Hercules, CA) to 
collect background well-factors. Well factors are collected from individual wells at the 
beginning of a PCR experiment and are used to correct for non-uniformity in fluorescence 
(usually as a result of pipetting error).  
 
Cycling conditions for the real-time PCR reaction were as follows. An initial step of 50 °C 
for 2 min was included before the PCR amplification to eliminate contaminating PCR 
product. This was achieved using uracil-N-glycosylase, which removes uracil residues from 
DNA molecules. As Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen, 11733-046) 
contains dUTP instead of dTTP, contaminating PCR product from prior PCR amplification 
is digested by uracil-N-glycosylase while cDNA template, which contains dTTP, remains 
intact. Denaturation was carried out at 95 °C for 2 min. Amplification was carried out over 
35 cycles of 95 °C, 15 s; 60 °C, 30 s; 72 °C, 30 s. Sixty °C was used as the primer 
annealing temperature for all primer sets used (Table 2.1). 
 
2.2.1.5 Agarose Gel Electrophoresis 
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PCR product was visualised using agarose gel electrophoresis. Agarose gels (2%) were 
prepared by microwaving 1 g of agarose (Invitrogen, 15510-027) with 50 ml of 1x TAE 
buffer. Aqueous ethidium bromide (10 mg/ml) was added to the molten agarose to a final 
concentration of 200 ng/ml. Agarose gels were placed into an electrophoresis tank with 1x 
TAE buffer containing 200 ng/ml ethidium bromide. Ten µl of neat PCR product was 
mixed with 2 µl of 6x loading buffer by pipetting up and down. PCR product mixed with 
loading buffer (10 µl) was loaded into each lane of the agarose gel. Electrophoresis was 
conducted at 100 V for 25 min. Ethidium bromide fluorescence was visualised using a 
KODAK Gel Logic 100 system (Kodak). 
 
Primer target Primer sequence 5’ – 3’ 
Forward Reverse 
MOR CCT GCC GCT CTT CTC TGG TT CGC ATG GGT CGG ACT GGT TG 
DCX CAT AGT GCC CAC TGT AGC TTC CAG ACA AGG ATC GGG TCA 
Fas AGC TGA GGA GGC GGG TTC AT CAT TCT TCC ATA TCG GGC AC 
Cyclophilin A GGG GAG AAA GGA TTT GGC TA ACA TGC TTG CCA TCC AGC C 
Glyceraldehyde-P 
dehydrogenase 
(GAPDH) 
GTG CCA GGC GTG TCA T GAA GCG TTC GTG AAT AAC  CTT 
18s rRNA CTT TGG TCG CTC GCT CCT C CTG ACC GGG TTG GTT TTG AT 
Table 2.1: Primers used for real-time PCR analysis. 
 
2.2.2 Western Blotting 
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2.2.2.1 Protein Extraction 
 
E18.5 cerebral cortical extract in PBS was solubilised in RIPA buffer. A mammalian 
protease inhibitor cocktail (Sigma, P8340-5ML) was added to slow protease-mediated 
protein degradation. Protein extracts were sonicated to break up viscous gDNA using an 
Ultrasonic Processor sonicator (Heat Systems Ultrasonics, Inc., Farmingdale, NY) at the 
settings: cycle time, 5 s; % duty cycle, 20%; output control, 2.5. 
 
2.2.2.2 Protein Quantification 
 
Protein quantification was achieved using a bicinchoninic acid (BCA) based assay (Pearce, 
23225). This assay uses BCA to chelate cuprous ions (Cu1+) after they have been reduced 
from cupric ions (Cu2+) by protein in an alkaline environment. Chelation of cuprous ions by 
two molecules of BCA produces a purple product that absorbs strongly at 562 nm. 
Absorbance at 562 nm has a linear relationship with increasing protein concentration. 
 
2.2.2.3 Protein Electrophoresis and Membrane Transfer 
 
Protein extracts were diluted to a concentration of 1 µg/µl in lithium dodecyl sulfate (LDS) 
sample buffer (Invitrogen, NP0007). Protein samples were reduced with reducing agent 
(Invitrogen, NP0004) at 70 °C for 10 min, then 20 µg of protein was loaded per lane of a 4-
12% ZOOM gel (Invitrogen, NP0923BOX), and the samples were electrophoresed at 100 V 
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for approximately 1 h in MES buffer (Invitrogen, NP0002). The electrophoresed protein 
was run with Seeblue II protein size standard (Invitrogen, LC5925). Protein was transferred 
to Immobilon-FL PVDF membrane (Millipore, IPFL00010), that had been pre-soaked in 
methanol, in transfer buffer at 20 V overnight. Only one brain sample was loaded per lane. 
Where littermates were used for western blotting, brain samples were electrophoresed, 
western blotted and quantified by densitometry separately, then averaged within the litter to 
obtain separate n values. 
 
2.2.3 Antibody Incubation 
 
The next morning, the PVDF transfer membrane was rinsed in PBS then blocked in PBS 
containing 5% reduced fat trim milk for 2 h at room temperature. The PVDF membrane 
was then rinsed in PBS and incubated with PBS containing 2% BSA and primary antibody 
for 4 h. The membrane was washed in PBS containing 0.1% TWEEN for 3 x 5 min, then 
incubated with secondary antibody conjugated with Alexa-488 (1:5,000, Invitrogen) for a 
further 2 h. Membranes were washed as for the primary antibody and transferred protein 
bound to antibody visualised with a Fujifilm FLA5000 fluorescence scanner (Fujifilm 
Medical Systems, USA) at 600 V. 
 
Epitope Animal primary 
antibody raised in 
Company Dilution 
MOR Rabbit  Chemicon, Temecula, 
CA (AB5511) 
1:1,000 
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DCX Guinea Pig Chemicon (AB5910) 1:20,000 
NeuN Mouse Chemicon (MAB377) 1:1,000 
GAD 65+67 Rabbit Abcam (AB11070) 1:1,000 
GFAP Mouse Chemicon (MAB360) 1:1,600 
Table 2.2: Primary antibodies used for western blotting. 
 
2.3 Immunohistochemistry 
 
2.3.1 Tissue Preparation 
 
After removal from the uterus, foetuses at E15.5 were rapidly decapitated and whole heads 
were fixed overnight in PBS containing 4% paraformaldehyde (PFA). The brains of E18.5 
foetuses and P5 pups were dissected out in ice-cold PBS. Brains were fixed overnight in 
PBS containing 4% PFA at pH 7.4. The next morning, brains destined for cryostat 
microtome sectioning were cryo-protected in PBS containing 30% sucrose and stored at -80 
°C until sectioning. Brains destined for paraffin embedding were dehydrated using a graded 
ethanol/xylene series and embedded in paraffin wax. 
 
2.3.2 Tissue Sectioning 
 
Fixed-frozen tissue was mounted in Jung Tissue Freezing Medium (Leica Instruments, 
Nussloch, Germany) and sectioned at 20 µm (rodent tissue) or 40 µm (human tissue) using 
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an HM 500 OM series cryostat microtome (Microm, Heidelberg, Germany). Sections were 
mounted on Superfrost Plus microscope slides (Esco, Erie Scientific, Portsmouth, NH), air 
dried and stored at -80 °C until staining. 
 
Brains embedded in paraffin wax were sectioned on an 820 series microtome (American 
Optical Co., Buffalo, NY), and sections were mounted on Superfrost Plus microscope 
slides (Esco, Erie Scientific, Portsmouth, NH). 
 
2.3.3 Fluorescence Immunohistochemistry for Fixed-Frozen Brain Sections 
 
Frozen sections were air-dried and permeabilised at room temperature in PBS containing 
0.05% Triton X-100 for 15 min and blocked for 1 h at room temperature in PBS containing 
2% BSA and 10% goat serum. Sections were incubated overnight at 4 °C with primary 
antibodies.  
 
All antibodies were diluted in PBS containing 2% BSA and 10% goat serum. Sections were 
washed 4 times for 10 min each in PBS containing 0.1% TWEEN. Sections were then 
incubated with the appropriate secondary antibodies for 1 h at room temperature. Sections 
were washed as for the primary antibody and mounted in Prolong Gold antifade reagent 
with DAPI for fluorescent visualisation of the cell nuclei (Invitrogen, P-36931). In the 
present study, DAPI was used as a fluorescent counterstain to help clarify anatomical 
topography where appropriate. 
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2.3.4 BrdU Staining for Fixed-Frozen Sections 
 
Frozen sections were thawed at room temperature and air dried. Sections were 
permeabilised at room temperature in PBS containing 0.05% Triton X-100 for 15 min, then 
sections were washed in PBS for 2 min, followed by a 5 min incubation in 40 mM Tris (pH 
8) containing 10 mM CaCl2, 6 mM MgCl2 and 10 mM NaCl (DNAse I incubation buffer). 
DNAse I incubation buffer was then replaced with 150 µl of DNAse I incubation buffer 
containing 250 µg/ml DNAse I (bovine pancreas, grade II, Boehringer Mannheim, 104 
159). Sections were incubated with DNAse I for 10 min at 37 °C. Sections were washed 3 x 
2 min in PBS containing 10 mM EDTA that chelated divalent cations and deactivated the 
DNAse I. Sections were then blocked in PBS containing 2% BSA at room temperature for 
1 h. After incubation overnight at 4 °C with rabbit anti-MOR antibody, sections were 
washed 3 x 5 min in PBS containing 0.05% TWEEN. Sections were then incubated for 2 h 
with goat anti-rabbit-Alexa 555 antibody at room temperature and washed 2 x 5 min as 
above. Sections were then incubated with anti-BrdU Alexa-546 conjugate for 2 h at room 
temperature. Sections were washed once in PBS for 5 min and were immediately fixed in 
4% PFA for 5 min to prevent diffusion of the antibody (Appendix 3, panel C). Sections 
were washed again in PBS for 5 min and were mounted in Prolong Gold antifade reagent 
with DAPI. 
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2.3.5 Fluorescence Immunohistochemistry for Paraffin-Embedded Sections 
 
Paraffin-embedded sections were de-paraffinised in xylene and rehydrated through a graded 
ethanol series. Antigens were retrieved in a boiling water bath at 100 °C in 10 mM sodium 
citrate, pH 6.0 for 10 min. The pH of this solution is of critical importance. Tissue sections 
were then left to cool in citrate solution for 30 min. 
 
For retrieval of the Ki67 epitope, sections were put straight into a pressure cooker filled 
with 2 l of boiling 10 mM sodium citrate, pH 6.0. The pressure cooker lid was then locked 
down and the sections were left for 10 min after the cooker had come up to pressure. After 
10 min at pressure, the pressure cooker was de-pressurised, and the lid was taken off. Cold 
tap water was run into the pressure cooker for 10 min. Ki67 required retrieval in a pressure 
cooker, which allows the sodium citrate to reach temperatures greater than 100 °C. Unlike 
the other antigens, Ki67 could not be retrieved by boiling with citrate at 100 °C. 
 
All sections were processed as for the frozen sections with specific primary antibodies as 
described above. Bound primary antibodies were visualised by staining with appropriate 
fluorescent secondary antibodies. BrdU immunohistochemistry was also visualised by 
diaminobenzidine (DAB) staining using a Vectastain Elite ABC Kit (Vector Laboratories, 
Burlingame, CA) according to the manufacturer’s instructions. Slides were mounted in 
either DPX (BDH, Poole, UK) or Prolong Gold antifade reagent as appropriate. 
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2.3.6 DAB Staining 
 
DAB (Sigma-Aldrich, D12384-1G) was used to stain BrdU-labelled nuclei via anti-BrdU 
(PRB-1)-biotin ABC staining. Immediately prior to staining, a 0.5 mg/ml solution of DAB 
was prepared in PBS. This yielded a clear solution with a white precipitate. Hydrogen 
peroxide was added to the solution to a final concentration of 0.03%. DAB solution was 
incubated with tissue at room temperature until sufficient staining was evident. This usually 
took 10 min. DAB stained slides were counterstained using 0.2% thionin. Slides were 
dehydrated in non-reagent grade ethanol, cleared in xylene and mounted in DPX. 
Epitope Animal Source Dilution 
MOR Rabbit Chemicon (AB5511) 1:1,000 
DOR Rabbit Chemicon (AB5503) 1:1,000 
KOR Rabbit Abcam (AB10283) 1:1,000 
GLAST Guinea Pig Chemicon (AB1782) 1:1,000 
Nestin Mouse R&D Systems 
(Minneapolis, MN) 
(MAB1259)  
1:100 
Vimentin Mouse DakoCytomation 
(Denmark) (M0275) 
1:100 
Doublecortin (DCX) Guinea Pig Chemicon (AB5910) 1:500 
PCNA Mouse Chemicon (CBL407) 1:50 
BrdU/IdU (PRB-1) - Biotin Mouse Invitrogen (A21301MP) 1:50 
BrdU/IdU (PRB-1) – Alexa 546 Mouse Invitrogen (A21308) 1:100 
BrdU/IdU (PRB-1) – Alexa 488 Mouse Invitrogen (A21303) 1:100 
BrdU (Br-3) - Biotin Mouse Invitrogen (MD5215) 1:25 
Neuronal nuclear antigen (NeuN) Mouse Chemicon (MAB377) 1:200 
 74 
Phospho-histone H3 (Mitoses) Rabbit Abcam (AB5176) 1:1,000 
Ki67 Rabbit Abcam (AB15580) 1:25 
Table 2.3: Primary antibodies used for immunohistochemistry. 
 
 
Epitope Conjugate Animal Source Dilution 
Rabbit IgG Alexa 555 Goat Invitrogen(A-21428) 1:500 
Rabbit IgG Alexa 488 Goat Invitrogen(A-11008) 1:500 
Mouse IgG Alexa 488 Goat Invitrogen(A-11001) 1:500 
Mouse IgG Alexa 555 Goat Invitrogen(A-21424) 1:500 
Guinea Pig IgG Alexa 488 Goat Invitrogen(A-11073) 1:500 
Vectalab ABC 
Elite 
Streptavidin-HRP NA Vector Laboratories, 
Burlingame, CA (PK-
6200) 
NA (Kit 
specifications) 
Biotin Alexa 488 NA (Streptavidin) Invitrogen(S-32354) 1:500 
Table 2.4: Secondary antibodies used for immunohistochemistry. 
 
2.4 Statistical Considerations and Analysis 
 
2.4.1 The Use of Multiparous Species in Developmental Studies 
 
Developmental studies that utilise multiparous species as model research systems, such as 
the mouse, need special consideration for statistical analysis. A litter effect often arises 
because littermates are more similar to each other than to animals of other litters (Holson 
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and Pearce, 1992). This brings with it statistical complications that have been the subject of 
debate for decades, primarily in the field of teratology (Palmer, 1974; Weil, 1974). 
 
In highly inbred animal models such as rodents, these shared similarities are likely to arise 
simply as a consequence of the shared maternal environment. This has been observed in 
parameters as diverse as morphological features, levels of neuroendocrine hormones, as 
well as teratological parameters (Haseman and Hogan, 1975; Holson and Pearce, 1992; 
Zorrilla, 1997). The consequence of designating littermates as single observations (or single 
‘n’s) is to inflate the n value of the experiment in question. An inflated n value leaves the 
experiment open to a type 1 error, or rejection of the null hypothesis when the null 
hypothesis is in fact true. The seminal study by Holson and Pearce (1992) used Monte-
Carlo simulations to show that selection of even 2 pups per litter can lead to 3 fold inflation 
in alpha level. 
 
The simplest and most robust way to circumvent confounding litter effects is simply to 
define a pregnant dam as the smallest sampling unit of an experiment. All results presented 
in this thesis use the pregnant dam as the base definition of n. This minimises spurious 
findings from biased experiments that have not considered litter effects. However, this 
increases the cost and work involved in the study, since more pregnant dams are needed. 
Surprisingly, the risky practise of using littermates as a sampling unit is prolific in the 
literature (Haseman and Hogan, 1975; Holson and Pearce, 1992; Zorrilla, 1996; 
Wainwright, 1998). 
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2.4.2 Statistical Analysis of Variance 
 
All statistical analysis in the current thesis research was performed using SPSS for 
windows v14.0 (SPSS, Chicago, IL). Where only two means were compared, Student’s t-
test was used to determine equality of means. For analysis of variance where only one 
measurement was taken from an animal, the univariate procedure was used. For cases 
where repeated measurements were taken from a single animal, the GLM repeated 
measures procedure was performed. Repeated measures ANOVA also requires that 
sphericity is not violated. Mauchly’s test of sphericity was used to test this assumption. 
Corrections for violations of sphericity are provided by SPSS in the form of Greenhouse-
Geisser, the Huynh-Feldt and the Lower-bound corrections. For analysis of variance tests, 
normality was determined by Q-Q plot and if necessary, transformed by taking the natural 
logarithm or the square root of the raw data. 
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3. MOR is Expressed on Radial Glia but not on Migrating Neurons 
in the Late Foetal Mouse Brain 
 
3.1 Introduction 
 
In vitro studies suggest that opioids exert an inhibitory effect on cellular proliferation. 
Opioids also have a measurable effect in vivo on proliferating systems within the central 
nervous system. The presence of  MOR within germinal zones of the developing foetal 
brain was anticipated but needed to be unequivocally established, since numerous studies 
have generated conflicting results with regard to the location of MOR mRNA, protein, and 
ligand binding within proliferative regions (Kent et al., 1982; Leslie and Loughlin, 1993; 
Georges et al., 1998; Leslie et al., 1998; Zhu et al., 1998; Reznikov et al., 1999; Tong et 
al., 2000). 
 
Early studies in our lab by Drs. Mrkusich, Day and Miller noted the presence of MOR 
mRNA expression in the E16 rat VZ, using mRNA fluorescence in situ hybridisation 
(Mrkusich et al., 2004) (Fig. 3.1). It was important at the start to determine the expression 
patterns of MOR in the developing brain. Fluorescence immunohistochemistry was used to 
co-label expression with a selection of neuronal and glial markers that would reveal cells in 
which the receptor was expressed. Reznikov et al. (1999) found opioid receptor expression 
within the VZ of the developing mouse foetus but failed to distinguish exactly which cells 
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the receptors were expressed on, noting they could be either migrating neurons or 
progenitor cells. It was decided to look for MOR expression at a time-point just before 
parturition in the mouse (E18.5) as well as a point during neurogenesis (E15.5). This 
decision was based on the studies of Kent et al. (1982), who showed opioid receptor 
radioligand binding in the ependymal zone of the rat just before parturition, and Rius et al. 
(1991) and Leslie et al. (1998) who demonstrated that the opioid peptides beta-endorphin 
and enkephalin, respectively, displayed peaks of expression just before birth, 
 
 
Fig. 3.1. MOR mRNA expression in the VZ of the E16 rat telencephalon. Cy3 labelled cRNA was used as a 
probe for fluorescence in situ hybridisation as described in Mrkusich et al. (2004) and Day et al. (2007). Panel 
A shows DAPI counterstaining of sagittal sections (12 µm) through the developing cortex and associated 
dorsal proliferative regions. Panel B shows MOR mRNA hybridisation fluorescence signal, especially strong 
in the VZ. Panel C shows an overlay of panels A and B. Staining and photography was performed by Dr E.M. 
Mrkusich. Brain regions are labelled according to the Boulder Committee conventions (1970). cp, cortical 
plate; iz, intermediate zone; svz, subventricular zone; vz, ventricular zone. Scale bars: 200 µm 
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Localisation of MOR in the E18.5 mouse was determined in the neuroepithelia of the LV, 
the third ventricle (3V), and the aqueduct (Aq). As development of the cerebral cortex was 
the primary focus of the current study, analysis of the neurogenic VZ of the E15.5 dorsal 
telencephalon for expression of MOR, as well as DOR, was also conducted. Unfortunately 
an anti-KOR antibody that yielded convincing, specific staining on rodent tissue could not 
be found. 
 
The proliferative epithelia of the E18.5 mouse still exhibit high levels of proliferation; 
however, it is gliogenesis, not neurogenesis, that predominates at this late stage of cellular 
proliferation in the late foetal mouse brain (Malatesta et al., 2000). Even though 
neurogenesis has largely ceased by E18.5, radial glial cells are still the dominant cell 
phenotype found in the lateral ventricle. GLAST, vimentin, and BLBP-positive radial glial 
cells are present in all regions of the late foetal mouse brain, including the telencephalon, 
diencephalon, midbrain, hindbrain/cerebellum, and the spinal cord (reviewed in Götz and 
Huttner, 2005). For localisation of MOR, GLAST was chosen as a radial glial marker. Data 
showing the subcellular localisation of GLAST on the radial glial cell has yet to be 
presented. However, glutamate transport by GLAST is vital for normal brain development 
thus it must, at least in part, be localised to the plasma membrane of the radial glial cell 
(Matsugami et al., 2006). 
 
 To complement GLAST, DCX was chosen to serve as a marker for migrating neuroblast 
cells. As MOR affects proliferation in the developing brain, PCNA (proliferating cell 
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nuclear antigen) and BrdU were used as markers to assess whether or not MOR expressing 
cells were proliferative. 
 
As a secondary proliferative zone dedicated to the production of neurons destined to reside 
within the internal granule layer of the cerebellum (reviewed in Goldowitz and Hamre, 
1998), the EGL yields another opportunity to examine the relationship between MOR 
expression and regions of proliferative activity. Interestingly, MOR expression was shown 
on neuroblasts cultured from the EGL of the cerebellum (Hauser et al., 2000). As the 
cerebellum is a structure that develops extremely late in the brain, the cerebellum was 
probed for MOR expression at E18.5, P5, and P12. 
 
3.2 Experimental Design 
 
3.2.1 Tissue Preparation and Staining 
 
Animals were taken for tissue preparation and sectioning at E15.5, E18.5, P5, and P12. 
Animals at E15.5 and E18.5 were injected with single doses of BrdU and sacrificed 3 h 
later for tissue processing. All staining was performed alongside negative controls in which 
the primary antibody had been omitted. 
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3.2.2 Image Acquisition and Analysis 
 
Analysis of different immunohistochemical markers was consistently performed on the 
same part of the brain by using anatomical landmarks such as the foetal striatum and the 
lateral-dorsal corner of the LV. Epifluorescent photomicrographs were taken with an 
Olympus AX70 photomicroscope (Olympus Optical Co., Hamburg, Germany) equipped 
with appropriate narrowband fluorescence filters. Images from the photomicroscope were 
captured using an Olympus DP70 CCD camera. 
 
Confocal microscopy was used to determine co-expression or sub-cellular localisation of 
MOR with other markers in a single cell of a tissue section. Z-plane image stacks were 
acquired at 0.6 µm intervals as this is the limit of resolution for confocal microscopy in the 
z-axis. Confocal microscopy was performed using either an MRC 600 Bio-rad confocal 
system (Bio-rad, Hercules, CA) with a Nikon Diaphot inverted microscope, a Leica TCS 
4D confocal microscope (Leica Lasertechnik, Heidelberg, Germany), or an Olympus 
FV1000 (Olympus Optical Co., Hamburg, Germany). All three dimensional 
reconstructions, .avi files and three channel fluorescent images were constructed from Z-
stacks performed with the Olympus FV1000 confocal microscope. Photomicroscope and 
confocal images were overlaid and background corrected for presentation purposes using 
ImageJ v1.34s (NIH, USA) and Adobe Photoshop CS2 or CS3 software. 
 
3.3 Results 
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3.3.1 MOR Antibody Validation 
 
The anti-MOR antibody used in this study was raised against an exon 4 peptide in the 
carboxy-terminus of MOR. Correct specificity of the MOR antibody was demonstrated by 
obtaining the expected staining pattern in sections of the dorsal horn in mouse spinal cord 
(Fig. 3.2, panel A) and also by observing strong, diffuse staining of foetal (E18.5) striatum 
(Fig 3.2, panel B; Fig. 3.3, panels A and C). In contrast, patchy MOR staining was found in 
the P6 mouse striatum (Fig. 3.2, panel D). This was expected, given the ontogeny of MOR 
expression in the developing striatum. It has previously been shown that as the striatum 
develops, MOR adopts a patchy expression pattern (Winzer-Serhan et al., 2003) as 
demonstrated in Fig. 3.2, panel D. Additionally, lysates prepared from cortical dissections 
corresponding to the same cortical/ventricular regions displayed in Fig. 3.3 were examined 
by Western blotting and stained using the anti-MOR antibody (Fig. 3.2, panel C). A band at 
approximately 45 kDa, corresponding to the expected size of the unprocessed MOR 
protein, and a band at 70 kDa, corresponding to the glycosylated form of the receptor, were 
observed. 
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Fig. 3.2. Analysis of rabbit anti-MOR specificity. Panel A shows MOR staining (red) in a transverse section 
of the adult spinal cord. MOR was expressed strongly in the dorsal horn (white arrows) where MOR regulates 
sensory neurons. Nuclei were counterstained with DAPI (blue). Panel B shows a low power view of the 
striatum in the E18.5 mouse telencephalon. The striatum is delineated by white arrows and stained diffusely 
for MOR, as is characteristic at this developmental stage. The mouse telencephalon was counterstained with 
DAPI. Lysates prepared from the dorsal cortex of E18.5 mouse brains were separated by LDS-PAGE, 
transferred to PVDF membrane, and then probed with a rabbit anti-MOR antibody (lanes 2 and 3). 
Immunoreactive bands corresponding to MOR (45 kDa) and the glycosylated MOR (70 kDa) are indicated. 
Lane 1 contains pre-stained MW standards (panel C). Panel D shows a higher power view of the mouse 
neonatal striatum (P6). MOR immunofluorescence appears patchy, as opposed to the diffuse staining seen in 
late foetal striatum. Patchy regionalisation (shown by white arrows) is characteristic of opioid peptides and 
opioid receptors during early neonatal development of the murine striatum. Scale bars: 100 µm. 
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3.3.2 MOR Staining and PCNA Staining 
 
In the E18.5 brain MOR IR was found within the ventricular neuroepithelium of the LV 
(Fig. 3.3, panels A-D), 3V (panel E), and Aq (panel F). PCNA is a marker for proliferating 
cells and cells that have recently divided, allowing regions of proliferative activity to be 
identified. PCNA IR can be seen in the nuclei of cells that line the wall of the LV, 
consistent with previous reports (Ajioka et al., 2006). PCNA-positive cells extend into the 
cortical neuroepithelial layer that covers the developing striatum (panels A and C). 
Importantly, we show in Fig. 3.3, panels A-D, that MOR IR is expressed in the same 
location as the PCNA IR, and that these MOR-positive and PCNA-positive cells extend 
along the cortical neuroepithelium (panels B and D). Panels E and F show regions of the 
3V and Aq, respectively, which, similar to the LV, express MOR and PCNA at the 
ventricle wall. 
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Fig. 3.3. MOR and PCNA IR in the E18.5 neuroepithelia of the LV, 3V, and Aq. Panels A and C show MOR 
IR (red) in coronal and sagittal sections of the LV, respectively. Proliferating cells (PCNA-positive) were 
stained (green). The cortical neuroepithelium (cne) in panels A and C is indicated by the white arrows. Higher 
magnification images of the boxed regions are presented in panels B and D and show that MOR IR was 
localised to the same area as PCNA IR. Panel E shows a confocal image of a coronal section of the ventral 3V 
in which MOR IR was tightly associated with a periventricular band of PCNA staining cells (located between 
the white arrows). Similarly, the proliferative zone of the Aq wall (white arrows, F) contained many PCNA 
IR nuclei and MOR IR cells. Scale bars: 200 µm (A and C), 50 µm (B and D), and 20 µm (E and F). 
 
3.3.3 MOR and BrdU Staining in the VZ 
 
To examine the relationship between MOR expression and proliferation in detail, a more 
defined cohort of proliferating cells was labelled with BrdU. BrdU is only incorporated into 
cells undergoing DNA synthesis (cells in S-phase of the cell cycle). Dual-staining for BrdU 
and MOR was examined in the VZ of the LV in E15.5 and E18.5 mouse brains (Fig. 3.4). 
Confocal imaging of the E15.5 brains (panel A) showed that most of the BrdU stained 
nuclei (green) in the VZ were also MOR-positive (red). Examples of double-labelled cells 
are indicated by arrows. As not all of the MOR-positive cells were in S phase, many did not 
stain for BrdU. At the VZ in the E18.5 brains, fewer BrdU-stained nuclei were detected 
(Fig. 3.4, panel B), consistent with the decreased level of corticogenesis at this later 
developmental stage. Examination of orthogonal views by confocal microscopy (side bars) 
showed that the cytoplasm surrounding most BrdU-positive nuclei was MOR-positive 
(arrowheads) even when the x, y view suggested the nuclei were negative for MOR 
staining, as is the case for the cell in Fig. 3.4, panel B marked by an asterisk.  
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Fig. 3.4. MOR and BrdU IR in the E15.5 and E18.5 VZ. Panels A and B show confocal images of the VZ in 
E15.5 and E18.5 mouse brains, respectively. Panel A shows that most of the BrdU-positive nuclei (green) 
were found in MOR-positive cells (red) in the E15.5 brain. Examples of dual-labelled cells are indicated by 
arrows. Panel B shows the same region of brain in an E18.5 brain similarly stained. Orthogonal views (z-
plane transects at the yellow lines) are presented, and the x, y-plane comprising the main panel is indicated 
within the z-planes as green lines. Within the x, y-plane, a BrdU-positive/MOR-positive cell (arrowhead) and 
a BrdU-negative/MOR-positive cell (arrow) are indicated. A cell which appears to have stained negative for 
MOR within the x, y plane but can be seen to be MOR-positive within the y,z-plane is indicated by an asterisk 
(*). Scale bars: 10 µm (A and B). 
 
3.3.4 Proliferation in the Developing Cerebellum 
 
The proliferative zone of the developing cerebellum is the EGL, located at the periphery of 
the cerebellum and densely packed with proliferating cells that stained strongly for PCNA 
(Fig. 3.5, panel A). In contrast to the LV, 3V, and Aq, MOR IR was not observed within 
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the proliferative zone of the foetal cerebellum (Fig. 3.5, panels B and C) but was present, 
however, in the Purkinje layer. As the high density of cells within the developing 
cerebellum makes interpretation of immunohistochemical staining of PCNA IR difficult, 
cells in S phase were labelled by BrdU incorporation. E18.5, P6, and P12 pups were given 
BrdU (50 mg/kg) 1 h prior to sacrifice, and the cerebellum was stained for MOR IR and 
BrdU incorporation. Figure 3.6, panel A shows that the EGL of the E18.5 cerebellum 
contained many BrdU-positive nuclei (green) that did not stain for MOR (red); whereas, the 
developing Purkinje/molecular layer stained for MOR but contained few BrdU-positive 
nuclei. At P6 the Purkinje layer stained intensely for MOR, and the EGL contained 
abundant BrdU-positive nuclei with minimal MOR staining (panel B). By P12 (panel C), 
proliferation was much reduced, but MOR IR in the Purkinje layer was still clearly evident. 
 
 
Fig. 3.5. PCNA and MOR IR in the E18.5 cerebellum. Panels A and B show both PCNA and MOR IR, while 
panel C shows only MOR IR. The EGL in panel A is clearly defined by intense PCNA staining (green) at the 
periphery of the cerebellum (panel A, low power, and panel B, high power). MOR IR (red) is seen within the 
Purkinje and molecular layers of the cerebellum just beneath the EGL (A and C). Little MOR IR, however, is 
present within the EGL, which is shown demarcated by the white lines in panel C. Scale bars: 200 µm (A) and 
20 µm (B and C). 
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Fig. 3.6. Proliferation and MOR IR in the developing cerebellum. The E18.5 EGL was readily identified by 
its intense staining for BrdU (green, A, demarcated by white lines). MOR IR (red) was seen within the 
Purkinje and molecular layers (Pk/Mo) of the cerebellum just beneath the EGL. Little MOR IR, however, was 
present within the EGL. Panel B shows proliferation and MOR expression in the P6 cerebellum similarly 
stained. Strong MOR IR was present in Purkinje cells (white arrows) of the Purkinje layer, as well as the 
internal granule layer (IGL). Little MOR IR was seen within the EGL (indicated by the arrowheads) where 
most of the proliferative BrdU-positive cells were found. Similar staining patterns were seen in the P12 
cerebellum (panel C) with the Purkinje cells being clearly defined as MOR-positive, but with decreased 
proliferation (BrdU-staining) in the EGL. Scale bars: 50 µm. 
 
3.3.5 MOR and GLAST Staining 
 
Radial glia are the neuronal progenitors of the cerebral cortex. They stained for GLAST 
(Fig. 3.7, panels A-D, green staining) and had processes that extended from the LV wall to 
the pial surface to provide the scaffold on which pyramidal and interneurons migrate. 
Higher magnification confocal images of radial glial cell bodies at the LV wall in E15.5 
(panel C) and E18.5 (panel D) brains showed that immunoreactivity for GLAST (green) 
and MOR (red) was located in the plasma membrane of cells. At E15.5 the VZ contains 
many cells that are both MOR IR and GLAST IR, although not all GLAST-positive cells 
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stained for MOR. Orthogonal views confirming dual-labelling of a MOR-positive and 
GLAST-positive cell (indicated by arrows) are shown in panel C. Similarly, in the E18.5 
VZ GLAST-positive cells that stained intensely for MOR (panel D) were clearly visible. 
Orthogonal views show that MOR was not evenly distributed within the cell membrane as 
is evident from cross-sections through the z-plane of the cell indicated by an arrow. Using a 
confocal approach, we found that as for the E15.5 VZ, not all GLAST-positive cells stained 
for MOR. To determine whether the progenitor cells in the neuroepithelium that overlies 
the striatum were also MOR and GLAST positive, sections encompassing the brain regions 
described in Fig. 3.3, panels A to D were stained. All of the MOR IR cells in this region 
were also GLAST-positive, however, these MOR IR and GLAST IR cells represented only 
a small fraction of the GLAST-positive population (Fig. 3.7, panels E and F). Even though 
GLAST-positive cells of the VZ expressed MOR, DOR IR could not be found (Fig. 3.8). 
The anti-DOR antibody was suitable for immunofluorescence in tissue, since the spinal 
trigeminal tract of a postnatal mouse stained brightly for DOR (panel C), as expected 
(positive control). 
 
Confocal analysis of the 3V and Aq walls (Fig. 3.9) revealed that the cells at the ventricle 
walls in these regions were also GLAST-positive (green) with long fibres that radiated 
perpendicularly (white arrows, panels A and C). This suggests that these cells radiating out 
from the 3V and Aq were also radial glia. Fig. 3.9 panels B and D show that some of these 
radial glia were also MOR IR (red), as indicated by arrows. 
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Fig. 3.7. MOR and GLAST IR in the E15.5 and E18.5 LV neuroepithelium. Panels A and B show low power 
images of the E15.5 and E18.5 VZ, respectively. Both panels show MOR IR (red) in the same region as 
GLAST staining (green). Panel C shows a higher magnification image of the E15.5 VZ in which MOR IR 
(red) and GLAST IR (green) can be seen within the same cell. Orthogonal views (z-planes) of the double-
labelled cell (indicated by the arrow) are presented in the side bars. Similarly, panel D shows a higher power 
image of the E18.5 VZ in which double-labelling for MOR and GLAST is more apparent. Nearly all the 
MOR-positive cells examined stained for GLAST, but many GLAST-positive cells did not stain for MOR. A 
GLAST-positive/MOR-negative cell is marked with an asterisk, and orthogonal views through a MOR-
positive/GLAST-positive cell (arrows) are presented in the side bars. Panels E and F show similarly stained 
regions of cortical neuroepithelium (equivalent to that in Fig. 3.3, panel D) from E18.5 brains in which MOR 
IR and GLAST IR are found within the same cell (arrowheads). Scale bars: 50 µm (A, B and E), 20 µm (F) 
and 10 µm (C and D). 
 
 
Fig. 3.8. DOR immunoreactivity in the E15.5 VZ. A confocal image of the E15.5 VZ shows radial glia 
stained for GLAST (green) (panel A). As in Fig. 3.7, panel C, these GLAST-positive radial glia also stained 
positive for MOR (red). However, when the same region of VZ is stained for DOR (red), there appeared to be 
minimal expression on the same GLAST-positive radial glia that also stained positive for MOR (panel B). 
Panel C shows a lower power photomicrograph of the spinal trigeminal tract, which stained strongly for DOR 
(red). DOR staining in the spinal trigeminal tract was performed under the same conditions as in panel B. The 
spinal trigeminal tract is counterstained with DAPI (blue). Scale bars: 20 µm (A and B) and 200 µm (C). 
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Fig. 3.9. MOR and GLAST IR in the neuroepithelia of the 3V and Aq in the E18.5 mouse. Panel A shows 
intense GLAST staining (green) at the wall of the 3V. GLAST IR processes that extended perpendicular from 
the ventricular wall can be clearly seen (white arrows). MOR IR (red) was also located around the 3V (A and 
B). White arrows in panel B identify some of the cells that stained for both MOR and GLAST. Panel C shows 
MOR and GLAST IR at the wall of the Aq. Similarly, GLAST IR processes extended perpendicular from the 
wall of the Aq (C, white arrows) with many of the GLAST IR cells also expressing MOR (D, white arrows). 
Scale bars: 50 µm (A and C) and 20 µm (B and D). 
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3.3.6 MOR and DCX Staining 
 
To determine if the MOR IR seen in the cortex was expressed on migrating neurons, 
sections encompassing the regions described in Fig. 3.3 were double-stained for MOR and 
the neuronal migration-specific marker DCX. Fig. 3.10, panel A shows MOR IR (red) and 
DCX IR (green) around the LV with MOR IR being predominantly localised to the edge of 
the LV wall (arrowheads). Confocal imaging showed that the vast majority of MOR IR 
cells were not DCX IR. Panels B and C show confocal images of a region of the 
neuroepithelium equivalent to that presented in Fig. 3.3, panels B and D. As for the LV 
wall, the MOR IR cells of the cortical neuroepithelium did not express DCX, with MOR IR 
(red) and DCX IR (green) being mutually exclusive for the majority of cells (panel B, 
arrowheads). Panel C shows a higher-magnification confocal image of two DCX-positive 
cells (asterisk) in the cortical neuroepithelium. Orthogonal views confirm that these cells do 
not express MOR, although they are in close proximity to MOR IR processes. 
 
 
Fig. 3.10. MOR and DCX IR in the E18.5 neocortex. Panel A shows a region of VZ at the LV wall in an 
E18.5 brain stained for MOR (red) and DCX (green). MOR IR is located mainly within the VZ at the LV 
wall, with few dual-labelled MOR IR/DCX IR cells apparent. Panel B shows an equivalent region of cortical 
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neuroepithelium to that presented in Fig. 3.3, panel D. Most of the MOR IR cells do not express DCX 
(arrowheads). Orthogonal views (panel C) are presented in the side bars of MOR-positive cells that confirm 
the absence of DCX IR within these cells. Panel C shows a higher magnification image of cells presented in 
panel B. Two DCX positive cells in the x, y-plane are indicated with an asterisk, and orthogonal views in the 
z-plane are presented in the side bars. Cytoplasmic staining for DCX (green) is clearly visible, and MOR IR 
(red) processes can be seen contacting the cell bodies (arrowheads). The orthogonal views confirm that the 
MOR IR seen adjacent to the cell bodies is not within the DCX-positive cell. Scale bars: 50 µm (A and B) and 
10 µm (B). 
 
3.3.7 Gradient of Proliferation and MOR Expression within the LV Cortical 
Neuroepithelium 
 
Previous studies have shown that proliferation is not uniform throughout the cortex, with 
distinct gradients occurring both medial-lateral and rostral-caudal at early and mid-stages of 
corticogenesis (Miyama et al., 1997). We therefore wished to examine the topology of 
proliferation at the end of corticogenesis (E18.5) in the mouse. Proliferative cells were 
labelled with BrdU and labelled nuclei counted using a stereological approach on paraffin-
embedded sections. BrdU-stained nuclei were much more numerous at the anterior region 
of the LV than the posterior such that an anterior to posterior gradient of proliferation 
existed in the E18.5 mouse cortex (Fig. 3.11). A significant linear regression was fit to the 
data collected from three mouse embryos (n = 3 separate litters) (R2 = 0.82, P < 0.05). The 
density of MOR IR cells was determined by counting fluorescently stained cells using a 
photomicroscope. Cell counts for MOR IR were expressed in Fig. 3.11 as the number of 
cells per unit area. The density of MOR IR followed the opposite trend to that for BrdU 
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labelling, with MOR expression decreasing in a posterior to anterior manner, with the 
greatest density of MOR-positive cells in the posterior sections. A significant linear 
regression was fit to the data collected from three mouse embryos (n = 3 separate litters) 
(R2 = 0.91, P <0.05). 
 
 
Fig. 3.11. Gradients of proliferation and MOR expression in the dorsal VZ of the LV in E18.5 mice. BrdU 
incorporation decreased in an anterior to posterior direction (P < 0.05) (black squares), while the number of 
MOR IR cells (empty circles) increased anterior to posterior (P < 0.05). Staining for BrdU incorporation was 
performed on paraffin-embedded sections and counted stereologically; whereas, MOR IHC was performed on 
fixed, then cryopreserved, 20 µm sections using non-stereological methods. To correct for the effects of tissue 
shrinkage that occurs with paraffin embedding, the relative distance from the first anterior appearance of the 
LV (set arbitrarily at 0 units) to its disappearance posteriorly (1 unit) is plotted along the x-axis. The y-axis 
represents the density of BrdU-stained nuclei (mm−3×105) and MOR-stained cells (mm−2×103). Values 
represent the mean ± S.E.M. (n=3 separate litters). P values were determined by regression analysis. 
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3.4 Discussion 
 
The present study demonstrated that MOR is expressed within the cortical neuroepithelium 
of the E15.5 LV, and the neuroepithelia of the LV, 3V, and the Aq of the E18.5 mouse 
brain. The cells in these regions incorporate BrdU, and hence are proliferative. MOR IR 
cells within ventricular neuroepithelia were also GLAST IR indicating that they are radial 
glia. MOR IR cells in proliferating regions were not DCX IR, suggesting that the MOR-
positive cells within neuroepithelium are radial glial progenitor cells and not migrating 
daughter neuroblasts. The same staining pattern was seen at all the ventricular surfaces 
examined. 
 
3.4.1 Antibody Validation 
 
While validating the rabbit anti-MOR antibody, western blots were performed to identify 
detected proteins according to molecular weight. Western blotting using the anti-MOR 
antibody (AB5511) detected two bands, one at 45 kDa and the other at 70 kDa. These 
bands correspond to the unprocessed MOR protein and the glycosylated form, respectively. 
Several studies support the existence of MOR glycosylation (see Table 3.1) at similar 
molecular weights (Eppler et al., 1993; Liu-Chen et al., 1993; Ding et al., 1996; Chalecka-
Franaszek et al., 2000; Christoffers et al., 2003; Kivell et al. 2004). Also, the ExPASy 
Proteomics Server identifies 4 potential glycosylation sites on the murine MOR protein 
(http://ca.expasy.org/uniprot/P42866). 
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Species 
 
Detection method 
 
Detected size of opioid 
receptor protein 
 
Study 
 
Rat 
 
Isolated using biotinylated 
beta-endorphin 
 
60-70 kDa, reduced to 40 
kDa with glycosylase. MOR 
protein sequence isolated. 
 
 
Eppler et al., 1993 
Mouse Detected with [3H]beta-
FNA 
66 kDa, reduced to 43 kDa 
with glycosylase 
Liu-Chen et al., 1993 
 
Rat 
 
Detection with three 
different antibodies 
 
A diffuse band at ~60 kDa 
 
Ding et al., 1996 
 
Rat 
 
Two antisera raised against 
C and N termini of MOR 
 
Band spanning 60-75 kDa 
 
Chalecka-Franaszek et al., 
2000 
 
Mouse 
 
Modified Oprm gene to 
include hexahistidine tag 
and FLAG tag 
 
Glycoprotein found at 80 
kDa. MOR protein sequence 
identified with MALDI-MS 
 
Christoffers et al., 2003 
 
Rat 
 
Commercially available 
Chemicon antibodies 
(AB1774 and AB1580) 
 
Two bands at 50 and 70 kDa 
 
Kivell et al., 2004 
 
Table 3.1: Studies that have reported glycosylated forms of the MOR. 
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3.4.2 Implications of MOR Localisation 
 
3.4.2.1 MOR in the VZ and the SVZ of the E15.5 and E18.5 Mouse 
 
MOR expression in the VZ of the E15.5 mouse dorsal telencephalon has implications for 
both neurogenesis and gliogenesis during construction of the cerebral cortex, as well as 
corroborates immunohistochemical results from the study of Reznikov et al. (1999). The 
presence of MOR on radial glia means that direct opioid signalling may impact upon 
developmental processes. Expression of opioid system receptors and ligands on cells of 
astrocytic lineage (Vilijn et al., 1988; Hauser et al., 1990; Ruzicka et al., 1995; Stiene-
Martin et al., 1998) perturbs both proliferation and differentiation in vitro (Stiene-Martin et 
al., 1991b; Stiene-Martin et al., 1993; Hauser et al., 1996). 
 
Interestingly, no DOR expression was found in the cortical VZ of the E15.5 mouse. This 
result contrasts with that of Reznikov et al. (1999) who found diffuse DOR staining in the 
VZ. Other studies, however, have demonstrated that in contrast to MOR and KOR, DOR 
expression is generally very low in the foetal rodent brain (Leslie et al., 1998; Zhu et al., 
1998). 
 
Intense MOR expression on PCNA-positive cells of the dorsal-rostral (Fig. 3.3, panel B) 
and dorsal-lateral (panel D) SVZ of the E18.5 mouse was surprising, given past radio in 
situ hybridisation studies (Leslie et al., 1998; Zhu et al., 1998). However, based on older 
radioligand binding studies that found signal within the developing SVZ (Kent et al., 
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1982), as well as literature that documents the sensitivity of neonatal astrocytes to opiates 
(c.f. literature published from the groups of Hauser and Coscia), this result was consistent 
with a significant number of previous studies (see above). 
 
The extensions of the SVZ in the late foetal mouse brain observed in Fig. 3.3, panels A-D, 
are a result of the fusion of the lateral ventricle at the cortico-striatal boundary. The rostral 
regions of SVZ (Fig. 3.3, panels A and B) produce cells for the rostral migratory stream in 
the adult brain. The dorsal-lateral regions of SVZ shown in panels C and D are a rich 
source of glia in the developing postnatal brain (reviewed in Brazel et al., 2003). Astroglia 
from the SVZ are a source (albeit a very minor one) of cortical neurons (Ganat et al., 2006) 
as well as neurons for the ventral forebrain in the postnatal rodent (De Marchis et al., 
2004). As well as being a proliferative area in the neonate, the SVZ retains neurogenic 
capability in the adult mammal (Lois and Alvarez-Buylla, 1993) and contributes to 
increases in cell number (partly due to increased proliferation) in response to injury in the 
rat cerebral cortex. Interestingly, after injury in the brain, neurons migrate to the area of 
injury (reviewed in Romanko et al., 2004). Thus the expression of the MOR on astrocytic 
lineage cells of the SVZ is potentially of wider interest to areas of neuro-repair and 
regeneration in the adult brain. 
 
The existence of an anterior to posterior gradient of proliferation within the proliferative 
zone of the E18.5 dorsal forebrain and an inverse gradient of MOR expression is consistent 
with the idea of MOR activation being anti-proliferative. It is, however, speculative to 
suggest that MOR signalling maintains or regulates the gradient of proliferation in vivo, as 
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there is still little direct supporting evidence to indicate that opioid ligands have an 
antiproliferative effect in vivo via MOR signalling within the context of the perinatal rodent 
forebrain (Stiene-Martin et al., 2001). The data we have presented in this study does, 
however, place expression of the receptor on the appropriate cells for modulation of 
corticogenesis, and it is of interest to note that morphine exposure through the period E12 
to P6 in the rat decreased cortical neuronal density (Seatriz and Hammer, 1993). 
 
3.4.2.2 MOR in the Developing Cerebellum 
 
In contrast to the epithelia lining the ventricular walls, the proliferative zone (EGL) of the 
developing cerebellum lacked MOR immunoreactivity in the E18.5 brain. The cerebellum 
is a late-developing structure and is extremely immature in the late foetal mouse 
(Goldowitz and Hamre, 1998). We, and others, have conclusively shown that the rodent 
cerebellum expresses MOR mRNA and protein, predominantly in the Purkinje layer and 
the deep cerebellar nuclei (Mrkusich et al., 2004; Xu et al., 2006, Zhang et al., 2006). 
Mrkusich et al. (2004) demonstrated the presence of opioid receptor mRNA as well as 
protein, via immunohistochemistry, in Purkinje cells and the deeper cerebellar nuclei. This 
was also demonstrated immunohistochemically by Zhang et al. (2006). Xu et al. (2006) 
corroborated these findings in mice using a green fluorescent protein-tau reporter under 
control of the exon 1 MOR promoters by demonstrating MOR promoter activity in Purkinje 
cells as well as the deeper cerebellar nuclei. Interestingly, several years earlier, the presence 
of opioid receptor expression in the cerebellum was discounted by both radio in situ 
 102 
hybridisation studies as well as immunohistochemical studies (Mansour et al., 1994; 
Mansour et al., 1995; Ding et al., 1996; Zhu et al., 1998). 
 
Given the relative immaturity of the cerebellum at birth and its continued development up 
to the third postnatal week (Goldowitz and Hamre, 1998), we reasoned that MOR 
expression may increase after E18.5. This was, however, not the case since the P6 and P12 
cerebellum showed strong MOR staining of Purkinje cells, as in the adult, but replicating 
(BrdU-positive) cells still lacked MOR expression in the postnatal brain. These data 
suggest a different role for MOR signalling in the developing cerebellum than that in the 
ventricular neuroepithelia. The data also corroborate our previous report that MOR mRNA 
is expressed in Purkinje cells of the developing cerebellum (Mrkusich et al., 2004). 
 
The lack of MOR staining in the EGL of the cerebellum was surprising, given findings 
published in the literature (Hauser, 1992; Hauser et al., 2000). Hauser (1992) reported that 
morphine treatment inhibited BrdU incorporation in neuroblasts from the EGL (IC50 = 22.5 
nM). The inhibitory effect of morphine exposure was shown again in vitro, along with 
MOR immunostaining on isolated neuroblasts from the EGL. As the anti-MOR antibody 
used in the current study has no difficulty in detecting MOR in Purkinje cells, the striatum, 
and in dorsal horns of the spinal cord, MORs in the EGL may have been expressed at such 
a low level that our detection system was not sensitive enough to find them. Alternatively, 
EGL neuroblasts may have up-regulated MOR as a consequence of these cells being 
cultured in vitro in the studies of Hauser (1992) and Hauser et al. (2000). 
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3.4.3 Technical Considerations 
 
It should be noted that the antibody used in this study (Chemicon, rabbit anti-MOR, 
AB5511) was raised against exon 4 of MOR. Exon 4 containing splice variants of the MOR 
include MOR-1, as well as the exon-11 containing splice variants MOR-1H to MOR-1L 
(Abbadie et al., 2004). However, this antibody does not recognise the rodent carboxy 
terminus MOR splice variants such as MOR-1A to MOR-1F. As these MOR carboxy 
terminus splice variants differ in their responses to endogenous opioid peptides as well as 
exogenous opiates (Bolan et al., 2004; Pasternak et al., 2004), future work is needed to 
characterise the foetal expression patterns of these variant receptors in relation to MOR 
expression. We have previously detected mRNA coding MOR in the developing rat 
cerebellum (Mrkusich et al. 2004). This study used riboprobes that detected the 5’ UTR of 
MOR mRNA. Using the anti-MOR antibody described in this study, we found good 
correlation between MOR mRNA and protein expression in all regions of the cerebellum 
apart from the EGL. As others have shown differential immunohistochemical localisation 
for carboxy terminus splice variants in the adult rat CNS (Abbadie et al., 2000), it is 
possible that the discordance between protein expression and mRNA localisation in the 
EGL may be attributable to expression of a splice variant lacking exon 4. Alternatively, the 
discrepancy may simply reflect the lower resolution of mRNA in situ hybridisation and the 
confounding factor of high cell density in the developing cerebellum that would reduce the 
signal-to-noise ratio. 
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In the present chapter, MOR expression in proliferative neuroepithelia of the developing 
mouse brain was observed only on replicating radial glia (BrdU-positive, GLAST-positive 
cells) around the ventricular neuroepithelia, but not on newborn migrating neurons (DCX-
positive cells). As there is evidence in the literature to support the hypothesis that MOR 
signalling modulates proliferation, particularly in astrocytes in vitro, the possibility of 
MOR modulation of cell cycle progression in the developing foetal brain warrants further 
investigation. 
 
The results presented in this chapter have been published in Brain Research (Sargeant et al., 
2007). 
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4. MOR is Expressed on Glia of the Foetal Human Forebrain 
 
4.1 Introduction 
 
4.1.1 The Need for Human Studies 
 
The wealth of data collected on the complicated relationship between opioids and cellular 
proliferation has been obtained mainly from rodent models. The little data that does exist 
on how opioids interact with human CNS progenitor cells has been obtained from studies 
using dissociated tissue in culture (Sheng et al., 2007). Such studies are limited as valuable 
information regarding spatial distribution, and how cells might interact with their 
surrounding cellular matrix, is lost. As the development of the rodent brain does subtly 
diverge from primate brain development in aspects other than sheer size and proportions, it 
is therefore important to gather data on the endogenous opioid system in vivo, in the 
developing human foetus. 
 
4.1.2 Anatomical and Cellular Contrasts between Human and Rodent Corticogenesis 
 
4.1.2.1 Neuronal Contribution from the VZ and the SVZ 
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The primary proliferative zone of the developing rodent forebrain is the VZ (Dehay and 
Kennedy, 2007). During the peak of neurogenesis in the mouse forebrain (E14 (Miyama et 
al., 1997; Caviness et al., 2003)), the largest proliferative region is the pseudostratified VZ; 
whereas, the smaller SVZ is a zone where intermediate progenitor cells (basal progenitors) 
undergo terminal, neurogenic divisions. In contrast to the developing rodent cortex, the 
primate SVZ dwarfs the VZ at the equivalent developmental stage. Furthermore, the 
primate SVZ is split by the inner fibrous layer into the inner and outer SVZ (Smart et al., 
2002). Another difference is the primate SVZ generates inhibitory interneurons (Letinic et 
al., 2002); whereas, in the rodent brain, this is primarily the role of the ganglionic 
eminences (Bulfone et al., 1993; Porteus et al., 1994; De Carlos et al., 1996; Lavdas et al., 
1999). It has been suggested that enlargement of the primate SVZ is directly related to the 
evolutionary enlargement of the primate cerebral cortex (Zecevic et al., 2005). 
 
4.1.2.2 Cell Cycle Ontogeny 
 
As well as these anatomical and functional differences between the proliferative zones of 
the primate and rodent, cell cycle kinetics are also markedly altered. In the rodent forebrain, 
there is a consistent increase in cell cycle time as development progresses (Miyama et al., 
1997), whereas in the primate the neurogenic interval increases from the onset of 
neurogenesis until mid-corticogenesis after which there is a large decrease in cell cycle 
time at the commencement of genesis of layer III of the cerebral cortex (Kornack and 
Rakic, 1998, see Chapter 1). Irrespective of the differences between rodent and primate 
corticogenesis, both the positioning and occurrence of non-ventricular surface mitoses at 
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the preplate stage of corticogenesis (very early in development) are remarkably similar 
(Carney et al., 2007). Also, the primate SVZ, like the rodent SVZ, is heavily involved with 
generation of supragranular layer neurons (Tarabykin et al., 2001; Lukaszewicz et al., 
2005).  
 
4.1.2.3 Neuronal Progenitor Cell Types 
 
Radial glial cells were first identified as a scaffold upon which neurons migrated in the 
primate brain using GFAP immunohistochemistry (Rakic, 1972; Levitt and Rakic, 1980). 
Even though both murine and primate radial glia serve as a scaffold for migrating neurons, 
and neuronal progenitor cells (Mo et al., 2007), rodent radial glia do not express the 
intermediate filament GFAP until they differentiate into astrocytes (Tramontin et al., 2003). 
In addition, rodent radial glial nuclear movements are restricted to the VZ, whereas in the 
human, radial glial nuclei are free to migrate into the SVZ or the intermediate zone to 
undergo mitosis (Howard et al., 2006). 
 
Furthermore, in the foetal human brain, neuronally restricted progenitor cells that express 
markers such as beta III-tubulin and DCX can also undergo mitosis to produce neurons 
(Howard et al., 2006; Mo et al., 2007). In spite of much research into rodent brain 
development, such cells have not yet been found in the developing mouse brain, although 
the recent discovery of short neuronal precursor cells in the foetal rodent brain (Gal et al., 
2006) has provided a possible murine equivalent for human neuronally restricted 
precursors. 
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4.1.2.4 Rate of Evolutionary Change 
 
Primate genes involved with brain development and behaviour evolved significantly more 
quickly than their rodent counterparts over the same time (Dorus et al., 2004). In fact, 
genes involved with brain development and behaviour were the fastest evolving genes in 
the primate. Some of these genes included ASPM (abnormal spindle-like, microcephaly 
associated) and microcephalin, both of which regulate brain size in the human (Cox et al., 
2006). Interestingly, Dorus et al. (2004) also showed that MOR gene had evolved 
significantly faster in the primate than in the rodent, suggesting that the MOR was part of 
the genetic shift that contributed to increased complexity in the human brain. 
 
Although the developing primate and rodent brain have a lot of features in common, there 
are aspects of significant difference. This makes it important to assess whether results 
obtained in the rodent model can be extrapolated to the human developing cortex. Thus, the 
aim of the work presented in this chapter was to determine if the immunohistochemical 
findings from the mouse, that showed MOR expression on radial glia of the late foetal 
forebrain (Chapter 3), was also true for the human foetal brain.  
 
4.2 Research Design 
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4.2.1 Immunohistochemical Markers 
 
In order to assess MOR IR, the same antibody was used for the human studies as that used 
for the mouse studies. This was possible because the antigenic peptide used to generate the 
antibody (from the carboxy terminus of MOR) does not vary in peptide sequence between 
rodents and humans. Human radial glia were identified by staining for vimentin, a class III 
intermediate filament protein (Herrmann and Aebi, 2000), rather than GLAST as in the 
mouse. To further characterise MOR staining, nestin (NeuroEpithelial STem cell marker), a 
class VI (or class IV) intermediate filament, that is expressed by proliferating 
neuroepithelial and radial glial cells (Hockfield and McKay, 1985; Frederiksen and McKay, 
1988) was also used. Nestin is expressed by neuronal progenitor cells (Frederiksen et al., 
1988; Cattaneo and McKay, 1990). As in the mouse, DCX is expressed on migrating 
neurons.  
 
4.2.2 Tissue Processing and Image Acquisition  
 
All immunohistochemistry was performed on fixed-frozen, 40 µm thick, coronal cryostat-
microtome sections. Images were captured using an Olympus FV1000 confocal system. 
Cell counting was performed on sections of human foetal forebrain within the dorso-lateral 
SVZ at the level of the caudate-putamen. Image manipulation and cell counting was 
performed using Fireworks (v7.0.2.295) and ImageJ (v1.37) software. 
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4.3 Results 
 
4.3.1 Sample Fixation 
 
Human foetal brain samples were gifted from Associate Professor Tailoi Chan-Ling and 
transported from Sydney University in sterile PBS. Fig. 4.1 shows the brain samples on 
arrival. Brains were fixed prior to transport from Australia by a number of different 
methods that included either fixation in PFA or ethanol (Table 4.1). 
 
Brain ID 
number 
Age (GW) Fixation Protocol 
 
1 
 
12 
 
PBS containing 4% PFA overnight 
2 16 8 min PBS containing 4% PFA, 40 min 70% ethanol  
3 16 PBS containing 4% PFA overnight  
4 19 8 min PBS containing 4% PFA, 40 min 70% ethanol 
5 20 PBS containing 4% PFA overnight 
Table 4.1: Fixation parameters for the brain samples obtained from As. Prof. T.C-L. 
 
Sectioning and Nissl staining of brain 1 (12 gestational weeks (GW)) showed it consisted 
almost entirely of brainstem (8.4, Appendix 4); however, all other brain samples contained 
regions of forebrain that could be used to investigate opioid receptor staining and its 
relationship with glial markers. Because human brain tissue that had been fixed overnight 
in 4% PFA gave inconsistent immunostaining results, it was decided to use the human brain 
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samples that had been fixed in ethanol after 8 min in 4% PFA for the rest of the analysis 
(brains 2 and 4). 
 
 
Fig. 4.1. Human foetal brain samples on arrival from Australia. Panel A shows brain 1, which was 12 
gestational weeks (GW) (red arrow). Panel B shows brain 2, a 16 GW brain that had been fixed in ethanol. A 
16 GW brain (brain 3) that had been fixed in 4% PFA (panel C) demonstrated the different effects of fixation 
on gross sample morphology, as compared with panel D. Panel D shows a fragmented 19 GW brain (brain 4) 
that had been fixed in ethanol, and panels E and F show a 20 GW brain that had been quartered before 
packaging and transport (brain 5). 
 
4.3.2 Human Foetal Brain Sample and Reconstruction 
 
Brain number 3 was obtained as a number of small fragments on arrival. The foetal brain 
was photographed and the image was reorganised to allow identification of brain regions 
(Fig. 4.2). 
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Fig. 4.2. Photography and identification of a main structures. Panel A shows the 16 GW foetal brain (brain 3) 
on arrival in its sample container. Digital rearrangement of the photograph presented in panel A allowed for 
determination of anatomical aspects of the brain (panel B). On the right hand side of panel B are images 
created from MRI data taken from 16 GW foetuses (Sbarbati et al., 2004). Subsequent microscopic 
morphology confirmed the rearrangement presented in panel B. 
 
4.3.3 Opioid Receptor Antibody Staining in the Human Brain 
 
Frozen tissue was sectioned from regions of forebrain that contained striatum. Ligand 
binding studies have shown the human striatum expresses both MOR and KOR (Vonkeman 
et al., 1996; Voorn et al., 1996; Daunais et al., 2001). When sections of human forebrain 
were stained with antibodies for MOR and KOR, fibre tracts within the striatum were 
clearly stained. This anatomy is in agreement with the known function and distribution of 
these opioid receptors in the striatum (Fig. 4.3, panels C and D). Omission of the primary 
opioid receptor antibodies resulted in no staining in adjacent sections of striatum, showing 
that staining was not due to non-specific binding by the secondary antibody (Fig. 4.3, 
panels A and B). 
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Fig. 4.3. Opioid receptor staining in the 16 GW human striatum. Panel A shows MOR staining (red) and 
DAPI staining for nuclei (blue). Panel B shows an adjacent section of human striatum stained with only the 
goat anti-rabbit-Alexa 555 antibody. This image was captured and manipulated identically to that in panel A. 
Panel C shows MOR IR in the human striatum. Fibre tracts were clearly stained for MOR (red). Panel D 
shows the striatum of the same brain stained for KOR. This staining was similar to that of MOR. Scale bars: 
200 µm (A and B) and 100 µm (C and D). 
 
Upon investigation of the dorso-lateral VZ/SVZ, MOR-positive cells that had the same 
staining characteristics as in the late foetal mouse brain were identified. Interestingly, no 
such KOR-positive cells could be found in this region. Staining for KOR was not 
undertaken in the mouse. The MOR-positive cells present in the dorso-lateral SVZ of the 
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16 and 19 GW human brain were present up to the ventricular edge (Fig. 4.4, panels A and 
B); however, they were not present in great numbers in the VZ, as seen in the late foetal 
mouse brain (Fig. 4.4, panel C). 
 
 
Fig.4.4. MOR staining at the LV surface in the human and in the mouse. Panels A and B show MOR staining 
at the lateral ventricular wall (dashed line) in the 16 and 19 GW human dorsal telencephalon. MOR positive 
cells were present in the SVZ but did not populate the VZ. Panel C shows that in the E18.5 dorso-lateral VZ 
of the mouse, MOR staining is present in both the SVZ, and also at the ventricular wall, in contrast to the 
human foetal staining pattern seen in panels A and B. Scale bars: 50 µm. 
 
4.3.4 MOR Co-labelling in the Foetal Human Dorso-Lateral SVZ 
 
In order to better characterise which types of cell express MOR in the SVZ of the human 
foetal brain, co-labelling of MOR immunofluorescence was investigated with other markers 
for glial or neuronal cells. In this study, vimentin was used as a radial glial marker, and 
nestin was used to determine whether MOR expressing cells were potentially neurogenic. 
Staining for vimentin (Fig. 4.5) or the other intermediate filament protein nestin, revealed 
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the radial glial scaffold which was still present at 19 GW. Staining for DCX was used to 
assess whether migrating neurons or neuroblasts expressed opioid receptors. MOR IR co-
labelled strongly with vimentin at both 16 and 19 GW (Fig. 4.6, panels A and B), but also 
co-labelled with nestin (panels C and D). As with the mouse, MOR staining in the SVZ 
displayed little or no co-labelling with DCX (panels E and F). 
 
 
Fig. 4.5. Vimentin staining of the radial glial scaffold at 19 GW in the developing human cortex. Panel A 
shows a low power view of basal processes of the radial glia in the developing human cerebral cortex stained 
for vimentin. A higher magnification view (orthogonally cut in the x-axis) shows radial processes in 
longitudinal as well as in transverse section (shown in the x, z-axis at the bottom of the picture). Scale bars: 
100 µm (A) and 50 µm (B). 
 
 116 
 
 117 
Fig. 4.6. Cellular co-expression of MOR and the markers vimentin, nestin and DCX. MOR IR (red) in the 16 
and 19 GW SVZ showed cellular co-labelling with vimentin in a high proportion of MOR IR cells (panels A 
and B). Co-expression of MOR occurred less with nestin in the two brains examined (panels C and D), 
whereas, co-expression of MOR and DCX did not occur in the SVZ. Scale bars: 50 µm. 
 
Co-expression of MOR and other markers was determined by analysing high-resolution 
images of cells in the x, y and z-axes. Examples of cellular co-expression of MOR with the 
markers vimentin and nestin are shown in Fig. 4.7. As seen in the mouse, cells that 
expressed MOR in the SVZ showed intense labelling in distinct subcellular locations.  
  
 
Fig. 4.7. Orthogonal views of cells co-expressing MOR IR and vimentin or nestin. Image series A shows 
cellular co-expression of vimentin (green) and MOR (red) in a single cell of the 16 GW SVZ. Image series B 
shows co-expression of MOR and nestin in the 19 GW brain. MOR expression is intense but does not label 
the entire cell cytoplasm/plasma membrane in a diffuse manner, as seen with vimentin, giving a patchy, 
localised staining pattern instead. Scale bars: 5 µm (A) and 10 µm (B). 
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In order to characterise cell marker expression of MOR expressing cells, MOR-positive 
cells from the SVZ were counted, and proportions of cells co-labelled for different markers 
were determined. Results are presented as a proportion of all MOR expressing cells 
counted. Cells were counted from a 16 GW and a 19 GW brain (brains 2 and 4). In the 16 
GW brain, most MOR-positive cells (86%) were vimentin-positive. Few MOR-positive 
cells displayed dual-labelling for nestin (only 9%), and negligible numbers of cells co-
labelled for DCX (4%). In comparison with the 16 GW brain, the 19 GW brain showed that 
fewer MOR-positive cells co-labelled for vimentin (58%); whereas, the proportion of dual-
labelled nestin-positive cells had increased (40%). No dual-labelled DCX-positive cells 
could be found. 
 
 
Fig. 4.8. A graph showing proportions of MOR expressing cells that co-express the markers vimentin, nestin 
and DCX. The majority of MOR expressing cells in the 16 GW SVZ (grey bars) express vimentin, but, less 
than 10% of MOR expressing cells also expressed nestin. In the 19 GW SVZ (white bars), proportions of 
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MOR expressing cells dual-labelled for vimentin and nestin changed such that fewer cells co-labelled for 
vimentin, and more cells were co-labelled for nestin. In both brains analysed, very few MOR-DCX dual-
labelled cells were found. Numbers above the bars represent the number of cells counted for each category. 
 
4.4 Discussion 
 
The current chapter has described MOR, as well as KOR, expression in the caudate-
putamen, where opioid receptor labelling in the human brain has already been characterised 
(Vonkeman et al., 1996; Voorn et al., 1996; Daunais et al., 2001; Wang et al., 2006). 
Importantly, MOR staining was also shown in the dorso-lateral SVZ of the 16 GW 
forebrain. These MOR-positive cells were sparsely populated and stained intensely for 
MOR IR. Furthermore, they also expressed vimentin, an intermediate filament expressed by 
radial glia, and some of the cells also expressed the neuronal progenitor marker, nestin. 
Very few of these cells expressed the neuronal marker, DCX. Preliminary quantitative data 
showed that the 16 GW brain had higher co-expression of MOR with vimentin; whereas, 
this double-labelling was much less in the 19 GW brain. Conversely, little MOR-nestin co-
expression was seen in the 16 GW brain, but this dual-staining pattern increased four-fold 
in the 19 GW brain. The MOR-positive cells seen in the human SVZ closely resembled 
MOR-positive cells of the foetal mouse brain dorsal SVZ. In contrast to the foetal mouse, 
no marked MOR staining could be identified at the lateral ventricular edge. 
 
The observation that KOR IR was not present in the same regions of human foetal SVZ is 
consistent with a study by Stiene-Martin et al. (2001) who showed that MOR-IR far 
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exceeded that of DOR and KOR in the P2-5 rodent SVZ. However, this result contrasts 
with the study of Sheng et al. (2007) who showed that cultured nestin-positive neuronal 
progenitor cells expressed KOR and that stimulation of these receptors promoted cellular 
proliferation. These neuronal progenitor cells were cultured from 7-9 GW human foetuses, 
in contrast to the older foetuses used for the present study (16 and 19 weeks old). This 
difference in developmental stage may account for the lack of KOR IR observed in the 
present study. 
 
In contrast to the developing E18.5 (Chapter 3) and P2-5 (Stiene-Martin et al., 2001) rodent 
brains, where MOR IR was found at the ventricular wall, the human brain showed no 
robust MOR staining at the LV; MOR staining was only present in the SVZ. This 
difference between rodent and human may be explained by the fact that the rodent and the 
human VZs are divergent in both relative size and contribution towards the developing 
cerebral cortex (Dehay and Kennedy, 2007).  
 
Identification of MOR IR glia in the human foetal brain is important because it highlights a 
similarity to the rodent brain in which glia in the developing late foetal (Chapter 3) and 
postnatal (Stiene-Martin et al., 2001) animals express opioid receptors and opioid ligands 
(Vilijn et al., 1988; Hauser et al., 1990; Stiene-Martin et al., 1991a). It also shows that glia 
within the SVZ of the human may be susceptible to the proliferative effects of direct opioid 
signalling seen in vitro (Hauser et al., 1996) as well as the proliferative effects observed in 
vivo (Stiene-Martin et al., 2001). Furthermore, the finding that MOR was expressed on 
nestin-positive cells shows that some of these cells may have been multipotent neuronal 
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progenitors, suggesting that opioid signalling has the potential to directly impact upon 
neurogenesis in the human foetal forebrain. 
 
As was consistent with the mouse study, MOR expression was restricted to glia (shown by 
GLAST in the mouse), not neurons or neuroblasts within the proliferative zones. Radial 
glia at mid-gestation in the human forebrain display marker heterogeneity (Howard et al., 
2006). Similarly, the use of two different intermediate filament markers in the present study 
showed that MOR-positivity was not exclusive to one type of radial glial marker and that 
one marker could not wholly characterise the type of glial cell that expresses MOR. Two 
different models could account for this observation. MOR-positive glia could be comprised 
of a heterogeneous population of cells that have subtly different lineages. Alternatively, 
MOR expression may occupy one type of cell that is in different states of differentiation 
such that at any one point in time, MOR expression appears on radial glia bearing different 
markers. These models are reminiscent of the arguments used to explain marker 
heterogeneity observed on murine radial glia by others (Malatesta et al., 2003; Anthony et 
al., 2004, respectively). 
 
Although only two different brains were analysed in detail, each brain at the two time 
points analysed displayed markedly different co-expression profiles with regards to MOR, 
vimentin and nestin. It is interesting that MOR-nestin co-expression increased from 16 GW 
to 19 GW, because in the rodent, as time progresses during neurogenesis, nestin expression 
has been shown to decrease, not increase (Frederiksen and McKay, 1988). MOR has 
previously been shown to induce nestin expression (differentiation) in embryonic stem cells 
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(Kim et al., 2006). However, as only one brain was analysed per time point, it is not 
possible to determine whether these changes were real shifts in marker profiles of whether 
the values simply represented experimental variation. Further study with more foetal tissue 
as well as other glial markers, such as GFAP, to investigate MOR expressing cells within 
the human SVZ is required. Although, because similar MOR-positive glia that were 
identified in the SVZ of the rodent were also seen in the human SVZ, the rodent may 
represent a reasonable model for human brain development, at least in terms of opioid 
signalling. A large-scale study of MOR-positive glia in the rodent would be of value as a 
first step in identifying heterogeneity or differentiative dynamics within the population of 
MOR-positive (thus probably opiate sensitive) glial cells. 
 
In conclusion, the current study has demonstrated with a high degree of certainty that the 
proliferative, MOR-positive glia observed in the rodent SVZ are also present in the 
developing human brain. Thus, the developing mouse brain faithfully replicates aspects of 
these cells in that they are morphologically similar in their staining characteristics and 
display glial, but not neuronal (DCX), markers. This observation has not been previously 
reported in the literature and is significant as it demonstrates that opioid system physiology 
in the developing rodent brain replicates at least some aspects of opioid physiology in the 
foetal human brain. Given that opioid signalling has been extensively characterised as 
being modulatory on proliferation and differentiation and that human foetuses are exposed 
to opiates as a course of analgesic treatment or as a recreational drug in the mother, the 
characterisation of MOR expression on glia of the d
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for health of the foetus in mothers exposed to opiates as well as possibly being important as 
an endogenous modulatory system during normal human brain development. 
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5. Acute Morphine Exposure Lengthens Cell Cycle within the Dorsal 
Forebrain of the E15.5 Mouse 
 
5.1 Introduction 
 
Several studies have detailed how acute exposure to opioid compounds affects proliferation 
and cell cycle parameters in the developing forebrain (Vertes et al., 1982; Bartolome et al., 
1991; Reznikov et al., 1999; Stiene-Martin et al., 2001). Although these studies outlined 
the anti-proliferative impact of opiate exposure, they did not extrapolate these effects to the 
overall development of the brain. For example, Reznikov et al. (1999) showed changes in 
cell cycle parameters in response to opiates and concluded that opiates modulate 
proliferation in the developing mouse telencephalon. However, no developmental 
consequences on brain structure or cognitive/motor function were drawn from these data. 
 
Takahashi et al. (1996a) showed that the developing cerebral cortex can be divided into two 
cell populations: the P and the Q fractions. Early in corticogenesis, radial glia undergo 
mainly P/P divisions to expand the proliferative cell pool. This progenitor pool expansion 
greatly influences the final cumulative output of neurons since precocious P/Q or Q/Q 
divisions deplete the progenitor cell pool and cause a dramatic decrease in neuronal output 
in the final stages of corticogenesis. Whether progenitor cells undergo P or Q divisions in 
the developing cerebral cortex is dependent on cell cycle length, particularly G1 phase 
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length (Calegari and Huttner, 2003). Interestingly, INM to the apical VZ also plays a part in 
maintaining the progenitor cell pool. Altered INM can lead to ectopic mitoses that increase 
the number of cells exiting the cell cycle (Murciano et al., 2002; Cappello et al., 2006; 
Tamai et al., 2007). Interference of INM by deletion of Cdc42 results in a massive increase 
of basal progenitor cells during corticogenesis (Cappello et al., 2006). 
 
Given the known actions of opiates on cellular proliferation, we speculated that morphine 
exposure during the period of corticogenesis may alter cell cycle progression in dividing 
radial glia, potentially modulating neuronal output given the putative relationship between 
cell cycle duration and outcome of radial glial division. Using a time course of BrdU pulse 
labelling and immunohistochemical detection of mitotic nuclei, we report the effect of 
acute morphine treatment in the E15.5 mouse embryo on cell cycle progression in the 
developing cortex. 
 
5.2 Methods 
 
5.2.1 Morphine and BrdU Treatment 
 
On the morning of E15 (6 am), pregnant dams were injected s.c. with either 10 mg/kg 
morphine sulfate (aq) (Hameln Pharmaceuticals GmbH, Germany) or a sham treatment of 
an equivalent volume of saline. The same dose of morphine or saline was administered 
every three hours. Six hours after the first injection of morphine, animals were given BrdU 
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(50 mg/kg), intraperitoneally. Animals were sacrificed by cervical dislocation at selected 
time points. 
 
5.2.2 Measurement of Proliferation and INM 
 
To determine whether morphine treatment altered the number of proliferative cells in S 
phase, 3 morphine-treated and 3 saline-treated controls were given BrdU, then sacrificed 1 
h later and the pups processed for DAB staining for BrdU incorporation. BrdU-positive 
nuclei in coronal sections of the dorsal-lateral VZ were counted from the first anterior 
appearance of the third ventricle in a 200 µm-wide column, perpendicular to the ventricular 
surface. Sections were matched to this brain region throughout the study. 
 
To determine whether morphine altered progression of INM, pregnant dams were given 
BrdU, then sacrificed at hourly intervals over a 6 h period (Fig. 5.1B). Pups from 9 
morphine-treated and 8 saline-treated controls were examined along with pups from 5 
morphine-treated MOR KO animals (Schuller et al., 1999) and 6 saline-treated MOR KO 
controls. MOR KO animals (on a C57BL/6J background) were used to determine whether 
or not observed changes in INM were due to signalling through MOR and were kindly 
supplied by Professor John Pintar and Professor MacDonald Christie. To assess INM, the 
same column of VZ used to determine the number of proliferative cells was stratified into 
8x 20 µm bins from the apical surface of the VZ. BrdU-positive nuclei were considered to 
reside within a particular bin if they lay within or on the lower-most boundary of that bin. 
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5.2.3 Relative Rate of G2/M transition 
 
To determine the effect of morphine on G2/M progression, 6 morphine-treated dams and 6 
saline-treated control animals were sacrificed 2 h after BrdU injection (Fig. 5.1C). Staining 
for both BrdU and phospho-histone H3 was undertaken and the fraction of phospho-histone 
H3-stained nuclei and BrdU/phospho-histone H3 dual-labelled nuclei determined for the 
same area of ventricle as for the 1 h BrdU-labelled animals. At least 200 phospho-histone 
H3 stained nuclei per animal were counted. 
 
5.2.4 Morphine Treatment Effect on the Duration of the Cell Cycle and Exit from the 
Proliferative Pool 
 
To determine whether morphine treatment altered the duration of the cell cycle, 8 
morphine-treated dams and 5 saline controls were administered BrdU, sacrificed 16 h later 
(Fig. 5.1D), and stained for BrdU and phospho-histone H3. The rationale for the 
experiment was that after 16 h, a fraction of the BrdU-labelled cohort will have re-entered S 
phase and transitioned through G2/M such that any dual-labelled BrdU/phospho-histone H3 
nuclei will represent cells that have undergone one complete cell cycle (S phase to S 
phase). Takahashi et al. (1995b) showed that 16 h after BrdU injection in the E15 mouse 
VZ, BrdU-labelled, proliferating cells have transitioned a whole cell cycle and have entered 
mitosis. Animals received 10 mg/kg doses of morphine (or an equivalent volume of saline) 
subcutaneously every 3 h until 6 h after the BrdU injection, after which point morphine 
injections were given every 6 h until sacrifice. Animals were E15.5 at the time of sacrifice. 
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To assess the extent of phospho-histone H3/BrdU co-labelling 16 h after BrdU 
administration, the dorsal telencephalon was divided into medial and lateral halves. 
Counting in the dorsal telencephalon was further subdivided by categorising cells into 
apical (VZ) or basal (SVZ) regions. Late G2 nuclei as well as mitotic nuclei were assessed 
for BrdU incorporation. Nuclei in G2 phase possess punctate, or speckled phospho-histone 
H3 (serine 10) staining as a result of progressive phosphorylation of heterochromatin that is 
required for mitosis (Hendzel et al., 1997). Mitotic nuclei were discriminated from 
interphase nuclei by intense phospho-histone H3 staining as well as mitotic morphology. 
Phospho-histone H3 (serine 10) staining can be used to discriminate between G2 and 
mitotic nuclei. Phospho-histone H3 staining is also specific to these phases of the cell cycle 
as during telophase of mitosis, histone H3 is dephosphorylated such that no staining can be 
seen in G1 phase nuclei (Hendzel et al., 1997). 
 
Exit from the proliferative pool (cell cycle exit) was determined by staining for BrdU and 
Ki67, counting BrdU-labelled cells and determining the fraction that also stained for Ki67. 
Stained nuclei were counted in a 200 µm tissue column comprising the most medial and 
most lateral regions of the dorsal VZ/SVZ. Approximately 600 BrdU-positive nuclei were 
counted for each of the medial and lateral regions. The slides were coded such that the 
researcher counting was unaware whether they originated from a morphine-treated or 
saline-treated control animal. 
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Fig. 5.1. Diagrams of BrdU pulse-chase experiments. BrdU pulse-chase paradigms are represented for cell 
cycle assessment experiments (see 5.2 - Research Design) and for tracking INM of BrdU-labelled nuclei. A) 
For measurement of the proliferative index of the VZ, animals received an injection of BrdU that labels cells 
during S phase (DNA synthesis) (red, line A). Animals were sacrificed 1 h later, approximately half way 
through G2 phase. B) To follow cohorts of BrdU labelled nuclei in their INM from the basal to the apical VZ 
as they progress through G2, animals received a pulse of BrdU and were sacrificed at hourly intervals from 1 
h post-injection to 6 h post-injection (sacrifice represented by red intervals on blue line B). C) Measurement 
of G2/M phase transition required sacrifice 2 h post-BrdU injection (blue, line C) since most mitotic nuclei 
were labelled with BrdU after 2 h. D) In order to assess cell cycle exit and to make a relative cell cycle 
measurement, animals received a BrdU injection and were sacrificed 16 h later (green, line D). At the time of 
sacrifice, the BrdU pulse-labelled cohort of nuclei that were still proliferative had progressed approximately 
one full cell cycle. Upon sacrifice, BrdU-labelled nuclei were observed in G2 phase and mitosis, although 
other BrdU nuclei would also be in S phase and others would most probably have advanced to G1.  
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5.2.5 Imaging and cell counting 
 
Brightfield images were captured using an Olympus AX70 photomicroscope (Olympus 
Optical Co., Hamburg, Germany) equipped with an Olympus DP70 CCD camera. Confocal 
microscopy was performed using an Olympus FluoView FV1000. Confocal images were 
overlaid and labelled using Olympus FluoView v1.6a Viewer and Adobe Photoshop CS3 
software. Cells were counted using ImageJ software (v1.37). 
 
5.2.6 Statistical analysis 
 
Data taken from hourly INM measurements of migrating BrdU cohorts was analysed by an 
ANCOVA test to allow for time as a co-variate. Data from G2/M phase progression, 
relative cell cycle time and cell cycle exit were assessed for normality using a Q-Q plot and 
transformed by taking the natural logarithm or the square root of the raw data. Since these 
experiments involved repeated measurements, analysis of data was performed using the 
general linear model repeated measures procedure. 
 
5.3 Results 
 
5.3.1 Morphine Slows INM 
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Representative images of BrdU-labelled nuclei migrating from the basal VZ to the apical 
VZ are shown as a time course for morphine-treated animals and saline-treated controls 
(Fig. 5.2). One hour after BrdU administration, nuclei from cells in S phase reside in the 
basal VZ region; however, by 3 h post-BrdU treatment, a cohort of labelled nuclei had 
undergone INM and moved to the apical VZ where they underwent mitotic division. 
Morphine treatment delayed the INM such that by 3 h post-BrdU treatment, few labelled 
nuclei were present at the apical VZ (LV wall) in morphine-treated animals compared with 
saline-treated controls.  
 
Initial quantitative analysis of INM (Fig. 5.3) showed a difference in the proportion of cells 
accumulating in the apical VZ between saline-treated and morphine-treated animals. Fig. 
5.4, panel A, shows that morphine treatment did not change the number of cells labelled by 
BrdU (S phase cells); whereas, panel B shows that morphine treatment delayed (or slowed) 
INM such that it took longer for labelled nuclei to reach the apical VZ (P = 0.013, 
ANCOVA) and longer to leave the basal VZ (panel C) (P = 0.036, ANCOVA). This only 
became evident 4 h post labelling, a timing effect also observed by Cappello et al. (2006). 
The basal VZ was defined at a 60 µm layer, positioned 40 µm basally from the ventricular 
edge as this region is where the vast majority of nuclei reside during S phase (Fig. 5.2, 1 h 
after BrdU injection). Slower INM did not occur when the experiment was repeated (panel 
D) using a MOR KO mouse strain. Additionally, no pyknotic nuclei, markers of apoptosis, 
were observed in any of the groups. 
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Fig. 5.2. Acute morphine treatment slows INM in the VZ of the LV in the E15.5 mouse. Regions used for cell 
counting in the basal VZ and apical VZ are indicated by green and red boxes respectively. Nuclei were 
counted as being in the apical VZ if they resided within 40 µm of the lateral ventricle wall, or as basal nuclei 
if they were in a 60 µm region above the apical VZ. One hour after BrdU administration, BrdU staining 
(brown) is seen in the basal VZ where cells were undergoing S phase. The saline-treated control animals and 
morphine-treated animals look similar, however; by 3 h after BrdU-labelled nuclei have migrated to the apical 
VZ during G2 phase, it can be seen that fewer cells accumulated at the apical surface of the VZ in the 
morphine-treated animals. By 5 h post-labelling it can be seen that more BrdU-labelled nuclei were left in the 
basal VZ in the morphine-treated animals. Scale bars: 50 µm. 
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Fig. 5.3. Histogram plots showing INM of BrdU-labelled nuclei within the VZ. Histograms show the 
proportion of BrdU-labelled nuclei (y-axis) in a given 20 µm bin stratified within the VZ (as described in 5.2 
– Research Design). Bins represented on the x-axis range from 1 (at the apical surface of the VZ) to 8 (at the 
basal VZ). As time progresses, BrdU-labelled nuclei occupied more apical positions, as shown by a shift to 
the right, or the apical side of the histogram (black arrows). Morphine slowed this process down such that 
BrdU-labelled nuclei took a longer time to accumulate at the apical VZ. Histograms are accompanied by cell 
cycle diagrams (right) that show which part of the cell cycle BrdU-labelled nuclei progressed to in the saline-
treated control animals (red line). 
 
 
Fig. 5.4. Morphine does not alter total BrdU labelling in E15.5 mouse foetuses but does slow INM in the 
embryonic VZ. A) Graph A shows that morphine treatment did not change the total number of BrdU-labelled 
nuclei counted per 200 µm length of basal VZ when compared with saline-treated control animals (values are 
the mean ± SEM). B) Graph B shows that morphine slowed the migration of BrdU-positive nuclei into the 
apical VZ, as indicated by accumulation over time of BrdU-labelled nuclei in the most apical 40 µm region of 
the VZ. Morphine-treated animals (○) exhibited lower proportions of total BrdU-labelled nuclei in the apical-
most 40 µm of VZ compared to saline-treated animals (). This effect was only observed 4 h or more post-
BrdU labelling. C) Graph C shows that the basal VZ exhibited a complementary pattern of BrdU-labelling 
over time after the BrdU pulse. The proportion of total BrdU-labelled nuclei retained by the basal 60 µm of 
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VZ (y-axis, as defined in Fig. 5.3) declined over time; however, morphine-treated animals showed a slower 
rate of decline, indicating BrdU-labelled nuclei were retained for longer in the basal VZ before migrating to 
the apical surface. D) Graph D shows that the morphine-induced slowing of accumulation of BrdU-positive 
nuclei within the apical VZ, observed in C57BL/6J mice (panel B), was not seen in morphine-treated MOR 
KO mice compared to saline-treated MOR KO mice. 
 
5.3.2 Relative G2/M Phase Measurement 
 
To corroborate the finding presented in Figs. 5.2, 5.3 and 5.4, we examined the effect 
morphine treatment had upon the time required for G2/M transition by labelling S phase 
cells with a single pulse of BrdU and then 2 h later sacrificing the animals and determining 
the number of mitotic profiles that showed BrdU labelling. Cells displaying mitotic profiles 
were detected by intense staining for phospho-histone H3. Fig. 5.5 shows representative 
photomicrographs of BrdU-labelled nuclei (green) and phospho-histone H3-stained nuclei 
(red) 2 h after BrdU administration. Panel A shows staining from a saline-treated control 
and panel B from a morphine-treated animal. Cells that were in late S phase had punctate 
BrdU staining (asterisks) and, as expected, reached the apical VZ ahead of those nuclei that 
showed solid BrdU staining. In the saline-treated animals, punctate BrdU/phospho-histone 
H3 staining can be seen at the LV wall in some cells (white arrows), and it is clear that 
more late S phase labelled-nuclei reached the apical VZ. In the morphine-treated animals 
(panel B), fewer mitotic profiles (phospho-histone H3-labelled nuclei) co-labelled with 
BrdU, and less late S phase-labelled nuclei have transitioned to the apical VZ by INM. 
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Panel C shows the fraction of phospho-histone H3-labelled nuclei that also stained for 
BrdU in the apical and basal VZ for saline-treated controls and morphine-treated dams. For 
the saline-treated control group, 86% of the apical phospho-histone H3 stained mitotic 
profiles also stained for BrdU; while, in the morphine-treated cohort only 43% were dual-
labelled. Similarly, 82% of the phospho-histone H3-positive basal progenitors also stained 
for BrdU in the saline-treated group while only 41% were dual-labelled in the morphine-
treated group. The effect of morphine on G2/M progression within the dorsal telencephalon 
was highly statistically significant (P < 0.01). 
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Fig. 5.5. Morphine treatment slows G2/M progression in the E15.5 pup. Panels A and B show staining of 
nuclei for phospho-histone H3 (red) and BrdU (2 h after BrdU injection) (green) in a representative saline-
treated control foetus (panel A) and a morphine-treated foetus (panel B). Many of the phospho-histone H3-
labelled mitotic nuclei at the apical surface in saline-treated animals showed punctate staining for BrdU 
(white arrows). Punctate BrdU labelling is characteristic of cells that are in late S phase at the onset of BrdU 
labelling (asterisks). In the morphine-treated animals, fewer BrdU-positive nuclei displaying punctate 
labelling were located near the apical surface of the VZ (panel B, asterisks). Similarly, fewer of the apical 
mitoses in morphine-treated animals stained for BrdU, and thus these nuclei appeared red only (arrowhead). 
Scale bars: 20 µm. Panel C graphically depicts the fraction of phospho-histone H3-stained nuclei (mitotic) in 
the apical and basal VZ that also stained for BrdU. The total number of mitoses counted are indicated above 
each bar. In the saline-treated controls (grey), most apical and basal mitoses were BrdU-labelled. Acute 
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morphine treatment (white) reduced the number of dual-labelled basal and apical mitoses approximately two-
fold. Values are the mean ± SEM (n = 6 saline-treated control dams and 6 morphine-treated dams).  
 
5.3.3 Relative Cell Cycle Length 
 
To determine whether the increased duration of G2/M transition caused by morphine 
exposure also measurably altered the duration of the cell cycle, we examined the fraction of 
cells that remained proliferative and were able to re-enter S phase and transition to mitosis 
for a second time. Preliminary experiments indicated that 16 h after BrdU administration, 
sufficient proliferative cells had entered a second round of mitosis to determine if morphine 
treatment increased the time required to transit the entire cell cycle. Examination of mitotic 
profiles in conjunction with phospho-histone H3 staining is able to identify nuclei that are 
in G2 phase by their morphology and speckled phospho-histone H3 staining. Mitotic nuclei 
stained intensely for phospho-histone H3 (red) and appear solid with the image capture 
settings used to detect G2 phase nuclei (Fig. 5.6). A confocal photomicrograph of the VZ of 
a representative saline-treated control animal (panel A) is compared with a morphine-
treated animal (panel B). Punctate labelled phospho-histone H3 nuclei (red), indicative of 
late G2 phase nuclei, were seen in transit to the apical surface of the LV (white asterisks). 
No punctate phospho-histone H3 stained nuclei were detected at the apical VZ. Dual-
labelling of these late G2 phase nuclei with phospho-histone H3 and BrdU, administered 16 
h previously, identified cell nuclei that were in G2 phase after a second round of DNA 
synthesis. In saline-treated animals (Fig. 5.6, panel A) several such nuclei could be 
identified (punctate orange/yellow staining, white arrows); whereas, in the morphine-
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treated animals (Fig. 5.6, panel B) such nuclei were seen in fewer numbers. Orthogonal 
views in the Z-plane confirmed the phospho-histone H3 and BrdU staining was located 
within the same cell nuclei. The location of the dual-labelled nuclei was analysed to 
determine whether morphine treatment slowed cell cycle progression differently in the 
medial and lateral regions of the dorsal VZ or if it affected basal versus apical divisions 
differently (panels C and D). The fraction of late G2 phase and mitotic nuclei that were 
BrdU-positive was determined and is shown in panels C and D.  
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Fig. 5.6. Morphine treatment decreases BrdU/phospho-histone H3 co-labelling 16 h after BrdU administration 
in basal and apical progenitors. Panels A and B show staining for BrdU and phospho-histone H3, as described 
in Fig. 5.5, in dams that were administered BrdU 16 h prior to sacrifice. Of interest are those BrdU-stained 
nuclei (green) that are undergoing a second round of mitosis and stain for phospho-histone H3 (red). Nuclei 
displaying punctate phospho-histone H3 labelling (white asterisks) are in G2 phase (panels A and B). Nuclei 
dual-labelled for phospho-histone H3 and BrdU have yellow punctate staining (white arrows) and are readily 
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detected in the saline-treated control animals (panel A). Scale bars: 20 µm. Panels C and D depict the fraction 
of phospho-histone H3-labelled nuclei that also stain for BrdU in the lateral and medial portions of the VZ, 
respectively. This population of labelled nuclei was further categorized as either basal or apical in either the 
medial or lateral portions of the VZ. In addition, the phospho-histone H3 staining was further characterised as 
to whether the nuclei showed punctate (G2 phase) or solid (mitotic) staining. Morphine treatment (white bars) 
reduced the number of basal BrdU-labelled G2 and mitotic nuclei in both medial and lateral regions. Similarly 
the fraction of apical BrdU-labelled G2 phase nuclei was reduced in both lateral and medial regions. No 
significant difference in the number of apical BrdU-labelled mitoses, however, was detected. Values are given 
as the mean ± SEM (n = 5 saline-treated control dams and 8 morphine-treated dams). The value above each 
bar is the total number of nuclei counted in each category.  
 
In all regions of dorsal telencephalon, including the lateral basal, lateral apical (panel C), 
medial basal and medial apical (panel D), a higher proportion of G2 nuclei were BrdU-
labelled than mitotic nuclei (P < 0.01), supporting our assertion that there is an advancing 
wave of BrdU-positive cells that are about to undergo mitosis. Interestingly, in both lateral 
and medial dorsal telencephalon, more basal progenitor G2 and mitotic nuclei were BrdU-
positive than the apical radial glia of the VZ (P < 0.01). The same effect of morphine 
treatment was seen in both the lateral and medial portions of the VZ. Overall, morphine 
treatment significantly decreased BrdU/phospho-histone H3 co-labelling in the dorsal 
telencephalon (P < 0.01). This result was consistent with a morphine-induced slowing of 
cell cycle. There was little difference, however, in BrdU co-labelling of the apical mitotic 
cells between morphine-treated and saline-treated controls because of the extremely rare 
occurrence of BrdU-positive apical mitoses (only 21 and 26 BrdU-positive total apical 
mitoses out of 1123 and 1611 total apical mitoses were counted in saline-treated animals 
and morphine-treated animals, respectively). Similarly, morphine treatment (8 h continuous 
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morphine exposure, n = 6 saline-treated, 6 morphine-treated dams, or 22 h continuous 
morphine exposure, n = 5 saline-treated, 8 morphine-treated dams) did not alter the relative 
fraction of basal to apical mitoses (Fig. 5.7) nor did it alter the number of either basal or 
apical mitoses counted per unit length of VZ. 
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Fig. 5.7. Morphine treatment does not change the number of mitoses or the proportion of basal to apical 
mitoses. Mitoses detected only with phospho-histone H3 were counted and compared between morphine-
treated and saline-treated contol animals in both lateral-medial and apical-basal position. Panel A shows that 
after 22 h of morphine exposure, the number of either apical or basal mitoses per unit length of ventricular 
surface does not change (n = 5 saline-treated litters and 8 morphine-treated litters). Panel B shows that in 
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comparison to saline-treated animals (grey bar) morphine did not alter the proportion of apical to basal 
mitoses after 8 h of morphine exposure (white bar) (n = 6 saline-treated litters and 6 morphine-treated litters). 
Similarly, panel C shows that after 22 h of morphine exposure, there was no difference in the proportion of 
basal to apical mitoses. Grey bars represent mitoses in the lateral half of the dorsal VZ; whereas, white bars 
represent mitoses in the medial half of the dorsal VZ. As expected, in both groups there was a much lower 
proportion of basal mitoses in the developmentally less advanced medial VZ (P < 0.01) (n = 5 saline-treated 
litters and 8 morphine-treated litters). Values are given as the mean ± SEM. Numbers above bars represent the 
total number of mitoses assessed for that category. 
 
5.3.4 Measurement of Cell Cycle Exit 
 
To determine whether acute morphine exposure influences whether progenitor cells 
undergo a proliferative division to yield another radial glial cell and a quiescent neuron 
(P/Q division) or exit the cell cycle entirely by dividing to form two quiescent cells (Q/Q 
division), the same cohort of animals used to analyze the effect of morphine on cell cycle 
progression was stained for BrdU and the proliferation marker Ki67. Ki67 is expressed on 
replicative cells but not on postmitotic cells that have entered G0 (Gerdes et al., 1984). 
Thus, 16 h after BrdU treatment, nuclei that have stained positively for both BrdU and Ki67 
have remained within the cell cycle (P); whereas, nuclei that have stained for BrdU alone 
have exited the cell cycle (Q). The fraction of BrdU-positive nuclei that stained for Ki67 
and the fraction of nuclei that stained for BrdU alone was determined in coronal sections of 
VZ, divided into medial and lateral portions (n = 5 saline-treated controls, 8 morphine-
treated animals). Fig. 5.8, panel A shows a representative region of basal VZ that contains 
nuclei that have stained for BrdU alone (red) (white arrows); whereas, cells that co-stained 
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for Ki67 (green) and BrdU appear yellow (asterisks). There was no significant effect of 
morphine treatment on the number of co-stained BrdU/Ki67-positive cells in either the 
medial or lateral regions of the VZ (P = 0.093). 
 
 
Fig. 5.8. Morphine does not affect cell cycle exit. Staining for the proliferation marker Ki67 (green) and BrdU 
(red) was performed on the same cohort of animals as in Fig. 5.6. Confocal imaging (panel A) was used to 
detect labelled nuclei (red) that have exited the cell cycle and therefore do not show green Ki67 IR (white 
arrows). BrdU-positive nuclei that are still proliferative stain for Ki67 and thus appear yellow (white 
asterisks). Scale bar: 20 µm. Panel B shows morphine treatment (white bars) did not alter the fraction of dual-
labelled Ki67/BrdU-positive nuclei compared to saline-treated control animals (grey bars) in either the medial 
or the lateral VZ. The fraction of BrdU-positive nuclei that also stained for Ki67 is presented as the mean ± 
SEM (n = 5 saline-treated control dams and 8 morphine-treated dams). The values above each bar represent 
the number of BrdU-stained nuclei counted.  
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5.4 Discussion 
 
In this chapter, we have shown that activation of opioid receptors by morphine influences 
cell cycle progression. We have previously reported that radial glia express MOR (Chapter 
3), and we provide supporting evidence in the present chapter that morphine causes an 
increase in the time required for G2/M transition. Although morphine acts predominantly 
through MOR, it can also activate DOR and KOR depending upon the dose used. The 
effects we observed are, however, likely to be mediated via MOR since slowing of INM to 
the apical surface of the VZ (Fig. 5.4) was not detected when the experiment was 
reproduced with a MOR KO strain. Additionally, we were unable to detect DOR on the 
radial glia in the VZ (Chapter 3, Fig. 3.8, panel B). It is also possible that morphine was 
acting indirectly on radial glia and basal progenitor cells at a paracrine or even an endocrine 
level, for example, by modulating the hypothalamic-pituitary-adrenal axis to influence 
levels of hormones such as growth hormone (Spiegel et al., 1982). However, the expression 
of MOR on radial glia, in our opinion, favours a direct mechanism of action on the radial 
glia. Whether or not the morphine mediated effects on cell cycle are consequences of direct 
opioid signalling through MOR on radial glia, or a downstream effect needs to be the focus 
of future studies in isolated cells and tissues. 
 
5.4.1 Technical Considerations 
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5.4.1.1 Justification of Morphine Dose 
 
The doses of morphine sulfate given in this experiment were close to what is required for 
analgesia in the mouse. For example, given s.c., the ED50 for morphine sulfate analgesia in 
the mouse is approximately 5 mg/kg, as measured by tail-flick latency (Schuller et al., 
1999; Gilbert et al., 2004). Mice receiving a morphine hydrochloride dose of 80 µmol/kg 
(equivalent to 30 mg/kg morphine sulfate) via s.c. injection reached peak plasma levels of 
morphine (18 µM) 25 min after injection (Handal et al., 2002). The half-life of morphine in 
mouse plasma was 28 min, and no detectable traces of morphine were found in the plasma 
3 h after s.c. injection. In the same study, no plasma morphine-6-glucuronide was 
detectable at any time after morphine injection. Based on these results, our dose of 10 
mg/kg (s.c.) of morphine sulfate would be expected to peak after 25 mins but would 
probably never exceed a plasma concentration of 6 µM (see 8.6 – Appendix 6 for 
calculations). Morphine would also not accumulate following repeat injections, since 
injections were given 3 h apart, more than enough time for morphine to be cleared from the 
system. However, based on Ki values of selective opioid receptor subtype ligands and EC50 
values using [35S]GTPgammaS (a G-protein substrate) (Clark et al., 1989; Mignat et al., 
1995; Olianas et al., 2006), these concentrations of morphine are high enough to stimulate 
all three opioid receptors,. In our study, therefore, as well as being a MOR agonist, 
morphine would also be stimulating KOR, and to a lesser extent, DOR present in the brain. 
 
5.4.1.2 G2/M Relative Measurement 
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The present chapter used BrdU/phospho-histone H3 dual-labelling to compare G2/M phase 
length between morphine-treated and saline-treated animals. As a single time-point was 
chosen (2 h post-BrdU injection) at which to sacrifice animals, a number of technical issues 
have to be considered in the interpretation of the results. 
 
5.4.1.2.1 Was G2 Phase or Mitosis Lengthened? 
 
One explanation for the observed decrease in BrdU/phospho-histone H3 dual-labelling 
could be that G2 phase was lengthened. However, the same result would have been 
observed if G2 phase stayed the same length but instead mitosis lengthened. This scenario 
would have resulted in decreased proportions of mitoses labelled by the 2 h-BrdU pulse and 
thus a lowered percentage of dual-labelled mitoses. However, as an increased number of 
mitoses was not observed (Fig. 5.7) and a slowing of INM to the ventricular surface was 
observed (Fig. 5.4) in the absence of ectopic mitoses, it is very likely that it was G2, and not 
mitosis, that was lengthened. The existence of 2 different G2 checkpoints has been reported 
(Xu et al., 2002) that may contribute to the lengthening of the time spent in G2 phase. 
 
5.4.1.3 Relative Cell Cycle Length Measurement 
 
Cell cycle length was compared between saline and morphine-treated animals by labelling 
cells with BrdU, sacrificing after 16 h and double-staining for BrdU and phospho-histone 
H3. This method is analogous to the method used to measure the cell cycle time of basal 
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progenitor cells by Takahashi et al. (1995b). Takahashi et al. (1995b) used a time course 
following BrdU injection to construct a ‘% labelled mitoses’ curve. To conserve animals, 
we used a single time point (16 h) in conjunction with analysis of BrdU labelling of two 
phases of the cell cycle (G2 phase and mitosis) using information from phospho-histone H3 
labelling. 
 
5.4.1.3.1 Was the Observed Difference in Dual-Labelling Due to a Faster or Slower Cell 
Cycle Time? 
 
After a survival time of 17 h post-labelling, Takahashi et al. (1995b) observed 50% 
labelling of basal mitoses with [3H]thymidine. The present study was reasonably consistent 
with these results, given that approximately 35% of mitoses in the basal progenitor cell 
population had been labelled with BrdU 16 h post-BrdU injection. The morphine-treated 
animals displayed much less dual labelling of mitoses. As this analysis only contained a 
single time-point, it was difficult to determine whether the morphine-treated animals 
displayed a quicker cell cycle time (more cells had entered and left a second round of 
mitosis before sacrifice) or a slower one (fewer cells entered a second round of mitosis 
before sacrifice). However, analysis of G2 phase nuclei BrdU labelling provides a reference 
point from which one can infer whether cell cycling was faster or slower (Fig. 5.9). If 
labelling of mitoses in the morphine-treated animal had already peaked and was declining 
(i.e. a faster cycling), one would expect the G2 phase nuclei to exhibit even less ‘% BrdU 
labelling’ as they become BrdU-labelled by cycling BrdU-positive cells up to 2 h (the 
length of G2 phase in the foetal forebrain (Takahashi et al., 1995b)) before the mitotic 
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nuclei. In fact, more % BrdU labelling of these G2 phase nuclei was observed, indicating 
that an increased proportion of BrdU labelling of mitotic nuclei immanent. Given that exit 
from the cell cycle was the same between saline-treated and morphine-treated animals (Fig. 
5.4, panel A and Fig. 5.8), and a higher proportion of BrdU staining of G2 phase nuclei than 
mitotic nuclei indicated an approaching cohort of BrdU-labelled nuclei, a lower proportion 
of dual-labelling in the morphine-treated animals suggests a slower cell cycle. 
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Fig. 5.9. BrdU labelling of G2 phase and mitotic nuclei. Panel A shows a cohort of nuclei approaching mitosis 
having entered a second round of the cell cycle since BrdU labelling. The green line above the cell cycle 
diagrams represents the cycling cohort of BrdU-labelled nuclei. Animals injected with BrdU 16 h prior to 
sacrifice show a higher proportion of G2 phase nuclei labelled with BrdU than the proportion of mitotic nuclei 
labelled with BrdU (refer to the graphs in Fig. 5.6). In contrast, panel B shows that the pattern of a faster 
travelling cohort of BrdU-labelled nuclei, where most cells have already completed a second round of mitosis. 
In this case, there is a lower proportion of BrdU-labelled G2 phase nuclei than BrdU-labelled mitoses. As seen 
in Fig. 5.6, a higher proportion of BrdU-labelled G2 nuclei, as opposed to a higher proportion of BrdU-
labelled mitotic nuclei, 16 h after BrdU labelling, is indicative of an approaching wave of BrdU-labelled cells. 
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Therefore, the lower proportions of BrdU-labelled G2/M nuclei seen after a second round of the cell cycle 
could indicate a slower cell cycle in morphine-treated animals. 
 
This experiment also includes an internal control. Takahashi et al. (1995b) showed at E15, 
that basal progenitor cells had a cell cycle time that was 2.5 h faster than cells of the VZ. 
Consistent with this observation, the basal progenitor cells in our experiment showed 
higher proportions of BrdU labelling than cells in the apical VZ. 
 
5.4.1.3.2 How Does Cell Cycle Heterogeneity Affect this Measurement? 
 
Dual-labelling with BrdU and phospho-histone H3 is insensitive to variations in the cell 
cycle. It is a snapshot that is biased. The E15 VZ contains a gradient of cell cycle times that 
range from 17.5 h in the medial VZ to 21 h in the dorsal VZ (Miyama et al., 1997). 
Calegari et al. (2005) also showed that significant cell cycle time heterogeneity exists 
within the VZ between neurogenic (Tis21-positive) and non-neurogenic (Tis21-negative) 
progenitors. The ‘snapshot’ taken in the current study may only be looking at one 
population of cells. It is possible that other populations of cells, not detected due to a 
slower, or much quicker cell cycle time than the dual-labelled mitoses observed, are not 
affected by morphine. 
 
5.4.1.4 Exit from the Cell Cycle – Measurement Using Ki67 
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Ki67/BrdU dual labelling is used to measure differences in cell cycle re-entry (Chenn and 
Walsh, 2002; Hodge et al., 2004), although the biology of Ki67 expression is still the topic 
of ongoing research. The consensus is that Ki67 labels all cycling cells (G1, S, G2, M) but 
not differentiated cells (G0). 
 
5.4.1.4.1 Is Ki67 expression restricted to proliferative cells? 
 
The absence of Ki67 expression from quiescent cells has been reported in a number of 
studies (Gerdes et al., 1984; Endl et al., 1997). Although it is generally accepted that Ki67 
is only expressed in proliferating cells (Scholzen and Gerdes, 2000), some Ki67 protein 
expression has been reported in quiescent cells in association with ribosomal RNA 
synthesis. However, in quiescent cells, Ki67 is greatly down-regulated compared to 
proliferating cells and requires optimal conditions for visualisation; hence, Ki67 IR cannot 
be detected in quiescent cells under standard histological conditions (Bullwinkel et al., 
2006), as employed in the current study. Thus, it should be a good marker for cell cycle exit 
in our study. 
 
5.4.1.4.2 How would an increase in cell cycle time impact upon measurement of BrdU/Ki67 
dual-labelling? 
 
A slowing in cell cycle would affect which part of the cell cycle a BrdU-labelled nucleus 
was in at the time of sacrifice. This has implications since if a cell was delayed such that it 
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had not yet made the decision to exit the cell cycle and was thus still Ki67-positive, this 
would artificially increase the observed number of proliferating cells. An increase in 
proliferating cells was observed in the lateral VZ for the morphine-treated litters (Fig. 5.8, 
panel B); however, this increase was not statistically significant. Also, the fact that after a 1 
h BrdU pulse no change in the number of BrdU-positive nuclei was observed (Fig. 5.4, 
panel A) also supports the view that morphine treatment did not significantly alter cell 
cycle re-entry. 
 
Although the present study found an opiate-induced decrease in the rate of cell cycle 
progression, it did not corroborate the findings of Reznikov et al. (1999) who reported 
increases in labelling index ([3H]thymidine-labelled cells per unit area of VZ) for the MOR 
and KOR ligands, DAMGO and bremazocine, respectively. We found no such increase in 
BrdU labelling with morphine (Fig. 5.4, panel A). It must be pointed out that the opiate 
used in our study is not a purely selective mu opioid ligand, like the synthetic enkephalin, 
DAMGO. The study by Reznikov et al. (1999), however, must be treated with caution, 
since a single pregnant female was used for each experimental group. Teratological studies 
of multiparous species such as mice are confounded by litter effects if the study selects 
littermates (within a litter) as its base definition of sample size (Haseman and Hogan, 1975; 
Holson and Pearce, 1992; Zorrilla, 1997). 
 
Modulation of the duration of G2 phase by opiates has been reported in other brain regions 
and other cellular systems. For example, chronic morphine exposure in the adult 
hippocampus in vivo markedly decreased cellular proliferation (Eisch et al., 2000) and 
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shortened G2 phase (Mandyam et al., 2004). In vitro experiments using the non-selective 
opiate ligands ethylketocyclazocine and etorphine, which both have low nanomolar affinity 
for opioid receptors, blocked T47D breast cancer cells in G2/M phase (Panagiotou et al., 
1999). This opiate-induced cell cycle block occurred simultaneously with an opioid induced 
modification of the actin/tubulin cytoskeleton. These data are in accordance with our 
observation that morphine alters INM, a process that is sensitive to microfilament 
disruption by cytochalasin B (Messier and Auclair, 1974; Murciano et al., 2002). 
Interestingly, it has also been shown in astrocytes cultured from neonatal mice, which a 
disproportionately large number of MOR-positive astrocytes were in G2/M phase (Stiene-
Martin et al., 1998). 
 
Our observation that both basal and apical mitoses showed a morphine-induced lengthening 
of G2/M phase suggests that morphine is inhibiting the cell cycle of neural/glial 
progenitors, rather than directly affecting INM. Slowing of INM would occur as well since 
INM and G2 phase are linked processes in radial glia. The study of Cappello et al. (2006), 
however, showed that INM in the Cdc42 KO mouse as well as in the Pax6 KO rat (Tamai 
et al., 2007) was uncoupled with G2 phase duration. In both the studies, disruption of INM 
caused ectopic mitoses. Murciano et al. (2002) and Messier and Auclair (1974) also 
demonstrated that pharmacological inhibition of INM with cytochalasin B in other 
neuroepithelia led to ectopic mitoses, with G2 phase left unchanged. In contrast, Ueno et al. 
(2006) showed that cell cycle progression is required for normal INM to the apical surface 
of the VZ. It is of interest that morphine allows the coordination of cell cycle and INM to 
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remain intact (i.e. no ectopic mitoses) while other studies have demonstrated that they can 
be easily uncoupled (Cappello et al., 2006; Tamai et al., 2007). 
 
The VZ of the embryonic brain contains gradients of important extrinsic fate determinants, 
such as the anti-neurogenic Notch1 (as well as the Notch1 ligand, Delta1) (Murciano et al., 
2002). Interestingly, expression of Notch1 is restricted to the ventricular wall, and BrdU 
labelling has shown that Notch1 is expressed by cells in late G2 phase, but not in cells in S 
phase or early G2 (Murciano et al., 2002). Regulation of the duration of G2 phase by 
opioids could potentially be a mechanism that regulates exposure of cells to ligands that 
regulate cell fate. While in our study, morphine was not observed to alter cell cycle exit, it 
cannot be ruled out that morphine may influence developmental maturation and cell fate, as 
has been shown in cultures of embryonic stem cells (Kim et al., 2006). 
 
In the present chapter, we have shown that morphine exposure in utero has acute effects on 
progenitor cell behaviour within the VZ of the developing telencephalon. Acute exposure to 
morphine slows the arrival of radial glial nuclei to the apical surface of the LV as well as 
increases the duration of G2/M phase of the cell cycle. These effects induced a detectable 
slowing of the overall cell cycle. Although it is likely that some phases of the cell cycle 
were left undisturbed, determination of whether a slowing in G2/M was the sole contributor 
to an overall slowing in cell cycle awaits further investigation. The biological implications 
and the impact on developmental processes of opioidergic perturbation of cortical 
progenitor cell cycle in vivo warrants future research. 
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Results from this chapter have been published in the European Journal of Neuroscience 
(Sargeant et al., 2008). 
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6. Chronic Morphine Exposure and Histogenesis of the Cerebral 
Cortex 
 
6.1 Introduction 
 
Studies have shown that opioids inhibit proliferation in astrocytic cells (Stiene-Martin and 
Hauser, 1990; Stiene-Martin and Hauser, 1991; Stiene-Martin et al., 1991b; Stiene-Martin 
and Hauser, 1993; Hauser et al., 1996). Given that MOR-IR has been identified on radial 
glia during corticogenesis (Chapter 3, Fig. 3.7, panel A) and acute morphine exposure 
affects cell cycle progression (Chapter 5), it is possible that chronic morphine exposure 
during corticogenesis will affect neuronal output from the VZ/SVZ and impact upon the 
final neuronal content of the cerebral cortex. 
 
6.1.1 Chronic Opiate Treatment and Effects on Cellular Proliferation 
 
In vivo, chronic opioid treatment decreases numbers of neurons within the cerebral cortex. 
Morphine (10 mg/kg/day) delivered by an osmotic minipump from E12 to P6, decreases 
neuronal numbers in the P6 rat somatosensory cortex (Seatriz and Hammer, 1993). 
However, because morphine treatment spanned both corticogenesis as well as a period of 
postnatal neuronal apoptosis (Verney et al., 2000), it was unclear from this study whether 
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morphine treatment acted to reduce cellular proliferation, increase neuronal cell death, or 
both. The fact that chronic morphine treatment decreases proliferation in the adult 
hippocampus (Eisch et al., 2000) would favour a mechanism by which morphine decreases 
proliferation. However, morphine treatment has also been shown to increase fas-mediated 
apoptosis in the adult brain (Emeterio et al., 2006). 
 
Since opiates can modulate the cell cycle as well as cellular proliferation and since 
disturbing these processes can have lasting consequences for the tightly co-ordinated 
sequence of events of corticogenesis, the aim of this study was to determine whether 
chronic morphine treatment over the period of corticogenesis in the foetal mouse perturbs 
cortical development. In order to determine whether chronic morphine exposure in utero 
induced general systemic toxicity, the weights of the pregnant dam, the E18.5 foetus and 
the P5 pup were analysed. To determine the impact of chronic morphine exposure on the 
development of the cerebral cortex, neuronal content was assessed both at the end of 
corticogenesis at E18.5 as well as postnatally, at P5. The P5 pup was analysed as at this 
stage, cortical laminations become clear and a morphine induced effect had been previously 
shown in the postnatal cerebral cortex (Seatriz and Hammer, 1993). 
 
6.2 Research Design 
 
6.2.1 Chronic Morphine Administration 
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Time-mated pregnant C57BL/6J dams began chronic morphine administration on the 
evening of E11.5 that lasted until the morning of E18. Morphine sulfate (10 mg/kg) was 
injected s.c. into the dams twice daily, once at 9 am and once at 9 pm each at a dose of 10 
mg/kg. Control animals were given equivalent volumes of saline. For analysis of foetal 
mouse cerebral cortices, pregnant dams were sacrificed by cervical dislocation at E18.5. 
Mouse foetuses were removed from the uterus and sacrificed by decapitation. Brains were 
rapidly dissected and fixed overnight in 4% PFA. 
 
6.2.2 Morphine Effect on Weight Gain in the Pregnant Dam and Mouse Pup 
 
Weights of the pregnant dams were recorded from E11.5 to E18, over the period of chronic 
morphine injection. To determine if morphine had an effect on weight gain in the 
developing mouse foetus, E18.5 mouse foetuses were dissected from the pregnant dam, as 
well as from associated amniotic membranes and placenta, blotted on tissue paper to 
remove mucus and weighed. 
 
To determine if chronic morphine exposure in utero had an effect on postnatal pup growth, 
pregnant dams were given one last injection of morphine on the evening of E18.5 and were 
then allowed to give birth on E19. On the morning of birth, approximately three pups from 
a morphine-treated litter were swapped for the same number of pups from a saline-treated 
control litter. This cross-fostering was performed to investigate the effect of in utero 
morphine exposure as well as the effect of drug exposure on the mother on pup weight. 
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Pups were allowed to survive until the afternoon of P5, at which point they were weighed 
and sacrificed by decapitation. 
 
6.2.3 Effects of Chronic Morphine Treatment on Proliferation and Neuronal Migration in 
the Foetal Cerebral Cortex 
 
To assess proliferation in the chronically morphine-treated foetal mouse brain, pregnant 
mice were injected with BrdU (50 mg/kg) on the morning of E18. Three hours later, 
pregnant dams were sacrificed, and E18.5 mouse brains were rapidly dissected out from the 
foetuses and fixed in 4% PFA. To determine whether or not chronic morphine treatment 
altered neuronal migration to the outer cerebral cortex, chronically treated pregnant dams 
were injected with BrdU on E15.5. Pregnant dams were allowed to survive until E18.5, at 
which point they were sacrificed as described above. 
 
E18.5 mouse brains from both experiments were paraffin embedded and sectioned in the 
coronal plane at 14 µm thickness. To see if chronic morphine treatment had a major impact 
on proliferation in the E18.5 forebrain or on migration of neurons born on E15.5 to the 
cerebral cortex, sections were DAB stained for BrdU labelling and background-stained with 
0.2% thionin. 
 
6.2.4 Real-time PCR Analysis of the Chronically Morphine Exposed E18.5 Cerebral Cortex 
 
 162 
To analyse DCX and Fas gene expression within the E18.5 chronically morphine-exposed 
cerebral cortex, brains were rapidly dissected out of the pup, and cortices were 
microdissected from the brain such that the front 2 mm of cortex and back 2 mm of cortex 
were cut off in a coronal plane and discarded. Cerebral cortex was removed from the 
remaining brain by removing cortex that lay on top of the striatum. To validate the use of 
cyclophilin A as an internal control (or ‘housekeeping gene’), cyclophilin A mRNA 
expression was compared to GAPDH mRNA and 18S rRNA expression in chronically 
treated samples of morphine (20 mg/kg/day) or naltrexone-treated (20 mg/kg/day) cerebral 
cortex. Morphine and naltrexone were initially used to analyse the effect of opioidergic 
modulation on transcription of housekeeping genes. However, experiments using 
naltrexone were later abandoned to focus resources on reaching conclusive results in the 
investigation of the effects of morphine on brain development. 
 
6.2.5 Western Blot Analysis of DCX in the E18.5 Cerebral Cortex 
 
Western blotting for DCX was performed on the same cortical homogenate samples that 
were used for real-time PCR analysis. Western blotting for DCX at E18.5 produced two 
closely associated bands that were semi-quantified by densitometry using ImageJ (v 1.37) 
software. 
 
6.2.6 Counting DCX Positive Neurons in the E18.5 Cerebral Cortex 
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In order to investigate whether a change in DCX expression in the cerebral cortex was due 
to a change in number of DCX-positive cells, or a change in DCX expression per cell, 
E18.5 cerebral cortex was fluorescently stained for DCX protein. Coronal sections of 
cerebral cortex at the level of the first appearance of the 3V were immuno-stained for DCX 
and NeuN. Nuclei were stained with DAPI. NeuN was used to clearly distinguish the 
cerebral cortex from the intermediate zone and white matter. DAPI-stained nuclei that were 
positive for DCX staining were counted in 3x50 µm columns per section of cortex and 
three sections of cortex were counted per animal. Measurements of cerebral cortex were 
performed at the lateral-medial positions of the cortico-striatal junction (lateral) as well as 
the dorsal-most region of cortex (medial) (Fig. 6.1). 
 
 
Fig. 6.1. Measurement of the E18.5 cerebral cortex. Panel A shows a trace of an E18.5 brain at the coronal 
level used for counting DCX-positive nuclei. Pink boxes at medial and lateral positions along the cerebral 
cortex represent areas where confocal scans were taken. Panel B shows a confocal micrograph of a lateral 
area of cerebral cortex. Red fluorescence is staining for NeuN; whereas, nuclei are stained blue with DAPI. 
Yellow rectangles represent the 50 µm columns in which DCX-positive nuclei were counted. The counting 
columns spanned the thickness of the cerebral cortex, as delineated by NeuN staining. Panel C shows the 
exact same region of cerebral cortex stained for DCX (green immunofluorescence). 3V, third ventricle; CP, 
cortical plate; LV, lateral ventricle; NE, neuroepithelium; Str, striatum. Scale bars: 100 µm. 
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6.2.7 Western Blot Analysis of P5 Cerebral Cortex 
 
Western blotting was used to determine if chronic morphine treatment induced changes in 
the abundance of neuronal and glial protein markers present within the P5 mouse cerebral 
cortex. P5 neocortex was microdissected from morphine and saline-treated mouse brain and 
homogenised in preparation for western blotting. Cortical homogenates were 
electrophoresed and immunoblotted for NeuN, GAD65+67 and GFAP. The housekeeping 
gene GAPDH was used as a loading control. 
 
6.2.8 Stereological Analysis of Nissl-Stained Neurons in the P5 Neocortex 
 
Stereological counting was used to determine the number of neuronal nuclei in the cerebral 
cortex. After paraffin embedding, P5 mouse brains were serially sectioned and Nissl stained 
with a 0.2% thionin solution. Random-systematic sampling was performed such that 
approximately 12x20 µm thick sections were sampled per brain, which were a distance of 
320 µm apart along the rostral-caudal axis. The term random-systematic refers to sampling 
that begins at a random start point but follows a systematic pattern (for example, every 8th 
section) thereafter. Ten-twelve coronal sections sampled in a random-systematic manner 
produces acceptably low levels of variation in stereological estimates of volume and 
number (Gundersen et al., 1999).  
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Stereological analysis was performed on the cerebral cortex, as defined by the Allen 
Reference Atlas (Allen Institute for Brain Science, 2007; http://www.brain-map.org/). 
Analysis of the 6-layered cerebral cortex extended medially to include the cingulate cortex 
and laterally far enough to include cortex up to but not including the entorhinal cortex. 
Analysis also spanned the entire cerebrum rostro-caudally. Analysis was also broken down 
into separate categories based on layers. The first two categories consisted of the 
infragranular layers: layers VI and V. The third category was made up of the supragranular 
cortical layers: layers IV and II/III. 
 
Neuronal nuclei were identified in thionin-stained tissue according to previously described 
criteria (Seatriz and Hammer, 1993). Briefly, neuronal nuclei were 5 µm or larger and 
possessed lightly staining nucleoplasm with distinct nucleoli; whereas, glial nuclei were 
characteristically smaller and were more densely stained. To confirm that these nuclei were 
in fact neuronal, NeuN immunofluorescence staining was conducted on sections of P5 
cortex for comparison (Fig. 6.2). 
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Fig.6.2. Neuronal and glial nuclear morphology. Panel A shows a section of P5 mouse cerebral cortex stained 
for NeuN (green). Nuclei are stained with DAPI (blue). Arrows show glial nuclei that do not stain for NeuN. 
Arrowheads show neuronal nuclei that do stain positively for NeuN. The nuclei of the glia that do not stain 
for NeuN densely stain for DNA (blue) and are smaller than neuronal nuclei (arrows, panel B). Neuronal 
nuclei are larger and have distinct characteristic multiple nucleoli (arrowheads, panel B). Panel C shows 
cerebral cortex that has been Nissl-stained with thionin. Arrows show densely staining glial nuclei; whereas, 
arrowheads show larger neuronal nuclei that have sparsely staining nuclei and contain nucleoli. Some 
neuronal nuclei are also surrounded by purple Nissl substance (rRNA). Scale bars: 20 µm. 
 
For estimation of the reference volume (volumes of the cortical layer categories), the 
Cavalieri principle was used (Gundersen and Jensen, 1987). Put simply, this involves 
measuring and summating the total area an object occupies on a sampled set of sections. 
The summated area of this object is then multiplied by the distance that separates any two 
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of the sections. For measurement of area, a grid was laid over a video display of a low-
magnification view of the cortical section. The points on the grid were 145 µm apart and 
thus occupied an area of 21,025 µm2. Points that lay on top of a given category of cortical 
layer were counted and summated for all 12 serial sections. The reference volume of that 
layer for that brain was then calculated by the following equation: 
 
Vref = ∑ai.t 
 
where Vref is the reference volume, ∑ai is the sum of all areas counted for a given object on 
the 12 serially sectioned slides and t is the distance that separates the random-
systematically selected sections. 
 
The density of neuronal nuclei within cortical layers was determined using an optical 
dissector method (see Bonthius et al., 2004). This involved using an unbiased counting 
frame that was laid over a real-time microscopic view of cortex (Fig. 6.3). Optical dissector 
samples were taken in a random-systematic raster pattern throughout the object of interest 
until over 100 samples were taken for the entire sampled set of sections. Sampling 100-200 
points is usually sufficient to restrict the coefficient of error due to random noise to 0.1-
0.07 (Gundersen et al., 1999). The unbiased counting frame was 20x20 µm in its x and y 
dimensions and 8 µm in its z dimension (3200 µm3). The z-plane movement of the 
microscope stage was measured by using a linear gage unit (Mitutoyo, Japan). In taking one 
measurement, the slide was focussed up until nuclei came into sharp focus. The stage was 
then focussed up a further 2 µm in the z-plane to guard against lost objects. Any nucleus in 
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focus that lay within the unbiased counting frame at this point was discounted, as this 
formed the exclusion plane. The cortical section was slowly focussed up by 8 µm and 
neuronal nuclei that came into sharp focus during this time were counted. 
 
 
Fig. 6.3. Demonstration of an optical dissector. The unbiased counting frame is represented by the black box, 
which has an area of 20x20 µm. The area within the box is the sample area. The solid left and bottom edges of 
the box are exclusion planes: if an object touches these lines it is not counted. Conversely, if an object touches 
the upper or right hand side broken lines it is included in the sample. As an example, these 6 panels represent 
the same x, y plane that moves 6 µm in the z plane. Panel 1 is the upper exclusion plane. Any nucleus that is 
in sharp focus on this plane is discounted, represented by the red asterisk. As nuclei come into focus, as in 
panel 2, they are counted, represented by the green asterisk. In panel 3, two nuclei in the optical dissector 
come into focus but must be discounted as they touch the solid exclusion lines. In panel 5, one more nucleus 
of neuronal morphology comes into focus. If this was a complete optical dissector, the end result would be 
that this optical dissector of 20x20x6 µm3 contained 2 neuronal nuclei. 
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The neuronal nuclear density of the cortical layers was calculated by dividing the total 
number of nuclei counted by the total volume sampled by the optical dissector method, and 
is represented by the following equation: 
 
Nv = ∑Q-/∑Vdis 
 
where Nv is the density of neuronal nuclei (neuronal nuclei/mm3), Q- represents the number 
of neuronal nuclei counted per optical dissector and Vdis is the volume of the dissector.  
 
Using the density and the reference volume, the total number of neuronal nuclei was then 
estimated by the following equation: 
 
N = Vref.Nv 
 
where N is the total number of neuronal nuclei. 
 
6.2.9 Statistical Analysis 
 
Analysis of variance for the weights of pregnant dams in response to chronic morphine 
administration, DCX-positive cell counting in the E18.5 cortex and stereological analysis of 
the P5 cerebral cortex was performed using the GLM repeated measures procedure (SPSS 
v14). Analysis of pup weights in the cross-fostering experiment was conducted using the 
GLM univariate procedure (SPSS v14).  For determination of the statistical significance of 
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the difference between two means when only one parameter was tested, Student’s t-test was 
used. 
 
6.3 Results 
 
6.3.1 Chronic Morphine Exposure and Weight Gain in Pregnant Dams 
 
Chronic morphine exposure from E11.5 to E18.5 decreased weight gain in the pregnant 
dam. At E11.5, pregnant dams weighed an average of 29 g (Fig. 6.4, panel A). However, at 
the beginning of morphine exposure (E11.5 – E13.5), there is a 1.4 g weight deficit 
between morphine-exposed mice and saline controls. Even though weight between the two 
groups of pregnant dams appears to diverge from E11.5 until E13, normal weight gain is 
restored after this time. The early reduction in weight gain manifests itself by the end of 
pregnancy as a small deficit in weight between the two groups (Fig. 6.4, panel A). The 
difference in weight between the morphine-treated and saline-treated mice is statistically 
significant (P < 0.01, adjustment for multiple comparisons: Bonferroni). Importantly, even 
though the weights of pregnant dams were decreased by chronic morphine exposure 
between E11.5 - E18.5, it did not affect the weight of E18.5 embryos (Fig. 6.4, panel B). 
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Fig. 6.4. The effects of chronic morphine exposure, in utero, on weight gain in the pregnant dam and in the 
late mouse foetus. Panel A shows a graph of weight gain of the pregnant dams. Compared to saline-treated 
controls (■), morphine-treated mice (○) display a lag phase from which they recover at E13.5. Panel B shows 
embryonic weight at E18.5 is not affected by chronic morphine administration. 
 
To investigate whether chronic morphine administration in utero had an effect on postnatal 
growth of the pup, some pups were cross-fostered to mothers from the opposite treatment 
group, left to P5 and weighed (Fig. 6.5). Similarly to the E18.5 embryos, chronic morphine 
treatment from E11.5 to E18.5 on the mouse pups did not alter the weights of P5 mice. 
Although in utero exposure to morphine had no effect on weight, morphine exposure on the 
mother from E11.5 to E18.5 did have an effect on pup weight. Saline-treated and morphine-
treated pups raised by a morphine-treated mother were on average 0.32 g heavier than pups 
raised by a saline-treated mother (P < 0.01). 
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Fig. 6.5. The effects of chronic in utero morphine exposure on the weight of cross-fostered pups at P5. Pups 
from the same litter at birth either remained with their birth mothers or were re-distributed to mothers from 
the opposite experimental group and left until P5. At P5, pups that were raised with saline-treated mothers 
(grey bars) were, on average, smaller than pups raised by morphine-exposed mothers (white bars). However, 
there was no effect of prenatal drug exposure on the foetus from E11.5 to E18.5 on the weight of the mouse at 
P5. n = 7 saline-exposed/saline-mother litters, 9 morphine-exposed/saline-mother litters, 11 saline-
exposed/morphine-mother litters, 12 morphine-exposed/morphine-mother litters. Values are the mean ± SEM. 
 
6.3.2 Real-Time PCR Analysis 
 
6.3.2.1 Real-Time PCR Validation 
 
Cortical dissections from E18.5 foetal mice that were chronically exposed to morphine 
were analysed by real-time PCR. The housekeeping gene that was used in these studies was 
cyclophilin A. Expression of cyclophilin A was compared to two other housekeeping genes, 
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18S rRNA and GAPDH. The expression of cyclophilin A was not found to vary in any 
consistent direction against these two other housekeeping genes (using the ∆∆Ct method) 
when animals that had been exposed to chronic naltrexone (20 mg/kg/day) and chronic 
morphine (20 mg/kg/day) were compared to each other. For this analysis, 8 morphine 
exposed foetuses from 4 litters and 7 naltrexone exposed foetuses from 2 litters were used 
(Fig. 6.6). 
 
 
Fig. 6.6. Quantitative comparison of Cyclophilin A with other housekeeping genes. Comparison of 
cyclophilin A with other housekeeping genes was conducted to determine whether opioid perturbation 
significantly altered levels of this internal control. Comparison with real-time PCR of GAPDH and 18s rRNA 
shows that cyclophilin A was not significantly affected when foetuses that were exposed to chronic morphine 
were compared to foetuses that were exposed to chronic naltrexone, an opiate antagonist. n = 7 naltrexone 
exposed foetuses (2 litters) and 8 morphine exposed foetuses (4 litters). Values are the mean ± SEM 
(calculated from individual foetuses). 
 
Primer efficiency was calculated for primer sets used in the present study. Template was 
diluted four-fold (2 ∆Ct values) for each step in a serial dilution that spanned 5 data points 
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(Fig. 6.7). All ∆Ct values obtained in duplicate were plotted against the log of the fold 
dilution, and primer efficiencies were calculated with the equation: 
 
Primer efficiency = (10(-1/slope))-1 (Peters et al., 2004) 
 
All primer efficiencies tested were close to 100% (Table 6.1) Efficiencies over 90% are 
desirable for quantification whereas efficiencies over 100% indicate the presence of primer 
dimer (Brisson et al., 2000). 
 
 
Fig. 6.7. Graphs used to determine primer efficiency values. ∆Ct values were plotted against the log of 
dilution to obtain the gradient that was used to determine the primer efficiency values for primer pairs. Panel 
A shows values used to calculate the primer efficiency for the primers used to amplify a fragment of 
cyclophilin A cDNA; panel B shows values obtained for primer pairs used to amplify DCX cDNA sequence 
and panel C is for MOR. R2 values shown on the graph demonstrate the quality of the data. Each data point 
represents the mean of 2 replicates. 
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Primer set Primer efficiency (%) 
 
CycA 
 
99.5 
DCX 117.1 
MOR-1 113.4 
Table 6.1. Primer sets shown with associated primer efficiency values.  
 
6.3.2.2 Melt Curve Profile Analysis 
 
To further assess the suitability of the selected primer sets, melt curve profile analysis was 
performed that allowed analysis of the purity of the respective PCR products. Melt curve 
analysis involves measuring the fall of fluorescence signal from Sybr green I intercalated 
with double-stranded DNA plotted against rising temperature of the reaction mixture. As a 
specific sequence of DNA will have a characteristic temperature at which the double helix 
will melt apart (which will reduce Sybr Green I fluorescence), the presence of a specific 
PCR product will provide a sharp peak on a graph that plots the first derivative of relative 
fluorescence units over temperature versus temperature of the reaction mixture (dRFU/dT 
vs. T). This represents the rate of change of fluorescence plotted against reaction 
temperature. A single peak on such a graph indicates the presence of a single product 
whereas a low diffuse peak from 75-85 °C is indicative of the presence of primer dimer. 
 
The melt curves for cyclophilin A, MOR and DCX PCR products all produce a single peak 
at 87 °C, 90 °C and 85 °C, respectively (Fig. 6.8, panel C). Melt curve analysis of negative-
control PCR reactions was also carried out to determine if contamination could have 
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confounded the experiments. Both reactions that used H2O as well as equimolar 
untranscribed mRNA as template did not display any fluorescence specific for the PCR 
products (Fig. 6.8, panel D). As well as ruling out contaminating PCR product, this also 
demonstrated that there was no measurable contaminating genomic DNA in the PCR 
reactions. 
 
6.3.2.3 Expression of MOR within the E18.5 Dorsal Telencephalon  
 
Data obtained from these experiments showed that expression of MOR mRNA was not 
significantly altered by chronic morphine administration compared with saline-treated 
controls. These results indicated that MOR mRNA is expressed within the dorsal cerebrum 
of the E18.5 foetus, corroborating the results of our IHC on MOR protein expression in this 
region (Chapters 3 and 4). MOR transcript was approximately 4000 (212) fold less abundant 
than the ubiquitous cyclophilin A transcript or 500 (29) fold less expressed than DCX 
mRNA within the dissected volume of tissue. 
 
6.3.2.4 Chronic Morphine Exposure and DCX mRNA Expression in the E18.5 Cerebral 
Cortex 
 
Chronic morphine exposure over the period of corticogenesis significantly decreased DCX 
mRNA expression within the E18.5 neocortex (P = 0.016, Student’s t-test, n = 8 saline-
treated dams, 8 morphine-treated dams). Morphine-treated animals showed an average 
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increase of 0.35 ∆Ct units compared with saline-treated animals (Fig. 6.8, panel A). This 
corresponds to a 22% decrease (1/2∆Ct) in DCX transcript expression in chronically 
morphine-treated cerebral cortices. 
 
 
Fig. 6.8. Chronic morphine treatment during corticogenesis decreases DCX expression in the developing 
cortex. Chronic morphine treatment increases the ∆Ct value at which DCX mRNA expression is detected in 
the E18.5 cortex (P = 0.016, Student’s t-test, n = 8 saline-treated litters and 8 morphine-treated litters) (panel 
A). Panel B shows PCR products electrophoresed on a 2% agarose gel and stained with ethidium bromide. 
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Lanes 1, 3 and 5 show DCX PCR product (187 bp) while lanes 2, 4 and 6 show cyclophilin A PCR product 
(287 bp) that was amplified from the same reverse-transcribed template as the respective DCX PCR products. 
Panel C shows a melt curve analysis in which dRFU/dT is plotted against reaction mixture temperature. DCX 
PCR product was identified on the melt curve analysis graph as a peak at 87 °C, and cyclophilin A PCR 
product could be detected as a peak at 85 °C. PCR products at the end point of the amplification reaction were 
pure except for small amounts of primer dimer, as shown by low levels of product detected at 76-83 °C. Melt 
curve analysis of negative controls (PCR reactions conducted using either ddH2O or equimolar un-reverse 
transcribed RNA as template) showed no specific DCX or cyclophilin A amplification product (panel D). 
Panel E shows densitometric analysis of a western blot for DCX that was standardised using the internal 
control, GAPDH. Chronic morphine treatment decreased DCX protein, as was seen for DCX mRNA (panel 
A), although this was not statistically significant. Panel F shows DCX and GAPDH immunoblots that were 
used in the densitometric analysis of DCX protein expression. Double bands were present, and both bands 
were used for densitometry. Values on bar graphs are the mean ± SEM. 
 
Cortical lysates were western blotted for DCX in order to corroborate the real-time PCR 
datum. Immunoblotting for DCX protein showed a major and a minor band at 
approximately 40 kDa. These bands represent both the phosphorylated and 
unphosphorylated forms of the DCX protein (Francis et al., 1999). Densitometric analysis 
of both DCX bands, standardised against the internal control GAPDH (a single band at 36 
kDa), showed that chronic morphine treatment decreased the average amount of DCX 
protein, although this relationship was not statistically significant (P = 0.15, Student’s t-
test, n = 3 saline-treated litters and 4 morphine-treated litters). 
 
6.3.2.5 Fas Expression 
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To determine if the decreased levels of DCX could have been a result of Fas-mediated 
apoptosis, Fas mRNA expression was analysed using real-time PCR. As expected from the 
literature (Cheema et al., 1999), Fas mRNA expression was found to be extremely low in 
the same microdissected E18.5 cortex analysed for DCX mRNA expression. Fas mRNA 
expression was the same for saline-treated as for morphine-treated cerebral cortex when 
standardised using cyclophilin A as the internal control (n = 3 saline-treated dams and 3 
morphine-treated dams) (Fig. 6.9). This graph, however, omits data points from two 
morphine-treated litters in which PCR amplification failed to detect Fas mRNA in 
microdissected E18.5 cerebral cortex. This, in conjunction with the fact that Fas 
amplification products were typically detected at 31-32 reaction cycles, demonstrates that 
only trace amounts of Fas mRNA were present within the E18.5 cerebral cortex. 
 
 
Fig. 6.9. Fas mRNA expression does not change between saline and morphine-treated E18.5 cerebral cortex. 
Fas mRNA expression (standardised to cyclophilin A mRNA expression) is not affected by chronic morphine 
treatment.  Fas mRNA expression is also barely detectable in the E18.5 cerebral cortex. Two morphine-
treated litters were omitted from this graph as Fas mRNA could not be detected from these cortical RNA 
extracts. (n = 3 saline-treated litters and 3 morphine-treated litters). Values are mean ± SEM. 
 180 
 
6.3.3 Effect of Chronic Morphine Exposure on Cellular Proliferation and Neuronal 
Migration 
 
Analysis of how chronic morphine treatment affects proliferation in the dorsal forebrain of 
the E18.5 mouse pup was measured by using a BrdU pulse at the end of chronic 
administration. Analysis of how chronic morphine administration affects neuronal 
migration from the VZ to the outside of the developing cortical plate was also analysed by 
injecting BrdU (50 mg/kg) at E15.5. Animals were allowed to survive until E18.5 and then 
were sacrificed. Unfortunately, due to difficulties in obtaining sufficient numbers of timed-
mated pregnant dams, analysis of the effects of chronic morphine on development of the 
cerebral cortex using BrdU pulse-chase paradigms was abandoned. However, preliminary 
results suggest that chronic morphine treatment had no major effects on total cellular 
proliferation (Fig. 6.10), as measured by BrdU pulse-labelling, and neuronal migration 
(Fig. 6.11) as measured by BrdU pulse-chase, in the developing cerebral cortex. 
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Fig. 6.10. Morphine does not have dramatic affects on total proliferation in the E18.5 dorsal forebrain. 
Chronic morphine treatment (panel B) does not visibly decrease acute BrdU pulse-labelling (brown nuclei) 
within either the subependyma (black arrows) or the intermediate zone (red arrows) of the E18.5 forebrain 
compared with the saline-treated control (panel A). Sections were counterstained with thionin. Scale bars: 200 
µm. 
 
 
Fig. 6.11. Chronic morphine treatment does not induce major abnormalities in neuronal migration. Neuronal 
nuclei that were BrdU pulse-labelled at E15.5 (brown staining) had migrated to the edge of the cerebral cortex 
by E15.5 (black arrows). Some BrdU staining can be seen at the ventricular edge (white arrows). Chronic 
morphine treatment (panel B) does not cause major abnormalities, when compared with the saline-treated 
control brain (panel A). Scale bars: 200 µm. 
 
6.3.4 DCX-Positive Cell Counting in the E18.5 Cerebral Cortex 
 
Real-time PCR analysis showed that DCX expression in the cerebral cortex was lower in 
chronic morphine-treated animals. To determine the nature of this decrease in gene 
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expression (i.e.: is it a reduction in the number of DCX-expressing cells or a reduction in 
DCX gene expression per cell?), E18.5 cortical sections were prepared and numbers of 
DCX-positive cells within the cerebral cortex were counted. At this stage, the entire cortex 
is positive for DCX staining. Only the pia and the SVZ show no DCX staining (Chapter 3). 
The same sections were also stained for NeuN to highlight the boundaries of the cerebral 
cortex. It was found that there was no difference in the number of DCX-positive cells 
within the E18.5 cerebral cortex, even though DCX expression had decreased (Fig. 6.12, 
panel A). Analysis of the number of DCX-positive neurons in the cerebral cortex and 
measurement of cortical thickness showed that even though morphine treatment had no 
effect, the region of lateral cerebral cortex analysed was larger than the medial cortex 
analysed (P = 0.01). 
 
 
Fig 6.12. DCX-positive cell counting and thickness of the E18.5 cerebral cortex. Panel A shows the number 
of DCX-positive DAPI-stained nuclei per counting column. Grey bars show the number of cells counted in 
the lateral cortex as opposed to cells counted in the medial cerebral cortex (white bars). There is no difference 
in the number of cells counted for each region of cortex between saline-treated controls and morphine-treated 
animals. There is however a slight decrease in the number of cells counted in the medial cerebral cortex as 
opposed to the larger lateral regions of cortex. Panel B shows the average cortical thickness of the same 
regions of cortex that were counted for DCX-positive cells. These measurements show the same patterns as 
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the DCX-positive cell counts. Grey bars show cortical thickness in the lateral cerebral cortex and white bars 
show cortical thickness in the medial cerebral cortex. n = 4 saline-treated dams and 4 morphine-treated dams. 
Values are the mean ± SEM. 
 
6.3.5 Analysis of the P5 Cerebral Cortex – Western Blotting 
 
To determine whether a change in neuronal content as a result of chronic morphine 
treatment could be detected by western blotting, P5 mouse neocortex was microdissected, 
homogenized and electrophoresed on an acrylamide gel. Western blotting was carried out 
for the neuronal markers, NeuN and GAD 65+67, the glial marker GFAP and the 
housekeeping gene, GAPDH (Fig. 6.13). Interestingly, no change in protein levels for the 
neuronal and glial markers tested could be detected (n = 4 saline-treated animals, 4 
morphine-treated animals (all from different litters)), despite the decrease in DCX mRNA 
observed after chronic morphine treatment at E18.5. All values were normalized against the 
housekeeping gene, GAPDH. 
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Fig. 6.13. Chronic morphine exposure from E11.5 to E18.5 does not change expression of neuronal and glial 
markers in the cerebral cortex at P5. Protein expression of the mature neuronal marker, NeuN, the 
GABAergic neuronal marker, GAD65+67, and the astroglial marker, GFAP, was not altered by chronic 
morphine treatment when standardised to GAPDH (panel A). Panel B shows specific immunostaining taken 
from fluorescent scans of four representative P5 cerebral cortex western blots. n = 4 saline-treated pups and 4 
morphine-treated pups (from different litters). Values are the mean ± SEM. 
 
6.3.6 Stereological Cell Counting in the P5 Neocortex 
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To analyse the cellular content of the P5 neocortex, thick paraffin embedded coronal 
sections of P5 brains that were chronically treated with either saline or morphine in utero 
were Nissl stained with thionin and counted via a stereological method to estimate the total 
number of nuclei that bore neuronal characteristics, the neuronal density and the reference 
volume of the cortical layers in question. Stereological measurements were taken from the 
supragranular layers (II, III and IV), layer V and layer VI. 
 
Using a repeated measures analysis, it was found that chronic morphine treatment from 
E11.5-E18.5 had a significant interaction with cortical layer number within the neocortex of 
the P5 pup (P < 0.05). Chronic morphine treatment had the largest impact on layer V of the 
neocortex causing a decrease in the number of neurons in this layer (Fig. 6.14, panel A). 
Using Cavalieri estimates, it was shown that morphine had little affect on the volume of the 
neocortical layers (panel B). The reduction in cellular number within the neocortex was 
therefore primarily a result of lower cell density and not a decrease in the volume of layer 
V. 
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Fig. 6.14. Stereological analysis of the cerebral cortex of the P5 mouse. Panel A shows that chronic in utero 
morphine treatment had little effect on the numbers of neurons in the supragranular layers (layers II, III and 
IV). Chronic morphine treatment did markedly decrease the numbers of neurons in layer V of the P5 cerebral 
cortex (P < 0.05). Layer VI did not display any change. Panel B shows that although morphine impacted on 
the numbers of neuronal nuclei in layer V, it did not affect the volume of the cortical layers. n = 4 saline-
treated animals and 3 morphine-treated animals (layers II/III/IV and layer VI); 3 saline-treated animals and 5 
morphine-treated animals (layer V). Values are the mean ± SEM. 
 
6.4 Discussion 
 187 
 
Collectively, the current experiments showed that chronic morphine treatment, in utero, 
perturbed corticogenesis without having any effect on the body weight of the animals. The 
amount of DCX transcript in the E18.5 cortex was decreased (P < 0.05), and, at P5 a 
reduction in the number of cells was detected that was layer specific (P < 0.05). 
 
6.4.1 Chronic Morphine Administration does not Decrease Weight in the Perinatal Mouse 
 
The interesting observation that morphine treatment of the pregnant dam had an effect on 
maternal weight (P = 0.01) could have a number of explanations. It was observed that 
morphine treatment produced opiate-induced hyperlocomotion, as has been described in the 
literature (Mori et al., 2004). This extra activity may have reduced weight gain in the 
pregnant dam due to increased energy consumption. Alternatively, or in conjunction with 
morphine-induced hyperlocomotion, morphine may have disrupted eating habits in the 
pregnant dam, as previously documented in the rodent (Markham et al., 1971). No 
monitoring of food intake was attempted in this study. 
 
Importantly, although chronic morphine treatment affected weight gain in the pregnant 
dam, it did not affect the weight of the E18.5 mouse foetus or P5 pup. When pups were 
cross-fostered between treatment groups at birth it was observed that exposure of the pups 
themselves to morphine in utero had absolutely no effect on pup weight at P5. However, 
pups that were raised by saline-treated mothers, whether the pups had developed in a 
morphine or saline-treated mother, were lighter than pups that were raised by morphine-
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treated mothers, even though morphine treatment of the mother had ceased 5 days earlier. 
The reason for this difference remains unclear, although it is possible that the smaller litter 
size of the morphine-treated mothers (an average of 5.4 pups, as opposed to 6.4 pups for a 
saline-treated dam’s average litter size) resulted in higher pup weights for morphine-treated 
mothers. However, it is interesting to note that human opiate exposed mothers show 
significantly increased feeding behaviour towards their infant (LaGasse et al., 2003). Taken 
together, little biological significance should be assigned to the statistical significance of 
the increase in pup weights observed in litters raised by morphine-treated dams. The lack of 
effect observed between morphine treatment in utero and pup weight contrasts with several 
studies in the literature, which show significant decreases in weight associated with 
prenatal methadone exposure (Buchenauer et al., 1974; Chandler et al., 1975; Hutchings et 
al., 1976; Zagon et al., 1977b) and morphine exposure (Tao et al., 2001). This disparity 
between our results and the literature is most likely a result of differences in dosage as well 
as duration of treatment. However, our results do indicate that long-term prenatal exposure 
to the opiate, morphine, does not necessarily result in reduced pup weight, a situation also 
seen in pregnant human opiate abusers (Lester et al., 2002). 
 
6.4.2 Morphine Induced Down-Regulation of DCX Expression 
 
Although chronic morphine treatment showed a lack of general growth effects, as measured 
by body weight, morphine decreased the amount of DCX mRNA expression within the 
cerebral cortex at the end of neurogenesis. This result may have one of two explanations. 
Either DCX mRNA was down-regulated in each cell by morphine treatment, or morphine 
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decreased the proportion of DCX expressing cells within the dissected volume of cortical 
tissue. The fact that no significant difference was detected between the numbers of DCX 
expressing cells in the E18.5 mouse cortex treated with morphine and saline suggests that 
the second explanation (a lowered DCX expression per cell) is the most likely cause of the 
decrease in DCX expression. 
 
There are a number of explanations for why DCX expression may be lower in morphine-
treated animals per migrating neuron. Morphine may be directly or indirectly signalling to 
DCX positive neurons to decrease DCX expression. Direct signalling is unlikely since 
migrating neurons do not express MOR (Chapter 3). Another explanation for the loss of 
DCX mRNA expression in the E18.5 forebrain is that morphine treatment may have caused 
apoptosis of DCX-positive neurons. Morphine treatment and withdrawal is known to cause 
apoptosis and up-regulation of Fas and FasL proapoptotic genes in other systems (Yin et 
al., 1999; Emeterio et al., 2006). However, in the late foetal mouse brain, Fas expression 
was barely detectable (Cheema et al., 1999; Fig. 6.9), and morphine had no effect on these 
levels in the late foetal cortex. It is unlikely that Fas-mediated apoptosis accounts for the 
decreased levels of DCX mRNA expression seen with chronic morphine treatment. 
 
Alternatively, morphine may perturb the development of radial glial cells in the VZ such 
that by E18.5, more radial glia in the developing forebrain have finished neurogenesis, and 
therefore there is less migratory activity and less DCX expression to be detected via real-
time PCR. It is conceivable that morphine treatment shifted maturation of the cortex. Given 
the short time in which the cortex is generated, a shift by even half a day could have 
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accounted for the observed reduction in DCX. Indeed, the intrinsically controlled 
programme of neurogenesis followed by neuronal progenitor cells (Shen et al., 2006) can 
be precociously matured by changing the surrounding cellular environment (McConnell, 
1988). In line with this, it is also interesting that morphine can cause premature 
differentiation of astrocytes cultured from the P1-2 mouse cortex (Stiene-Martin et al., 
1993). Given this evidence, the possibility that morphine treatment perturbs maturation of 
the neurogenic programme by modulating maturation/differentiation in astrocytic radial 
glia should be the focus of future research. 
 
6.4.3 Chronic Morphine and Loss of Cortical Neurons in the Postnatal Pup 
 
Hammer and Seatriz (1993) showed that chronic, continuous morphine treatment in the 
developing rat (E12-P6) decreased neuronal number in the cerebral cortex. To test for this 
in mice, western blot analysis of neuronal (NeuN and GAD65+67) and glial (GFAP) 
markers in the P5 mouse brain was conducted. Surprisingly, it was found that chronic 
morphine treatment over the period of corticogenesis did not change levels of neuronal or 
glial markers in the cerebral cortex. This meant that by P5, any difference in neuronal 
marker expression detected at the end of gestation had either been compensated or 
corrected for by the developing brain, or western blotting was too insensitive to pick up a 
difference. The latter explanation is a distinct possibility because of the loss of spatial 
information following homogenisation. 
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To determine if any differences in cortical architecture due to chronic morphine treatment 
persisted (or emerged) in the P5 brain, 6 days post-morphine exposure, stereological 
analysis of the different cortical layers was performed. Seatriz and Hammer (1993), using 
Nissl staining in the rat, found a decreased number of neuronal nuclei after chronic 
morphine exposure from E12 to P6. Interpretations in this study were limited by the broad 
window of morphine treatment used. Early in that same window (E14-E20), histogenesis of 
the cerebral cortex occurs in the rat. However, in the neonatal period (P0-P6), large 
numbers of neurons in the cerebral cortex (10-20%) undergo apoptosis (Verney et al., 
2000) as the brain develops its pattern of synapses and neuronal circuitry. Stereological 
analysis in the present study supported the findings of Seatriz and Hammer (1993) as 
chronic morphine treatment in the developing mouse brain reduced the number of cortical 
neurons. This only seemed to occur, however, in layer V of the neocortex, although the 
experiment may not have had the power to detect changes in other layers. Seatriz and 
Hammer (1993) also showed that layer V was most affected by chronic morphine 
treatment. We only treated with morphine from E11.5 to E18.5 in the mouse, a period that 
corresponds to the time of corticogenesis. From these data as well as the fact that chronic 
morphine treatment did not decrease numbers of DCX-expressing cells (neurons) in the 
cerebral cortex at the end of gestation (E18.5), it is probable that chronic morphine 
treatment in utero increased apoptosis in the neonate. This idea is consistent with the fact 
that the volume of the P5 cerebral cortex was unaltered. Also, Harburg et al. (2007) show 
that MOR KO augments neurogenesis in the adult hippocampus by increasing the number 
of surviving neurons, demonstrating that MOR may modulate apoptosis in the CNS. If it is 
the case that in utero morphine exposure increases apoptosis in the postnatal cortex, it is 
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interesting and significant that morphine has far reaching impacts that are still evolving 
long after morphine treatment has ceased. 
 
Neurons that reside in the infragranular layers of the cerebral cortex (layers V and VI) are a 
major output for the cerebral cortex that modulates motor and sensory function (Hattox and 
Nelson, 2007). Projection neurons of layer V are a heterogeneous population that can be 
divided into two groups, type I, which include the large corticospinal neurons (Gao and 
Zheng, 2004), and neurons which project to the pons, and type II, which project to the 
ipsilateral striatum or the contralateral cortex. Such neurons can also be subdivided by the 
use of molecular markers (Molnar and Cheung, 2006). Layer V corticofugal neurons are 
also crucial to movement. Beloozerova et al. (2003) showed that layer V corticofugal 
neurons, not layer V cortico-cortico or layer VI neurons, were highly active during both 
simple and complex locomotion.  Interestingly, decreased psychomotor performance has 
been linked to in utero opiate exposure in humans (Bunikowski et al., 1998). This is 
controversial as other research has shown this to be the result of confounding 
environmental factors (Hans and Jeremy, 2001). The largest study on prenatal drug 
exposure in humans to date, found that without correction for covariates, opiate exposure in 
utero depressed psychomotor performance (Messinger et al., 2004). With correction for 
covariates, this effect became statistically insignificant (P = 0.07). 
 
Our study has implications for opiate exposure on the human foetal brain since it showed 
that development of the cerebral cortex was sensitive to opiates over the period of 
corticogenesis, as morphine affected radial glial cell cycle progression, and postnatally, 
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apoptosis. Even though in utero exposure to morphine has effects on neurons both at the 
end of neurogenesis (E18.5), and in the neonatal mouse (P5), it remains to be determined 
whether or not these changes persist into adulthood. It has been shown that much neuronal 
apoptosis occurs after P5 (Verney et al., 1999). It has also been shown that neuronal 
apoptosis occurs in response to a lack of neurotrophic support from target neurons or cells 
(Raff et al., 1993; Davies, 2003). Fewer neurons at P5 may simply mean that the neurons 
that do exist have a higher chance of forming meaningful synaptic connections and thus 
have a higher chance of survival. Future studies should therefore be extrapolated to older 
developmental time points as well as into adulthood. Furthermore, even if morphine-
induced changes in the cerebral cortex persist into adulthood, it does not necessarily mean 
that the animal will be detrimentally affected at a behavioural level. For example, in the 
development of Parkinson’s disease, a human can sustain an 80% decrease in striatal 
dopamine before becoming symptomatic. It is thought that plasticity in cortico-basal 
ganglia-thalamocortical pathways may account for substantial compensation to 
dopaminergic dysfunction in Parkinson’s disease (Bezard et al., 2003). 
 
In conclusion, the current chapter has provided evidence that chronic morphine exposure in 
utero decreases DCX expression in the E18.5 cerebral cortex. This may be a result of a 
perturbation in the neurogenic programme, since a decrease in the number of neurons was 
not detected. Chronic morphine exposure in utero also has lasting implications to neonatal 
development. At P5, after morphine exposure had ceased, neuronal loss was detected in 
layer V of the cerebral cortex. It is unlikely that these effects were the result of system-wide 
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toxicity since no biologically significant changes in either foetal or postnatal pup weight 
were detected. 
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7. General Discussion 
 
7.1 Project Summary 
 
The overall aim of this thesis research was to characterise the effects of opiate exposure 
within the context of the developing cerebral cortex. Specifically, this was investigated by 
characterising the localisation of MOR in the foetal brain, determining the effects of 
morphine exposure on the proliferative populations of neuronal progenitors within the 
developing VZ, and assessing the effects of chronic, or long term opiate exposure on 
development of the cerebral cortex. We have demonstrated that the opioid signalling 
system can impact upon development of the cerebral cortex. This was shown by linking 
MOR IR with the neuronal progenitor cells, radial glia. MOR IR was found in the 
neurogenic (E15.5) as well as the gliogenic (E18.5) cortical neuroepithelia. The same 
MOR-staining that was seen in the E18.5 mouse forebrain was also seen in the foetal 
human brain at mid-gestation (16 and 19 GW). Although no direct effect on net 
proliferation could be demonstrated, it was shown that acute exposure to morphine could 
impact upon progression of the cell cycle of progenitor cells (G2/M phase) within the E15.5 
mouse forebrain. Finally, having demonstrated opioid receptors were present within 
proliferative zones of the foetal forebrain, and progenitor cells were sensitive to opiate 
exposure, it was shown that chronic opiate exposure could affect development of the 
cerebral cortex itself. Prenatally, these changes were subtle but supported the idea that 
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morphine may have perturbed developmental progression. Postnatally, however, chronic 
morphine exposure, in utero, resulted in fewer neurons in the cerebral cortex. These results 
indicate that development of the cerebral cortex is sensitive to opiate signalling. This 
research is significant because it is the first research that directly demonstrates morphine 
has the potential to modulate cortical progenitor cells (radial glia) in utero. These data also 
support the idea that opioid signalling plays an endogenous role in the developing brain, 
although this assertion requires further research. 
 
7.2 Future Research 
 
7.2.1 Remodel the In Vivo Experiments in an In Vitro Setting 
 
Working in whole animals is advantageous because the results that are obtained are not 
confounded by abstract molecular and physical environments. The primary disadvantage to 
in vivo research is that an animal is a complex system that is difficult to dissect at the 
molecular and biochemical level. Differential distribution of any given compound within an 
animal as well as the large amounts needed to treat animals (versus treatment of a culture 
dish of cells) are both factors that favour the use of in vitro systems for detailed analysis of 
biochemical processes. With these considerations in mind, future research should include 
organotypic slice culture in an investigation of the effects of opioids on development of the 
VZ. 
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Organotypic slice culture has several advantages over in vivo studies for investigating 
development of the VZ in that it has all of the benefits of in vitro work yet it maintains 
some of the normal local cell interactions and phenomena like INM and neuronal migration 
along radial processes. Radial glial INM, cell cycle and mitotic stages can be visualized in 
slices using fluorescent DiI labels (Miyata et al., 2002). These lipophilic fluorescent dyes 
label plasma membranes of living cells. Unfortunately, organotypic explants of VZ exhibit 
a slower cell cycle time than the VZ in vivo, as well as transient checkpoints at G1 and G2 
phase which disappear several hours after explant (Takahashi et al., 1999). However, the 
use of organotypic slice culture allows for the unrestricted use of opioid antagonists as well 
as biochemical tools like specific kinase and calcium store inhibitors. These could help to 
dissect the signalling mechanisms that lead to the morphine-induced slowing of cell cycle 
in the VZ observed in vivo. A good beginning for research on opioid signalling and 
intracellular signal transduction in organotypic slice cultures would be to test the work of 
Coscia and colleagues, which centres on transactivation of EGF receptors and the MAP 
kinase pathway (Belcheva et al., 2003; 2005). Opioid effects on proliferation that signal 
through the MAP kinase pathway have also been shown in other systems such as in 
hippocampal progenitor cells (Persson et al., 2003a). 
 
7.2.2 Use Opioid Antagonists to Identify Receptor Subtypes and Endogenous Activities 
 
Many studies that have investigated the effects of opiates on proliferation have used 
antagonists such as naltrexone to demonstrate that signalling occurs through the opioid 
receptors (Hauser et al., 1996; 2000; Stiene-Martin et al., 2001).  
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A few studies have demonstrated that some opioid peptide mediated effects cannot be 
antagonised by the opioid receptor antagonists, naltrexone and naloxone (reviewed in 
Wollemann and Benyhe, 2004). However, all studies (to the knowledge of the author) that 
have attempted to antagonise proliferative or developmental effects of opioids with opioid 
receptor antagonists have been able to do so successfully. The use of opioid antagonists 
would serve to refine the current research twofold. Selective opioid antagonists (Table 7.1) 
would enable a more precise description of the specific opioid receptors that modulate 
corticogenesis under normal conditions. Even though the present study has produced 
supporting evidence for a role of the opioid system in corticogenesis by showing that radial 
glia express opioid receptors and are sensitive to morphine, it is still possible that the 
effects observed in this study are pathological effects induced by supranormal opiate levels 
that bear little relevance to normal physiological conditions. 
 
Opiate antagonists were not used in the current research project because of the limited 
supply of animals, especially pregnant dams, which allowed for morphine tests but not 
antagonist tests. The decision was made to more thoroughly investigate the effects of the 
opiate morphine on brain development rather than to investigate fewer possibilities but with 
opioid antagonists included as well. To gain the full benefit from using antagonists, one 
would employ a battery of receptor-subtype specific antagonists. Given the available 
resources, this would have severely restricted the breadth of this thesis research. 
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Opioid Receptor Antagonist Notes 
 
MOR 
CTOP Highly selective mu antagonist, cyclic peptide 
CTAP Selective mu antagonist, cyclic peptide 
Beta-FNA Irreversible selective mu antagonist, non-peptide 
DOR Naltrindole Highly selective delta antagonist, non-peptide  
 
KOR 
Nor-BNI Selective kappa antagonist, non peptide 
DIPPA Irreversible, selective kappa antagonist, non peptide 
GNTI Highly potent, selective kappa antagonist, non peptide 
Table 7.1. Commercially available selective opioid receptor antagonists (Tocris Bioscience, 2007). 
 
7.2.3 Use Gene KO Animals to Delete Specific Receptors 
 
A more precise tool for the elucidation of the opioid receptor population involved in the 
morphine effects would be to use different as well as combinatorial opioid receptor KO 
animals. In this thesis, we used a MOR KO to provide evidence that the morphine-induced 
effects on INM were MOR-related. KOs eliminate the unknown aspects inherent in 
pharmacological receptor blockade such as receptor promiscuity and unknown accessibility 
of the antagonist to the foetal brain. However, even KO mice have their caveats in 
developmental research (see Chapter 1 for detailed examples). The best way to study how 
opioid receptors may contribute towards CNS development would be to employ an 
inducible KO, such as the tamoxifen inducible gene KO (Erdmann et al., 2007). A 
tamoxifen inducible gene KO is a conditional KO in which Cre-recombinase is expressed 
as a fusion protein with a mutated ligand domain of an estrogen receptor. Cre-recombinase 
activity is initiated by injecting tamoxifen into the animal. This Cre-recombinase activity 
will then induce recombination of DNA flanked by loxP sites. As recombination can be 
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temporally restricted by use of the tamoxifen system, it can also be spatially restricted by 
placing Cre-recombinase expression under the control of a cell-specific promoter. This 
system has been used before with success in the embryonic mouse brain (Burns et al., 
2007). To continue the research of the present study, loxP sites would be placed around any 
or all of the opioid receptor genes, and Cre-recombinase expression would be placed under 
the control of the radial glial-specific BLBP or hGFAP promoter. Injection of tamoxifen 
would therefore induce opioid receptor KO that is specific to radial glia. This approach has 
the technical advantages of both molecular biology and pharmacological receptor blockade 
in that specific receptors can be removed acutely, without time for the developing system to 
induce compensatory measures. 
 
7.2.4 Investigate Different Treatment Regimes – Continuous Administration by Osmotic 
Pumps 
 
Further research should also expand upon and refine drug administration regimes. 
Continuous release of opiates with miniosmotic pumps show reduced toxicity with chronic 
experiments (Hutchings et al., 1992). This does not matter so much with acute experiments, 
where the animal remains under the influence of the opiate for the duration of the 
experiment; however, it would be useful for longer duration treatments such as exposure 
over the entire period of corticogenesis. The use of a constant infusion of opiate in a 
chronic experiment would be beneficial as the animal would not withdraw from the injected 
opiate drug after it has been cleared from its system. The use of osmotic pumps would be a 
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good model for opiate administration in hospital where opiates may be infused 
intravenously or epidurally (George, 2006) 
 
Further research into cell cycle progression and chronic opiate administration is also 
required. The current study found acute courses of morphine slowed G2/M phase 
progression. Research into whether this occurs after chronic morphine exposure, or if some 
adaptive measures have occurred, would be of clinical relevance. Other studies have found 
that chronic morphine exposure markedly decreases proliferation in the brain, unlike acute 
exposure (Eisch et al., 2000). Future research should investigate whether such dramatic 
differences in response to chronic or acute drug exposure is a consistent theme in the 
developing brain. 
 
7.2.5 Use Other Clinically Relevant Opiates 
 
As well as mode of administration, the use of different opiates of clinical significance 
should also be considered. These include fentanyl, alfentanyl, codeine, pethidine, 
diamorphine (heroin) and methadone. Although morphine is an opiate of extremely high 
clinical significance, the fact that it does not induce opioid receptor internalisation but other 
opiates do (Arden et al., 1995; Keith et al., 1996) means that the effects of morphine 
described in this thesis should be examined using other opiates. Furthermore, different 
splice variants of MOR have been shown to have different affinities for different opioid 
ligands (Bolan et al., 2004). Whereas it is valid to say further research with selective 
antagonists is important for elucidation of a role for opioids in normal development, it is 
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just as valid to say future research should focus on the use of additional opiate compounds 
and administration regimes to strengthen its clinical relevance. 
 
7.3 Weaknesses in the Field of Opioids and Developmental Biology 
 
The study of how opiate drugs affect development had its roots in the panic that surrounded 
the recreational abuse of heroin and the use of methadone as a maintenance drug (Markham 
et al., 1971). Early morphometric studies found no significant effects of opiates on growth, 
apart from mild decreases in weight. It was not long after this, however, in the 1980s before 
people began to investigate potential effects of opiates on cellular proliferation, using tools 
such as [3H]thymidine (Vertes et al., 1982; Miller et al., 1982; Zagon and McLaughlin et 
al., 1983), and these continued with the characterisation of the opioid system in astroglia in 
the late 1980s and early 1990s (Vilijn et al., 1988; Hauser et al., 1990; Stiene-Martin et al., 
1991a). Over the 1990s, research that came mainly out of three labs (those of I. Zagon, K. 
Hauser and C. Coscia) now provide the bulk of the literature on how the opioid system 
interacts with neural development at a cellular scale. Apart from the lab of C. Coscia, which 
is investigating how opioids interact with the MAP kinase signaling pathway in glia 
(Belcheva et al., 1998; 2000; 2002; 2003; 2005), these studies on how opioids affect the 
proliferation of astroglial lineage cells have largely come to a halt. The reason why this 
research has stopped, in my opinion, is in part due to difficulty in reproducing some of the 
work that has been previously published. To some extent, this may be due to the context 
dependency and temporal sensitivity of opioid effects on development, possibly due to the 
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inherently indirect nature of opioid signaling on cellular proliferation via receptor tyrosine 
kinases (discussed further in Chapter 1). However, on a more aggressive note Petrie (1993) 
labeled the study of Zagon and McLaughlin (1983) as “lab specific”, having failed to 
replicate the reported growth-enhancing effects of opioid antagonism with naltrexone. We 
also had difficulty in replicating results published in the study of Reznikov et al. (1999). 
Although we noted that different opioid ligands were used (Chapter 5), we still failed to 
observe the 20-40% changes in S phase-labelling reported in the Reznikov study. 
 
These points aside, one particular aspect of the history of research on opioids and 
development seems curious. Results from some studies have reported massive effects on 
the number of cells in given brain structures. These include a 2.7 fold increase in the 
number of neurons in the molecular layer of the cerebellum in response to postnatal high 
dose naltrexone treatment (Zagon et al., 1983), a 28% decrease in the number of internal 
granule neurons of the cerebellum in response to postnatal low dose naltrexone (Zagon et 
al., 1986a) (a tremendous decrease in neuronal number given the internal granule layer 
houses half of the neurons in the brain (Ghez and Thach, 2000)) and a 40% increase in the 
[3H]thymidine labeling index of the E16 (c.f. E15 in the present study) mouse in response 
to an acute dose of DAMGO. Given the magnitude and significance of these results, it is 
unclear why the opioid system in the developing cerebellum has not been vigorously 
researched and widely acknowledged as a major modulating force in the proliferating 
cerebellum. It is also unclear as to why a signaling system that could increase the labeling 
index of the VZ by a massive 40% has not been pursued, given that corticogenesis is now 
an intense topic of study. Such a large induction of S phase-labeling seems unusual. To put 
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the sheer magnitude of a 40% increase in S phase labeling into perspective, overexpression 
of insulin-like growth factor in the mouse telencephalon increases cell cycle reentry by 
15% (Hodge et al., 2005) while EGF (20 ng/ml) increases BrdU labeling in cultures of SVZ 
cells by 40% (Agasse et al., 2006). Furthermore, a 40% increase in S phase labelling along 
with reported increases in mitotic indices at the ventricular edge in response to DAMGO 
(>20%) (Reznikov et al., 1999) would provide a major disruption to the model of 
corticogenesis put forward by Caviness et al. (2003) and would therefore be likely to cause 
obvious and long lasting morphological effects on cortical histogenesis. 
 
Despite the uncertainty of these large opioid induced changes, the present study provided 
some support for major effects similar to those reported in the literature. For example, 
Seatriz and Hammer (1993) showed that chronic morphine exposure reduced cortical layer 
V neuronal number by half in the postnatal pup. This was also demonstrated in the mouse 
(Chapter 6) where a similar effect was observed. Given that this effect was reproducible, 
why has such a large effect gone unnoticed in the literature? Perhaps this wane in opioid-
developmental research has come as a consequence of a number of studies pointing out in 
utero exposure to opiates in humans produces only weak effects, at best, on human brain 
development (Kaltenbach, 1994).  
 
An area that needs clarification is the importance of OGFr in brain development. The 
nuclear met-enkephalin receptor or ‘opioid growth factor receptor’, is a receptor that 
reportedly has anti-cancer potential (Cheng et al., 2007; 2008) and globally modulates 
cellular proliferation during organogenesis (Zagon et al., 1999b). The literature on this 
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receptor comes from mostly one lab (Zagon and colleagues), and it would be useful to have 
more molecular and biochemical background on the action of the receptor. Since the 
cloning of OGFr in 1999 (Zagon et al., 1999a), 31 papers have been published on or 
relating to that receptor (search “opioid growth factor receptor” on Pubmed Entrez). Of 
these 31 papers, only 5 are from groups other than Zagon’s laboratory group. Of these 5 
papers, 3 relate to global gene expression studies (Urosevic et al., 2004; Matejusova et al., 
2006; Oczko-Wojciechowska et al., 2006), one to cDNA expression library screening 
(Mollick et al., 2003) and one is an immunohistochemical study that used antibodies 
provided by Zagon and McLaughlin (Robertson and Andrew, 2003). Thus, none of these 5 
studies provide support for a direct proliferative function of the cloned receptor. This 
contrasts greatly with the multi-lab corroboration that was immediately forthcoming after 
cloning of the classical opioid receptors (Evans et al., 1992; Kieffer et al., 1992; Chen et 
al., 1993a; 1993b; Eppler et al., 1993; Li et al., 1993; Meng et al., 1993; Minami et al., 
1993; Thompson et al., 1993; Wang et al., 1993). A quick search on Medline reveals that 
the last 20 papers published on other developmentally associated proteins, specifically the 
TrkA neurotrophin receptor, notch1 and wnt7b consisted of studies from 19, 20 and 19 
different labs, respectively. Such numbers are indicative of a healthy research field with 
findings that are readily reproducible. 
 
Optimistically, research on opioid signalling and brain development has available several 
new opportunities. If opioid research can develop a niche within the field of brain 
development, it will be able to benefit from large gains in knowledge made since the early 
2000s. The significance of opioid-developmental research obviously extends to the clinical 
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arena; however, future research should perhaps focus on the endogenous biology of the 
opioid system in development. This approach has excellent potential as there is much 
opportunity to marry the knowledge already gained on opioidergic modulation of astrocytic 
proliferation with new-found roles for astrocytic lineage cells. The latter range from radial 
glia, which manufacture the neurons of the CNS, to astrocytes, which assume the role of 
stem cells within the adult brain. 
 
7.4 An Integrated Model of Opioidergic Signalling and Cortical Development 
 
Based on data taken from this project, the following hypothetical model of how opiates 
impact on corticogenesis, in vivo, can be made. 
 
Opioid receptors are expressed on neuronal progenitor cells of the cerebral cortex (Chapter 
3 and 4). Evidence for direct opioid signalling impacting on proliferation of astroglial 
lineage cells is presented by in vitro studies (Stiene-Martin and Hauser, 1993; Hauser et al., 
1996). Opioid signalling through MOR (possibly also KOR) on radial glial cells slows cell 
cycle progression in progenitor cells of the VZ. This occurs in vivo and may be restricted to 
G2/M phase of the cell cycle (Chapter 5). Acting through a perturbation of the cell cycle, 
opioids modulate progression of the intrinsic neurogenic programme to induce early 
maturation. This is a distinct possibility as a change in cell cycle time and INM alters the 
length of time a radial glial cell spends in an environment that may or may not favour 
differentiation (discussed in Chapter 5). Other studies show the intrinsic neurogenic 
 207 
programme may be influenced by external environmental cues to promote precocious 
maturation (McConnell, 1988) and that morphine influences differentiation in astrocytic 
cells (Stiene-Martin et al., 1993). The fact that less DCX (migratory marker) was expressed 
at the end of neurogenesis in response to chronic morphine treatment suggests that 
morphine throughout corticogenesis impacted upon the developmental maturity of cells 
within the VZ such that corticogenesis at E18.5 was at a more advanced stage. This 
modulation of glial maturation did not alter neuronal numbers at the end of corticogenesis 
but perturbation of subtle aspects of the neuronal progeny remains a possibility. 
 
Based on the observation that there are fewer neuronal nuclei at P5, but not at E18.5 (the 
end of neurogenesis), chronic morphine exposure and opioid signalling could also modulate 
apoptosis that occurs within the neonatal cerebral cortex. Opioid effects on neuronal 
apoptosis are supported by observations in the literature that have shown chronic morphine 
induced apoptosis in the adult brain (Yin et al., 1999; Emeterio et al., 2006). Apoptosis was 
not measured directly in the present study. 
 
Two major conclusions can be drawn from this thesis. 1) Support is given for the 
hypothesis that opioid receptors (present within the proliferating neuroepithelia of the 
developing forebrain) do not directly modulate proliferation. Rather, opioids lead to subtle 
perturbations in the intrinsic neurogenic programme of cortical progenitor cells. 2) The 
effects of opiate exposure on development of the cerebral cortex may be delineated into 
signalling that affects the prenatal histogenesis of the cerebral cortex, as well as the 
apoptotic remodelling of the cerebral cortex that occurs postnatally. Evidence for increased 
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apoptosis from the present study comes from the loss of neurons in the morphine-exposed 
P5 cerebral cortex, despite no differences in neuronal density in the E18.5 foetus (Chapter 
6). Thus, through development, it is possible that opioid receptors have different roles at 
different times. The possibility of multiple roles for opioid receptors during development of 
the brain mirrors the versatile nature of opioid receptors in modulating the wider 
physiological environment of the organism through independent actions on multiple organ 
systems. 
 
7.5 What is the Significance of Opioid Signalling in Development of the CNS? 
 
As well as providing evidence that the opioid system can modulate development of the 
cerebral cortex in the mouse, the finding that opioid receptors are expressed on progenitor 
cells within the human foetal brain (Chapter 4) makes the study relevant to human brain 
development in the face of opioid exposure during pregnancy. This significance is twofold. 
 
7.5.1 A Biological Role for the Endogenous Opioid System in Corticogenesis? 
 
The opioid system has long been implicated in cellular proliferation, especially in vitro, 
although some studies have provided strong evidence that opioids also modulate 
proliferation in vivo (Miller et al., 1982; Kornblum et al., 1987; Schmahl et al., 1989; 
Lorber et al., 1990; Bartolome et al., 1991; Stiene-Martin et al., 2001). However, our study 
is the first to demonstrate a clear set of effects of morphine on corticogenesis of the prenatal 
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mouse. This is important in the first instance since it provides evidence that the opioid 
system forms a part of the complex and dynamic system that is the developing cerebral 
cortex. Owing to the observed slowing in cell cycle, it appears that in the developing 
cortex, the holistic role for the opioid system would likely be growth limiting in nature. 
Although the opioid system may modulate normal development of the cerebral cortex, the 
extent to which it does this remains unclear, but it is likely that it only plays a minor role. 
This is evident from the normal brain morphology of the triple opioid receptor KO mice 
(Gaveriaux-Ruff and Kieffer, 2002); thus, either there must be some system redundancy, 
i.e., other systems that replace opioid signalling or it indicates that opioids are not active 
during normal development (see Chapter 1). In line with this, only minor developmental 
abnormalities are seen in humans prenatally exposed to opiates (Kaltenbach, 1994; Lester 
et al., 2002). The opioid system presumably comprises one of the many signalling systems 
that add complexity, control, and fine tuning to the development of the cerebral cortex. 
 
7.5.2 A Highly Utilised Drug with Lasting Consequences? 
 
Since the opioid system is implicated in cortical development, exogenous opiate drugs may 
interfere with this development. There are two ways in which humans may be exposed to 
opiates prenatally: exposure from opiates as a course of maternal analgesia and exposure 
from maternal opiate abuse. Maternal opiate abuse may also be further divided into 
uncontrolled opiate abuse or controlled maintenance programs that often employ opiates 
such as methadone or buprenorphine (Lejeune et al., 2006). Although large studies have 
found no major opiate-induced impacts on measures such as IQ and motor performance in 
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humans (Kaltenbach, 1994; Ornoy et al., 1996; Hans and Jeremy, 2001; Lester et al., 
2002), it cannot be ruled out that opiate exposure may subtly change aspects of human 
cognition, especially given the evidence in this thesis that opiate exposure during 
corticogenesis alters cellular behaviour and development. 
 
As discussed in Chapter 6, changes that occur early in life might not persist into adulthood. 
Even if these changes persist into adulthood, they may not actually result in behavioural 
abnormalities. The human cerebral cortex is a robust organ that displays substantial 
plasticity (Glazewski and Fox, 1996) and has the ability to restore cognitive function via 
astonishing compensatory changes after damage from stroke or mechanical injury (Nudo, 
2006). Answering the question of whether opiate exposure causes long lasting changes in 
human behaviour or intellect would require further research on adult human subjects. Even 
though prenatal opiate exposure in humans does not elicit major developmental defects, the 
fact the opioid system has been implicated in development of the cerebral cortex means 
further analysis of human subjects prenatally exposed to opiates is warranted. However, 
this may be somewhat of a flippant suggestion. In an overview of research from the human 
maternal opiate abuse field, Kaltenbach (1994) called for studies on the developmental 
effects of opiate abuse in humans to abandon multifactorial research paradigms that try to 
control for confounding factors such as socio-economic status and poly-drug abuse. Instead 
it was suggested that the best way to move forward in our understanding of how opiates 
affect human development is to include opiate abuse into the context of a ‘multi-effects 
model’ in which opiate exposure is considered within a cumulative framework of risk 
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factors that stem from maternal drug abuse and addiction. Animal and subsequent human 
biological research would therefore provide the basis of a part of this framework. 
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8. Appendix 
 
8.1 Appendix 1 – Reagent List 
 
• 10 x phosphate buffered saline (PBS) 
o NaCl     80 g 
o Na2HPO4 (Anhydrous)  14.2 g 
o KCl     2 g 
o KH2PO4    2.4 g 
Salts were dissolved in 800 ml ddH2O. This solution was then adjusted to pH 7.4 with 
HCL. The solution was then adjusted to 1 l. 10xPBS was split into 500 ml aliquots and 
autoclaved. 1xPBS (0.15M) was prepared from this stock. 
 
• 4% paraformaldehyde (PFA) 
o Paraformaldehyde   40 g 
o 1 x PBS    960 ml 
PFA was made up to a volume of 800 ml with 1 x PBS. This solution was adjusted to pH 
12 with NaOH. Once the PFA had dissolved, the solution was adjusted to pH 7.4 and made 
up to 1 l with 1 x PBS. 
 
• DAB solution (0.5 mg/ml) 
o DAB     5 mg 
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o 1 x PBS    10 ml 
o 30% H2O2    10 µl 
Immediately prior to use, DAB was added to PBS and vortexed. This left a white 
precipitate at the bottom of the tube that did not dissolve. H2O2 was then added and this 
solution was directly applied to histological sections to reveal HRP conjugates. 
 
• DNAse I buffer for BrdU epitope retrieval 
o Tris     4.85 g 
o CaCl2.2H2O    1.47 g 
o MgCl2.6H2O    1.22 g  
o NaCl     0.58 g 
Mix constituents in 1 l of ddH2O. 
 
• 50 x Tris-Acetate-EDTA (TAE buffer) 
o Tris     242 g 
o 0.5 M Na2EDTA (aq)   100 ml 
o Glacial acetic acid   57.1 ml 
Mix constituents and make up to 1 l with ddH2O. 
 
• 6x PCR product loading buffer 
o Glycerol    3 ml 
o H2O     7 ml 
o Bromophenol blue   A few crystals to colour 
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Mix constituents and store at 4 °C. 
 
• RIPA buffer 
o Tris     606 mg 
o NaCl     877 mg 
o Na2EDTA    37.22 mg 
o Triton X-100    1 ml 
o Sodium Deoxycholate  1 g 
o SDS     100 mg 
Mix constituents and make up to 100 ml with ddH2O 
 
• Western transfer buffer 
o Tris     3.03 g 
o SDS     1 g 
o Glycine    14.4 g 
o Methanol    200 ml 
These components were mixed and adjusted to a volume of 1 l with ddH2O. 
 
• Thionin Nissl stain 
o Stock thionin stain (1.3%) 
 Thionin   13 g 
 ddH2O    1 l 
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Thionin was stirred and heated for 1 h. Thionin solution was then filtered. 
o Working thionin solution (0.2%, pH 4) 
 1 M Acetic acid  80 ml 
 1 M NaOH   14.4 ml 
 1.3% thionin stock  76.4 ml 
These constituents were mixed and diluted to 400 ml with ddH2O. 
 216 
8.2 Appendix 2 – Nissl Staining Brain Sections 
 
• Deparaffinise and rehydrate paraffin embedded sections of brain: 
o 100% xylene for 10 mins x 2 
o 100% ethanol for 2 mins 
o 90% ethanol for 2 mins 
o 80% ethanol for 2 mins 
o 70% ethanol for 2 mins 
• Wash in ddH2O for 2 mins 
o NOTE: As phosphate salts cause thionin to precipitate, PBS must not be 
used for this procedure. This causes purple precipitate to collect on the tissue 
sections.  
• Stain in 0.2% thionin until desired colouring is obtained 
o This typically took 3-4 mins for procedures performed in this thesis research 
• Wash slides in ddH2O for 2 mins 
• Dehydrate and clear sections: 
o 70% ethanol for 2 mins 
o 80% ethanol for 2 mins 
o 90% ethanol for 2 mins 
o 100% ethanol for 2 mins 
o 100% xylene for 10 mins x 2 
• Remove excess xylene and mount sections in DPX mounting media  
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• Factors that decreased Nissl staining intensity: 
 
o Ethanol used in the dehydration step usually leeched thionin from the 
stained brain sections. To account for this, sections were usually initially 
over-stained in thionin. 
o Nissl staining intensity was also markedly decreased by antigen recovery in 
boiling sodium citrate. Nissl staining sections that had been stained for BrdU 
therefore required much more time to stain in thionin.  
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8.3 Appendix 3 – Optimisation of BrdU Staining on Frozen Tissue Sections 
 
Fig. 8.1. Optimisation of BrdU staining of fixed-frozen tissue. Optimisation of fluorescence staining for BrdU 
incorporation in frozen sections of tissue required an antigen retrieval technique that was not as harsh as using 
boiling sodium citrate buffer or 1-2N HCL, as is used in some studies. Epitope retrieval using DNAse I was 
chosen as it did not destroy the frozen tissue sections. Panel A shows a titration in DNAse I concentration 
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from 250-31.25 µg/ml. From these results, a concentration of 250 µg/ml was chosen for further DNAse I 
retrieval optimisation. Panel B shows optimisation of DNAse I digestion time. A digestion time of 10 mins 
was chosen for future experiments. Interestingly, over-digestion is shown in the neuroepithelium of the 
eyeball at 1 h. Panel C shows diffusion of the anti-BrdU antibody, PRB-1. BrdU staining (red fluorescence) 
can be seen around the lateral ventricle of the E15.5 brain. However, staining is diffuse and has spread out 
from its normal localisation within the VZ/SVZ. This phenomena was finally resolved by performing a 
postfixation step in 4% PFA for 5 mins after incubation with the anti-BrdU antibody. 
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8.4 Appendix 4 – Sectioning and Nissl Staining of 12 GW Human Brainstem 
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Fig. 8.2. Sectioning and staining of Brain 1. Brain 1 (12 GW) was sectioned at 40 µm thickness and Nissl 
stained in order to conclusively identify its anatomy. Brain 1 comprised entirely of brainstem, as shown by 
these Nissl stained sections. Regions of note are the inferior olivary nucleus on sections 39, 55 and 74 (red 
arrows), and the pons, on sections +59 and +75 (green arrows). 
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8.5 Appendix 5 – Pilot Experiment of the Effects of Morphine on INM 
 
 
Fig. 8.3. The morphine-INM pilot experiment. After establishing that there was no effect of morphine on 
BrdU labelling (Chapter 5, Fig. 4, panel A), it was decided to investigate whether or not morphine had any 
effect on INM to the ventricular surface (G2 phase). This preliminary experiment was performed to assess 
whether or not this idea was viable before committing large numbers of pregnant dams to full experiments. 
Panel A is from an E15 saline-treated control. It shows the VZ which is DAB-stained for BrdU that was 
injected 6 h prior to sacrifice. This same panel showed that nearly all cells had migrated to the ventricular 
surface. Panel B shows that acute morphine treatment resulted in an accumulation of BrdU-labelled nuclei in 
the basal regions of the VZ (the same drug administration regime was used as the one used to assess the effect 
of morphine exposure on INM in Chapter 5). Panel C shows VZ DAB-stained for BrdU that was injected 1 h 
prior to sacrifice as a comparison for INM to the ventricular surface. After assessing these results, it was 
decided to plan experiments that would investigate the effects of morphine on INM and G2/M phase duration. 
Animals used to generate the pictures presented here were not used in the final analysis of these experiments. 
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8.6 Appendix 6 – Calculation of Likely Concentration of Peak Plasma Morphine 
 
Morphine used in this thesis research was morphine sulfate (C34H40N2O10S · 5H2O, MW = 
758.83). 
 
We used a dose of 10 mg/kg morphine sulfate. That is: 
0.01 g/kg / 758.83 g/mol = 1.32 x 10-5 mol/kg  
or  
13.2 µmol/kg of morphine sulfate 
 
As there are two molecules of morphine in one mole of morphine sulfate, this means that 
10 mg/kg of morphine sulfate is 26.4 µmol/kg of morphine. As Handal et al. (2002) used a 
dose of 80 µmol/kg of morphine hydrochloride in their studies, the dose of morphine used 
in the present research is 
 
100 x (26.4 µmol/kg / 80 µmol/kg) = 33% 
 
of the dose of morphine administered to animals in the pharmacokinetic studies by Handal 
et al. (2002) who showed that a dose of 80 µmol/kg produced a peak plasma concentration 
of 18 µM. Therefore, our dose of 10 mg/kg is likely to produce a peak plasma concentration 
of  
 
18 µM x 0.33 = 5.9 µM 
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8.7 Appendix 7 – The Effect of Morphine on Growth of Different Cell Lines as Measured by 
MTT Assay 
 
Fig. 8.4. Morphine and growth of cell cultures. MTT assay was used as an indirect measure of proliferation on 
cell culture lines. The MTT assay uses a yellow tetrazolium salt that is reduced to purple formazan at the 
mitochondria to assay for respiration. Cells were cultured in RPMI media (Invitrogen, 11875-085) containing 
10% foetal bovine serum and 1% penicillin/streptomycin. Before the effects of morphine were tested on the 
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growth of three different cell lines (U-118 MG (human glioblastoma), SH-SY5Y (human neuroblastoma) and 
N2A (mouse neuroblastoma), the concentration of cells used in this assay was calibrated such that there was 
no ceiling effect. To determine whether morphine inhibited proliferation of these cell lines, cells were 
cultured in the presence of a range of concentrations of morphine (x-axis). It was shown that after 48 h of 
exposure to these concentrations of morphine, that there was no effect whatsoever on cellular proliferation as 
measured by MTT assay. All data points are the average of 3 replicates. Values are the mean ± SEM. 
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